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Summary 
This study was undertaken to investigate the effect of prolonged megadose ingestion of 
ascorbic acid on the risk of calcium oxalate kidney stone formation. Ten healthy male subjects 
(ages 20 to 30 years) participated in the study. Each was required to ingest a daily dose of 4 g 
ascorbic acid per day for a period of 5 days. Twenty-four hour urines were collected at 
various times prior to, during and after this protocol. During each 24 hour collection, aliquots 
were withdrawn and stored in the presence and absence of an EDTA preservative. Other 
aliquots were withdrawn for immediate ascorbate analyses. 
Urine samples were analysed for sodium, potassium, magnesium, calcium, citrate, 
oxalate, urate,· phosphate and creatinine. A new flow-injection method was designed, 
developed· and tested for the analysis of urinary ascorbate. Analytical data obtained from this 
method were compared with results obtained from a manual titration method using 
2,6 dichlorophenolindophenol. While the accuracy of both methods was found to be similar, 
results obtained by the flow-injection were more repeatable. All urine samples were analysed 
... 
.for ascorbate by both methods. In vitro crystallization experiments were performed on each 
urine to determine the limit of metastability and the rate of calcium oxalate crystallization. All 
data were statistically compared using the method of least-squares. 
Prolonged ascorbic acid ingestion had no effect on urinary calcium and oxalate nor on 
several other biochemical risk factors including urinary citrate, sodium, chloride and creatinine. 
Calcium oxalate metastable limits and crystallization kinetics were also unaffected, as were 
i 
values of the Tiselius risk index and calcium oxalate relative supersaturation. While risk-
reducing changes in urinary magnesium and pH occurred, these were offset by risk-increasing 
· changes in urinary potassium and phosphate. 
The investigation showed that in vitro conversion of ascorbate to oxalate occurs but that 
this can be prevented by the presence of EDTA in the collection vessel. The study also 
demonstrated that ingestion of large doses of ascorbic acid probably commences with high 
percentage absorption of the vitamin but that saturation is achieved within 24 hours. 
Continued ingestion results in less absorption with excess ascorbic acid being excreted 
unchanged in the urine. 
In a separate case study, prior to the commencement of the investigation described 
above, a healthy male participant was given a daily dose of 8 g ascorbic acid in a protocol 
which was planned to last 9 days. Significant crystalluria and haematuria developed on the 81h 
day after which further ascorbic acid ingestion was immediately suspended. In this individual, 
several risk factors changed significantly. These were urimiry oxalate excretion, metastable 
limit, Tiselius risk index and calcium oxalate relative supersaturation .. 
This study shows that prolonged ingestion of large doses of ascorbic acid does not 
increase the risk of calcium oxalate kidney stone formation. However, the results of the 
special case study highlight the fact that in some individuals, renal handling of ascor?ic acid 
may be impaired, leading to undesirable consequences. 
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Chapter 1. 
Introduction 
Kidney stone disease is diverse involving consideration of many factors other than 
ascorbic acid overindulgence. This has led to a great deal of consensus and controversy in the 
study of urolithiasis. This introductory chapter covers a broad spectrum of aspects ranging 
from a comprehensive history of ascorbic acid, more commonly known as vitamin C, to an 
overview of urolithiasis relating and linking the risk factqrs and stone forming mechanisms of 
urine. Oxalic acid, the biochemical end product of the metabolism of ascorbic acid, -is 
<!iscussed. The existing literature perspective of the effect of ascorbic acid on the stone 
forming potential of urine is detailed. 
1.1 Ascorbic Acid in General 
Ascorbic acid plays a role in health· and disease which has given rise to numerous 
controversial issues. A deficiency in the vitamin is sufficient to emphasise its essential need in 
order that the unpleasant symptoms of scurvy be avoided. However, controversial issues as to 
the effect of the vitamin in the prevention of common colds and influenza, together with the 
role it plays in the treatment of cancer, are causes of concern to the medical fraternity. This is 
because one of the end products of ascorbic acid's biochemical metabolism is oxalic acid, 
which is a possible causative factor in urolithiasis. 
,1.1.1 History of Ascorbic Acid 
Scurvy is defined as a disease which produces haemorrhaging into tissues, bleeding 
gums, loose teeth, anaemia and general weakness. It is a deficiency disease which must have 
existed throughout history, but was particularly noted during the long sea voyages of the 
Middle Ages. It would appear that there was a lack of communication in ancient medicine 
1 
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since documentation of ascorbic acid as a cure for scurvy dates back as far as the 13th century 
[1] and further reports do exist in the following four centuries. 
It has been known for a long time that the anti-ascorbutic effects of fresh fruit and 
vegetables diminish after the time of harvest. This occurs because of the loss of ascorbic acid 
due to a variety of oxidative processes involving oxygen from the air. This contributed to the 
confusion over the efficacy of fresh fruit and vegetables in the prevention and cure of scurvy, 
even as late as the beginning of the 20th century. 
Scurvy resulted in the death of many a sailor in the 16th century, since fresh fruit and 
vegetables were unavailable on the long sea voyages of the period. Eventually it was 
recognised that fruit juices diminished the number of cases of scurvy aboard the ships. The 
journal of Sir James Lancaster's voyage in 1601 shows the essential value of oranges and 
lemons with the quote [1 ], 
" ... the reasons why the general's men stood better in health was this; he brought to 
sea with him, bottles of the juice of lemons, which he gave to each one, as long as it would 
last, three spoonfuls every morning ... by this means the general cured many of his men ... " 
With hindsight, it is easy to recognise the necessity to establish the effectiveness of fresh 
fruit and vegetables in the cure of scurvy in order to overcome the confusion of the treatment 
of the disease. James Lind was the first to embark on a "clinical trial", of the various 
treatments of scurvy. 
The trial, shown in Table 1.1, consisted of twelve men with scurvy being maintained on 
the same daily diet. Six treatments were applied in groups of two amJ it was found that the 
.men on the citrus fruit treatment showed sufficient recovery to resum~_normal duties after two 
or three days. The other treatments had little or no effect on the disease, with the result that 
Lind concluded that citrus fruit was the most effective remedy for scurvy. However, Lind's 
recommendation that green vegetables, oranges and lemons be carried aboard on long sea 
voyages went unheeded. It appeared that he did not have sufficient influence in this regard and 
it was only when Sir Gilbert Blane was appointed as physician to the Household of the Prince 
2 
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of Wales that the advice was heeded. In 1795, Blane became a commissioner to the Board of 
-the British Navy and he authorised that lemon juice be a standard issue to the British Navy. 
The incidence of scurvy dropped dramatically and it is considered that it is largely due to Lind 
and Blane that this disease has been conquered at sea [1 ]. 
Table 1.1 A summary of James Lind's trials to find possible cures for scurvy. 
Group Treatment 
1 One quart of cider 
2 25 drops of elixir of vitriol three_times a day 
3 Two spoonfuls of vinegar before meals 
4 Half a pint of seawater 
5 Two oranges and one lemon 
6 A medicinal paste containing substances such as garlic and mustard seed 
Scurvy does occur on land, particularly in regions where fresh fruit and vegetables are 
unavailable during the winter months. This disease was more prevalent in the aristocracy since 
vegetables were considered to be a food for the lower class because they grew in "dirty soil". 
- Much of the failure to conquer scurvy, even at the beginning of this century; is due to a 
continuing reluctance, despite evidence, to recognise it as a deficiency disease. Arguments as 
'to the cause of the disease continued well into the first quarter of the 201h century. It was only 
after the discovery of foodstuffs which showed anti-ascorbutic properties, that arguments 
diminished. Anti-ascorbutic properties in certain products were identified, isolated and shown 
to be effective in the cure of scurvy. The first 25 years of this century resulted in the scientists 
unravelling the mystery of the elusive anti-ascorbutic factor. 
3 
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Holst and Frolich (1907) [cited by 1] used guinea pigs to test various dietary effects in 
attempts to ascertain the extent of anti-ascorbutic activity. They were able to show the 
effectiveness of fresh fruit and vegetables conclusively. In 1912, Casimer Funk showed that 
scurvy, together with various other diseases, is a deficiency disease which can be prevented in 
the presence of small amounts of nitrogen. He proposed that all these compounds were 
amines, and referred to them as ''vital amines" which has since been abbreviated to ''vitamines", 
and then to the more commonly known ''vitamins" [1 ]. 
1.1.2 Discovery and Structure 
The First World War led to further experimentation by a groups of women at the Lister 
Institute, which led to the development of a bioassay for ascorbutic properties in various food 
stuffs. The decade from 1920 to 1930 showed extensive research in the investigation of 
ascorbic acid, so called after an attempt to name the anti-ascorbutic factor, water soluble C. 
The Lister Institute established the reducing properties of the compound, despite the fact that 
the compound could not be isolated. This property was then used in chemical analysis of the 
compound, which avoided the time consuming bioassays previously employed. 
Numerous research groups tried to isolate the elusive chemical compound, but despite 
the attempts of these groups the stage was set for an unknown Hungarian scientist, Albert 
Szent-Gyorgyi. Szent-Gyorgyi isolated a substance from the adrenal cortex of cattle 
(procedure detailed in [1] ) and found that the substance, like all reducing agents, decolourised 
iodine. He calculated the relative molecular mass to be 88.2 or a multiple thereof. The 
lowering of the vapour pressure of water suggested a relative molecular mass of approximately 
180, indicating 176.2 to be the correct value. Finally,. combustion analysis enabled the 
molecular formula to be established as 4H80 6.- The compound was published under the name 
hexuronic acid. Despite the fact that Szent-Gyorgyi thought that hexuronic acid was ascorbic 
acid, his dislike of clinical trials prevented further work on the compound. Eventually the true 
nature of hexuronic acid was identified in 1932 by Svirbely, one of Szent-Gyorgyi's students. 
Szent-Gyorgyi then <;iiscovered that the vitamin was present in Hungarian paprika and that _ 
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isolation from this plant was simple; as a result, sufficient amounts of the compound could be 
isolated and its chemical structure determined [1 ]. 
Structure elucidation was a long and involved process carried out by Edmund Hirst. 
Boiling with hydrochloric acid indicated that at least 5 of the 6 carbons formed an unbranched 
chain. Ascorbic acid was then determined to be a weak monobasic acid and strong reducing 
agent. The first step in oxidation was reversible and involved the loss of two hydrogens, the 
product being named dehydroascorbic acid. The reversible oxidation with iodine was 
analogous to the known reaction with 2,3-dihydroxymaleic acid, indicating the possible 
presence of an ene-diol grouping, C(OH)=C(OH). Despite the acidity of the ascorbic acid, a 
carboxylic group was not found to be present. Dehydroascorbic acid was shown to be a 
neutral lactone, and with the easy inter-conversion between the two compounds, the possibility 
of ascorbic acid also being a lactone was indicated .. It was also known that two more alcoholic 
OH groups were present. Further reaction resulted in the formation of a derivative which still 
contained the two enolic hydroxyls. Further oxidation of the dehydroascorbic derivative 
yielded oxalic acid and threonic acid. This established the stereochemical relationship of 
natural ascorbic acid as be~onging to the L-series of sugars and also confirmed that the lactone 
carbonyl was directly adjacent to the ene-diol grouping. A series of organic reactions was 
carried out on the compound in an attempt to establish the size of the lactone ring. Ascorbic 










Figure 1.1 Fischer projection formula (left) and structural formula (right) of L-
ascorbic acid [1]. 
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The Birmingham group confirmed the structure of ascorbic acid by developing a 
synthetic route to L-ascorbic acid. The physical properties of L-ascorbic acid have been 
summarised in Table 1.2. 
Table 1.2 A summary of the physical properties of L-ascorbic acid [1}. 
Nomenclature 
Melting Point ec) 




(g.lOO em -3 @ 20° C) 
Density 
Hexuronic acid, cevitamic acid, redoxon 
L-ascorbic acid, L-xylo-ascorbic acid 
L-threo-2,3,4,5 ,6-pentahydroxyhex-2-eonic acid-4-lactone 
L-threo-hexono-1,4-lactono-2-ene 
-
190- 192 °C with decomposition 
176.14 
first (C-3-0H) = 4.25 
second (C-2-0H) = 11.79 
[a]0 20 = + 23° in water 
33(water), 3( ethanol), 1(glycerol), insoluble in benzene, 
ether, chloroform, fats and oils 
1.65 g.cm-3 
The work, published in 1933, was the culmination of painstaking and laborious synthetic 
chemistry; as such, it was appropriate that the Nobel Prize was awarded to Szent-Gyorgyi in 
1937. The growth and development of spectroscopic techniques in the years following the 
successful elucidation of the L-ascorbic acid structure have enabled it to be examined more 
closely. Further instrumental analysis of the structure of ascorbic acid included X-ray 
6 
Ascorbic Acid and Calcium Oxalate Kidney Stone Formation 
diffraction, ultraviolet spectroscopy, infrared spectroscopy, nuclear magnetic spectroscopy and 
mass spectrometry [1 ]. 
1.1.3 Medica/Aspects 
The exact physiological role of ascorbic acid is not fully understood, despite its 
numerous successful applications in various unrelated medical situations. Ascorbic acid has 
been used in the treatment of scurvy for hundreds of years. It has also been used in other 
medical conditions, with the result that megadose quantit~es are consumed daily. This is far in 
excess of the relatively tiny amount needed to prevent scurvy. Ingestion of quantities which 
significantly exceed the recommended daily diet are a cause of some concern since these 
excessively high intakes may cause undesirable side effects such as diarrhoea (2] and the 
possible increase in the kidney stone forming potential of the urine [1]. 
There are a number of diseases other than scurvy which have been associated with 
ascorbic acid deficiency, including anaemia, hypochondriasis and depression. Although it is 
widely believed that scurvy has been eliminated as one of the deficiency diseases in the western 
world~ it still exists in the chronically ill, the institutionalised elderly, chronic alcoholics and 
various other groups. For a healthy individual, 10 mg daily of the vitamin will prevent the 
onset of this disease, which seems to manifest when the body pool of ascorbic acid drops 
below 300 mg [1 ]. 
Increasing daily ascorbic acid dosage to approach megadose proportions is of little 
benefit, since absorption of the vitamin is limited. Approximately 95 % of a 100 mg daily dose 
is absorbed, whereas only 20% of a 5 g daily dose is absorbed [1]. The low renal threshold 
ensures that excess plasma levels are excreted and that there is a rapid increase in liver _ 
ascorbate catabolizing enzymes. When the plasma pool is between 1.4 and 2.0 %, the tissues 
are probably saturated with a body pool of up to 3000 mg [1]. Any excess dietary ascorbic 
acid is then excreted in the urine as ascorbic acid or one of its oxidative products such as oxalic 
acid. If there is a deficiency the tissues will absorb the ingested ascorbic acid; however once 
the tissues are saturated or if they are saturated at the outset of ascorbic acid ingestion, most of 
the ascorbic acid is excreted during the next 24 hours [1 ]. 
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In addition to the prevention and treatment of scurvy, ascorbic acid is used 
therapeutically in numerous other situations such as surgery, physical trauma and duodenal 
ulcer treatment since the vitamin is known to assist in the healing of wounds as well as to aid. 
the body in fighting and preventing infection. Ascorbic acid is also used in cases of diarrhoea, 
fever and in instances where the risk of inflammation and infection is high. Ascorbic acid can 
also be used in conjunction with iron supplementation in cases of anaemia due to a deficiency 
of iron. Controversy surrounds the use of ascorbic acid in a number of medical conditions, 
ranging from the common cold to mental illness, infertility and cancer [1 ]. 
1.1.4 Toxic Effects 
Since Linus Pauling's suggestion that ascorbic acid m(ly decrease the chances of cancer 
[cited by 1], many conflicting opinions have arisen in the literature, with the suggestion that 
ascorbic acid may even cause cancer. Evidence in this respect is mainl~ based on animal 
experimentation and is difficult to extrapolate to the human situation. Further concern, and of 
implicit rele~ance in this study, is that the conversion of ascorbic acid to oxalic acid results in 
an increase of oxalate in the body and hence increases the risk of calcium oxalate kidney stone 
formation. Large doses could also have the effect of slight discomfort of the intestinal tract, 
resulting in diarrhoea. Ascorbic acid may also be administered to enhance the effect of drugs 
that increase urinary output in patients with iron-overload. This is of some concern since the 
vitamin may actually increase the toxicity of iron which may lead to myocardiopathy in some 
patients. 
1.2 Oxalic Acid 
_ Since calcium oxalate concrements are the most common type of kidney stone [3], a 
discussion of the chemistry and the properties of oxalic acid is of importance in defining the 
pathogenesis of calcium oxalate nephrolithiasis T4]. Furthermore, since an understanding of 
the mechanisms underlying the formation of calcium oxalate stones is essential, much interest 
in the metabolism and excretion of urinary oxalate exists [5]. While calcium metabolism and 
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excretion have been investigated at length with regard to its relationship in nephrolithiasis, it is 
only in recent years that more attention has been focused on oxalic acid. 
1.2.1 Physiochemical Aspects 
Oxalic acid is the simplest carboxylic acid found in nature [3]. It is a significant 
constituent of many leafy green vegetables and plants and is also extensively used in industry as 
a cleaning agent. It is a strong orga·nic acid which forms acidic and neutral esters and diesters 
and mono- and diamides. The principle significance of oxalic acid in man is the precipitation of 
the calcium salt, which is extremely insoluble. The solubility is little affected by a change in pH 
in the range found in urine [6]. Ryall et al. [7] indicate that even though controversy 
surrounds urinary pH of stone formers as opposed to normal control subjects, pH does infact 
have an effect on the solubility of calcium oxalate crystals. Since calcium oxalate is insoluble, 
urine is often supersaturated with crystals of this salt [8]. There is much evidence to suggest 
that calcium · oxalate crystallization is retarded in normal urine by a wide range of 
inhibitors [7, 9]. 
1.2.2 Dietary Sources and Absorption 
Oxalic acid is found in a variety of fo9'fstuffs. Some oxalate rich substances have been 
summarised in Table 1.3 [5]. It is difficult to estimate the average dietary intake of oxalate, 
primarily because of the problem of complete extraction of oxalate from foods in the 
experimental assays [3]. This is emphasised in a practical manner when oxalate content in tea 
and coffee is examined. The amount of oxalic acid in tea and coffee will depend on the 
.strength of the beverage. Past reports have indicated a wide range of oxalate intake, from 
100- 1000 mg in a 24 hour period [Zarembski et al. 1962, cited by 3]. 
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Table 1.3 A range of foodstuffs known to be rich in oxalate [5]. 
beans chocolate marmalade strawberries 
beetroot cocoa parsley sesame seeds 
carrots coffee rhubarb tea 
celery grapefruit spinach 
Absorption of oxalic acid by the gastrointestinal tract is of interest due to hyperoxaluria 
and other gastrointestinal diseases [10]. In normal man, gastrointestinal absorption of oxalate 
is generally poor. A large proportion of the oxalate ingested exists as relatively insoluble 
calcium oxalate and, as a result, the crystals remain in the lumen of the gut. Dietary oxalate is 
known to contribute between 10 % [5] and 20 % of the urinary oxalate [11 ]. Research has 
indicated that during fasting, approximately 2.3 to 4.5 % of the administered oxalate load is 
absorbed [12]. However, the use of 14C-oxalate has shown that approximately 12 % of the 
· administered tracer load is absorbed in the fasting state [ 4]. 
Furthermore, various animal studies have shown that the absorption takes place over the 
whole tract, including the colon, and that the process is not a carrier-mediated process, but 
rather a non-energy requiring, non-saturable diffusion process [13] which is influenced by the 
concentration of free calcium in the intestinal lumen [11 ]. The mechanism of passive diffusion 
described by Binder [13] indicated that if the human intestine showed a similar mechanism of 
oxalate absorption as in animals, then the rate of qxalate absorption would be influenced by the 
concentration of oxalate in the luminal fluid (i.e. an increase in oxalate concentration in the 
fluid of the gut would result in increased absorption). Thus, it is probable that the moderately 
increased oxalate excretion in stone formers is due to a small increase in oxalate absorption, 
which in turn is due to the fall in the intraluminal concentration of calcium [11 ]. 
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1.2.3 Excretion and Renal Clearance 
Calcium oxalate is known to form a large percentage of upper urinary tract concrements .. 
It is precipitated in urine which is supersaturated with respect to calcium oxalate. The 
solubility of this compound is very low, even in aqueous solution; about 7 mg dissolves in 
1000 cm3 of distilled water [5]. The concentration in urine is always higher than this value but 
other urinary components contribute to its solubility. The presence of oxalate in the urine 
reduces its stability and it may thus be that even slight changes in oxalate concentration may 
result in serious effects on its crystallization properties. 
Urinary oxalate is important for the following reasons : 
• the majority of urinary concrements are composed of calcium oxalate [5, 14, 15], 
• the most common type of crystalluria is calcium oxalate, and 
• oxalate exerts a pronounced effect on the crystallization properties of urine . 
Oxalate has been shown to have a more powerful effect on the degree of calcium oxalate 
supersaturation in urine than has calcium [16]. Despite the enormous potential effects of 
oxalate on urolithiasis, relatively few investigations have been carried out in an attempt to 
establish the role of oxalate in the pathogenesis of the disease [7]. A possible explanation may 
lie in the fact that uri~ary oxalate is notoriously difficult to measure. To further complicate 
oxalate measurement in urine, ascorbic acid, if present, converts spontaneously to oxalate, 
particularly-in alkaline conditions [17]. This must be taken into account when reviewing 
-
previous literature relating the oxalate excretion of stone forming individuals and normal 
controls. Robertson et al. [18] state that "the inability to measure urinary oxalate accurately 
and precisely undoubtedly accounts for many of the apparent discrepancies between those 
investigators who have found significant differences in urinary oxalate amongst idiopathic 
stone formers and those who have been unable to do so". A literature search reveals several 
studies which report significantly higher oxalate excretion in stone formers than in normal 
individuals [5, 18, 19, 20, 21]. However, there are numerous papers which- indicate the 
contrary [22, 23, 24]. A contributory reason for this dichotomy of opinion could be due to the 
nature of the wide daily fluctuations observed in many of the chemical components of the 
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urine [7]. As mentioned earlier, in addition to the already technically difficult assay, is the 
complication of ascorbate interference. As a result, investigations which did not take 
preservative precautions in order to prevent this conversion or which employed oxalate assays 
which promote conversion, should be regarded with caution. 
Average oxalate excretion at night is generally found to be lower than average oxalate 
excretion during the day [25]. There are several factors which may cause an increase in 
oxalate excretion during the day. These include an increase in dietary oxalate during the day, 
the intake of oxalate precursors such as ascorbic acid, an increase in metabolic activity and a 
higher urine flow [5]. 
Urinary oxalate is derived from endogenous synthesis and absorption of oxalate in the 
gastrointestinal tract. Oxalate is a metabolic end product in man which cannot be further 
degenerated. As such, it is excreted virtually unchanged in the urine [3]. The metabolic 
pathways producing oxalate are shown in Figure 1.2. 
Serine Glycolate Hydroxyproline 
1r 
2 G!o lf 
PLP 
Glycine Glyoxalate a-OH ~-Ketoadipate 
LDH 1 4 3 xo TPP 
GAO a KG 
Ascorbate Oxalate Dietary Oxalate 
1 
Figure 1.2 The known metabolic pathways in formation of oxalate in humans [5}. See 
text for details. 
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The two major sources of oxalate in man are the conversion of ascorbate to oxalate and 
the metabolic pathways of glyoxylic acid [3]. Oxalate production is an intricate network of 
reactions. The pathways to the formation of oxalate are discussed below. The numbers in 
parentheses correspond to the relevant pathways in Figure 1.2. 
The conversion of ascorbic acid to oxalate (1) is of particular interest, especially since 
many members of today's health conscious society ingest large amounts of ascorbic acid on a 
regular basis [5]. This will be discussed in detail in Section 1.3. 
The inter-conversion of glyoxylate and glycine (2) has aroused great interest. Essentially this 
reaction is a transamination with the active form of vitamin B6 as the co-factor [5]. Literature 
investigations indicate that vitamin B6 may prevent calcium oxalate stone formation [26, 27]. 
However, Tiselius [5] provides conflicting statements on the nature and effect of vitamin B6 
and its active form, pyridoxyl phosphate. Glyoxylate is a very important precursor of oxalate 
and the series of metabolic reactions concerned with the conversions of this reactive substance 
are complex. Briefly, lactic dehydrogenase (LDH) and nicotinamide adenine dinucleotide 
oxidise glyoxylate to oxalate (3) in the cytosol [Sawaki et a/. 1966 cited by 3]. Glycolic acid 
oxidase (GAO) and xanthine oxidase (XO), although both capable of catalysing the conversion 
of glyoxylate to oxalate (3), are documented to be not of significant importance [28]. A 
further interesting process is the conversion of glyoxylate to a-hydroxy-(3-keto-adipate ( 4) by 
means of a-keto-glutarate (a-KG). The reaction requires both thiamine pyrophosphate (TPP) 
and Mg2+. It is the major degradation pathway for glyoxylate and hence a low activity in this 
process would probably increase the formation of oxalate [5]. The inter-conversion of 
glyoxylate and hydroxyproline (5) is also not significant and hydroxyproline does not appear to 
be an important precursor of glyoxylate or oxalate [29]. The oxidation of glycolate ·to 
glyoxylate (6) is driven by glycolic acid oxidase (GAO). 
Renal clearance of oxalate has been studied by isotopic methods [30, 31 ]. Filtration of 
oxalate at the glomerulus seems to be complete in view of the absence of significant protein 
binding of oxalate in the plasma. An oxalate : creatinine clearance ratio greater than one 
indicates that active secretion of oxalate must occur at some stage in the renal tract [30]. 
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Numerous attempts have been made to determine the amount of oxalate absorbed by the 
gut. Tiselius [5] summarises the data from previous research. The absorption appears to be in 
the range of 2- 12% and assuming an average intake of oxalate of about 1 - 2 mmol per day, 
the dietary contribution to urinary oxalate is of the order 0.02 - 0.24 mmol. Oxalate rich foods 
would clearly increase this (Table 1.3). 
Oxalate is absorbed in the gut by two processes: passive diffusion and active transport. 
The addition of metabolic inhibitors does not affect these processes. Absorption of oxalate is 
determined by the constituents of the intestinal fluids, the most important being calcium [5]. A 
high concentration of calcium oxalate in the intestine coincides with a reduced oxalate 
absorption. There are several other substances which form complexes with oxalate such as 
magnesium, aluminium and cholestyramine. 
Hyperoxaluria is the abnormally high excretion of oxalate in the urine [32]. There are 
several interrelated nutritional links to hyperoxaluria and calcium oxalate stone formation, 
other than ascorbic acid. These factors are listed in Table 1.4. 
Table 1.4 Nutritional links related to hyperoxaluria and calcium oxalate 
stone formation [33}. 
High oxalate consumption 
Low calcium intake 
Low magnesium intake 
Ingestion of the common food preservative, EDT A 
Primary or secondary deficiency of vitamin B6 
High dietary tryptophan 
Primary or secondary deficiency of vitamin B1 
High blood levels of vitamin D 
High sucrose intake 
Inadequate water consumption 
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The major causes of hyperoxaluria can be classified as two key pathogenic mechanisms : 
firstly, increased endogenous production of oxalate [3] primarily from its immediate precursors 
which include ascorbate, glyoxalate and glycolate [32] and secondly, increased oxalate 
excretion secondary to increased uptake or gastrointestinal absorption of oxalate [3] (i.e. the 
exogenous production of oxalate [5]). 
The causes of hyperoxaluria in their respective pathogenic mechanisms summarised by 
Tiselius [5] are listed in Table 1.5. 
Table 1.5 Possible causes of hyperoxaluria. 
Endogenous Oxalate Exogenous Oxalate 
Ascorbate in excess Excessive dietary oxalate 
Vitamin B6 deficiency Enteric hyperoxaluria 
Primary hyperoxaluria 
Intake of other oxalate precursors 
1.3 Ascorbic Acid and Kidney Stone Disease 
Urinary oxalate is essentially derived from 3 major sources : dietary oxalate, conversion . 
of two-carbon metabolites from glycolaldehyde and from ascorbic acid (34]. It has been 
established that dietary oxalate contributes approximately 20 % of the urinary oxalate (11 ], 
40 - 50 % by two-carbon metabolites [35] and 30 - 50 % by ascorbate [36, 37]. The 
proportions from any one source will depend on the intakes of other exogenous sources and 
the rate of endogenous production [38]. 
It is well established that L-ascorbic acid metabolises to oxalic acid in the manner shown 
in Figure 1.3 (38]. Despite the fact that this conversion is well known, the complete metabolic 
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processes are not fully understood. It has however been established that the carbon atoms 
involved in the formation of oxalic acid are carbon atoms one and two [36]. 
L-Ascorbic Acid 
L-De hydro Ascorbic Acid 
-~ 
' 
2,3 Diketo L-Gulonic Acid 
Oxalic Acid + L-Threonic Acid 
Figure 1.3 The biochemical pathway of the conversion of ascorbic acid to oxalic acid. 
Absorption of ascorbic acid by the gut is an energy requiring process (Hornig et al. cited 
by 39]. The reabsorption mechanism for ascorbic acid appears to be limited to a maximum rate 
of 2.16 cm3.min-1; thus when the vitamin is presented to the tubules at a rate greater than this, 
the excess ascorbic acid is excreted in the urine [40]. The proportion of ascorbic acid excreted 
unmetabolised in the urine increases with increasing ascorbic acid intakes [39]. Thus, as the 
dose increases, the absorption decreases and the process eventually attains a level· of 
saturation. It has been reported that large doses of ascorbic acid result in an excretion of 
approximately 80 % unchanged ascorbate in the urine [Takenouchi, 19~6 cited by 41 ]. It has 
been suggested that given the efficient elimination by the kidney an~ limited absorption of 
ascorbic acid by the intestine, the chances of ascorbic acid overload are unlikely [Hornig et al. 
cited by 39]. 
Surveys indiCate that 66 % of the general public uses vitamin and mineral supplements, 
either as multivitamins that include ascorbic acid, or alternatively, ascorbic acid on its own 
[33]. In today's health conscious society, ingestion of megadoses of ascorbic acid in excess of 
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the recommended daily allowance is common [42]. This is a cause of some concern 
considering that there is much controversy regarding the possibility that excessive dosage of 
ascorbic acid can increase intrarenal levels of oxalate to which the vitamin is metabolised, and 
hence that it can increase the risk of calcium oxalate lithogenesis. 
Members of the medical fraternity have expressed concern about the long term use of 
ascorbic acid, and warn of its side effects [43, 44, 45]. Lamden [46] indicates that despite 
ascorbic acid being a highly valuable and useful substance, it is an exceptionally reactive 
compound biochemically and should thus be treated with respect. His concerns related to 
ascorbic acid ingestion do not only involve the elevated oxalate levels in the urine which may 
promote the possibility of kidney and bladder damage due to the formation of stones, but 
include various other medically related disorders. Briggs [44] reports a case study of a 21 year 
old male who after daily ingestion of 4 g of ascorbic acid showed an increase in urinary oxalate 
11 times greater than when no ascorbic acid was being taken. Briggs remarks that the 
occurrence of individuals with high capacity to convert ascorbic acid to oxalate is probably 
rare, but unless they are identified, ascorbic acid supplementation at high doses could have 
undesirable results. There are numerous other papers which show that the ingestion of 
ascorbic acid increases the concentration of urinary oxalate significantly [25, 41, 42, 43, 47, 
48]. On the contrary, practitioners who have been prescribing high daily dosage of ascorbic 
acid for both short and long periods do not report any toxicity [2, 49]. Other research· studies 
have challenged the fact that oxalate levels are significantly raised, drawing attention to the 
various possible sources of error [38, 50, 51, 52, 53]. Singh et al. [54], show that ascorbic 
acid alone does not cause stone formation, though it may increase oxaluria in higher doses. A 
study by Hatchet al. [41] indicated that a significant increase in urinary oxalate occurred a 
week post cessation of ascorbic acid, ratber than during the period of ingestion. This suggests 
that ascorbic acid may be retained and the effects delayed, possibly only manifesting after a 
dormant period. 
L-ascorbic acid serves as a precursor of urinary oxalate in man, providing up to a third of 
the oxalate present in urine [36]. This pathway appears to have a low capacity since large 
amounts of ascorbic acid only cause moderate increases in urinary oxalate [55]. However, 
because the solubility of calcium oxalate in urine is low, even a small increase in urinary oxalate 
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in patients who are already hyperoxaluric could increase the likelihood of kidney stones [56]. 
Since the conversion of ascorbate to oxalate does occur, it might be expected that people with 
high ingestion of ascorbic acid may have high urinary oxalate. The literature however shows a 
conflicting picture, which can be divided into three sequences [38] : 
• high intakes of ascorbic acid result in only a few cases of increased urinary oxalate; . 
• increase of urinary oxalate is moderate and occurs only in cases of extremely high 
ascorbic acid intake; 
• large increases in urinary oxalate occur in most people on a high ascorbic acid load. 
In an attempt to distinguish between these three groups, Hughes eta/. [38] discovered a 
new pattern. Experimentation was carried out using four groups of subjects, each on different 
dietary loads of ascorbic acid. All subjects collected control urines (no ingestion of ascorbic 
acid) prior to ingestion of ascorbic acid loads of 1 g, 3 g, 6 g and 9 g per day. The results did 
not fall into any of the categories, but seemed to form a new pattern. Urinary oxalate 
concentration of each group was approximately doubled relative to control values, despite the 
different ascorbic acid loads. Thus, although there was an initial increase in urinary oxalate 
excretion, oxalate concentration in the urine did not increase with increasing ascorbic acid 
loads. None of the subjects showed a massive increase in urinary oxalate excretion, even after 
a load of 9 g of ascorbic acid per day [38]. The absence of the expected dose response curve 
(increasing urinary oxalate with increasing ascorbic add ingestion) can partly be explained by 
the fact that as the ·ascorbic acid dose increased, the percentage of urinary ascorbate 
(presumably an indication of absorption) decreased. An intake of 1 g of ascorbic acid daily 
resulted in a urinary excretion of ascorbate of 45 %. As the dose increased to 9 g of ascorbic 
acid daily, the proportion excreted decreased to 18 % [38]. The remaining ascorbic acid is 
presumably not absorbed since the active absorption mechanism of ascorbate in the gut is 
saturated. Hughes' study was conducted using normal controls. Obviously, further 
investigation is necessary using patients with urolithiasis [38]. 
Possible reasons for the conflicting opinions regarding the potential risk of kidney stone 
formation after ascorbic acid ingestion are- based on the type of data presented [42], the 
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precautions taken during the study and the methods of analysis, particularly for oxalate (38, 
41 ]. Methodology also includes storage of urine prior to analysis. Ascorbic acid is unstable in 
the pH range 1 to 12, but within this range it is more unstable at a higher pH [17]. Thus, at 
higher pH values, the conversion of ascorbate to oxalate occurs more rapidly leading to oxalate 
values that may be erroneously high. Addition of disodium-ethylenediaminetetraacetic acid 
(EDTA) as a preservative (17] is considered necessary to lower the pH of the urine and to 
reduce the conversion of ascorbate to oxalate by chelating the ascorbate in the urine. If a 
preservative is not used, the data obtained may give erroneously high results. Ascorbic acid 
encounters both acidic and basic conditions in the gastrointestinal tract and in urine [57], and 
hence it is of some consequence that a knowledge of the principle metabolic paths of the 
compound be established as this would be of considerable medical importance. A number of 
the older techniques used in the measurement of urinary oxalate adjust the pH of the 
experimental analyte to pH 7 with ethanol and leave the determinations to stand overnight for 
the precipitation of oxalate as the calcium salt [58]. As discussed, conditions of higher pH 
result in an increase in the conversion of ascorbic acid to oxalic acid, resulting in erroneous 
concentrations of urinary oxalate. Certain methods of analysis also require heating of the 
sample [58]. Experimental work in this area, carried out by Fituri et al. [52], indicates that 
heating the urine sample with raised ascorbate concentrations at 100 °C for 30 minutes results 
in significant increases in urinary oxalate concentrations, suggesting that the conversion of 
ascorbic acid to oxalic acid is promoted under these conditions. 
Furthermore, the purity of the ingested ascorbic acid preparations used in various studies 
has been questioned [52, 59]. The presence of tartaric acid in ascorbic acid tablets, may result 
in higher urinary oxalate since tartaric acid itself is metabolised to oxalate in man [60]. 
Sucrose is known to increase urinary oxalate [61] and thus increases the risk of urolithiasis. 
Hence the presence of tartaric acid .or sucrose in ascorbic acid preparati"ons may have resulted 
in exaggerated urinary oxalate levels. It is thus suggested that raised ·oxalate may be due to 
assay procedures [52] resulting in in vitro conversion of ascorbate to oxalate or perhaps it may 
be due to the ingestion of impure ascorbic acid. 
Investigation into the effects of ascorbic acid have been carried out in both normal 
subjects and renal stone patients [42]. Chalmers et al. [47] observed that recurrent stone 
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formers had consistently and significantly lower values for ascorbate excretions than did their 
normal counterparts. These results were unexpected, since from a biochemical point of view, 
it would have been expected that increased urinary oxalate and ascorbate excretion would be 
parallel to one another since ascorbate is a major precursor of oxalate [37]. Chalmers eta/. 
[47] found that this held for control samples, but thai this was not the case in stone forming 
individuals. These results indicate that there may be an impairment in the handling of ascorbate 
by stone formers. The increased oxalate and decreaSed ascorbate in stone formers can be 
explained in one of two ways : 
• 
• 
there is poor absorption of ascorbate from the gut, and hence unabsorbed ascorbate 
conversion to oxalate may occur at this site, with subsequent absorption of oxalate, or 
normal absorption of ascorbate by the gut, but there is an increased metabolism of 
ascorbate to oxalate in the tissues or urinary tract [47]. 
A subsequent study has shown decreased urinary excretion of ascorbate as well as citrate 
(both hydrocarboxylic acids) in stone forming individuals [21 ]. These authors suggest a 
possible inherent defect in a common carrier which absorbs hydroxycarboxylic acids from the 
gut. In the study [21 ], citrate and ascorbate were investigated in conjunction with one another 
in order to establish whether there is in vivo competition between the two for transport by a 
common carrier in the gut. Results indicated that citrate significantly hindered the uptake of 
ascorbate into the blood when given a combined load of ascorbate and citrate [21]. Maximal 
inhibition of ascorbic acid excretion was shown to occur 2 - 3 hours after the ingestion of the 
combined load. The results suggest a common-carrier for the two structurally related anions. 
In the period 4 - 5 hours aft~r the load, an increase in ascorbic acid uptake may indicate an 
increased availability of the carrier for ascorbate after the citrate has been cleared from the gut. 
The inhibition of ascorbic acid absorption by citrate is important in urolithiasis since the 
presence of citrate in stone forming individuals will enhance the malabsorption of ascorbic 
acid. 
Lewis [cited by 33] has a completely different point of view to most other workers 
regarding an increase in urinary oxalate levels. He suggests that raised oxalate levels may in 
fact prevent stone formation in several ways. Firstly, multigram doses of ascorbic acid result in 
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increased ascorbate in the urine, which will decrease the pH resulting in a decrease in calcium 
oxalate precipitation. Secondly, ascorbic acid in the urine is free to bind with the calcium ions, 
thereby reducing the likelihood of calcium oxalate precipitation. Furthermore, the spillage of 
ascorbic acid into the urine increases diuresis. Since stone formation requires static conditions, 
the increased flow of urine will decrease the probability of stone formation. 
The history of ascorbic acid and oxalic acid is interesting and the possible effects of the 
two components on urolithiasis is most significant. However, numerous other factors play a 
role in kidney stone disease. The following section incorporates these interrelating factors of ,,-. 
urolithiasis together with a history and background of this .disorder. 
1.4 Urolithiasis 
1.4.1 Historical Background 
Renal calculus has been recognised as a medical disorder which can be traced back 6680 
years, the age of a bladder stone removed from the mummy of an Egyptian Pharaoh housed in 
the British Museum [62]. Stone is one of the most common and distressing maladies dating 
back to pre-Christian times ( 460 to 370 BC) [63]. Goldman eta/. [64], give a comprehensive 
history of stones and the treatment thereof in ancient Egyptian times, the Middle Ages, and in 
numerous parts of the ancient and more modem day world. Hippocrates, [Joly 1931, cited by 
65], recognised both renal and vesical calculus, but would not allow his students to perform 
surgery. The Hippocratic oath states : 
"Neither will I cut them that have stone but will leave this operation to those who are 
accustomed to perform it". 
The oath resulted in wandering lithotomists who operated on bladder calculi until the end 
of the 17'h century. These aspirant urologists were described by William Clowes (1540 -
1604), surgeon to St. Thomas' Hospital, as "no better than runagates and vagabonds, 
shameless in countenance, lewd in disposition, brutish in judgement and understanding". The 
operators mutilated or killed more than they saved. The operation was only carried out 
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because the agonies of stone disease were so terrible. Thus, it is not surprising that some stone 
sufferers resorted to operating on themselves in order to relieve the pain caused by kidney and 
bladder stone. Possibly the mosf famous of these is Jan de Doot, a Dutch ~lacksmith, who. 
removed a 115 g stone from his own bladder whilst his wife was at the fishmarket. He 
survived the ordeal and today is immortalised in a famous painting which hangs in the Leiden 
Museum, showing him proudly displaying the stone in his left hand and the knife in his right 
hand [64]. 
Surgical methods were developed towards the end of the 17th century, but the operation 
remained plagued with infection and the difficulty of ·the surgical removal of stone was 
prominent, even into the 19th century [64]. The high incidence of urinary calculi and the 
ghastly nature of lithotomy and its consequences resulted in the search for a means to dissolve 
stones in the bladder [64]. Herbal remedies and concoctions:from plants were recommended 
from the 1st century for stone disease as well as other ailments, none of which were effective. 
Patients in England resolved to overcome the distress of stone disease by usil).g the popular and 
notorious potion devised by Joanna Stevens, who revealed the formula after a sum of five 
thousand pounds had been paid. It consisted of old tobacco-pipes (clay), eggshells, snail 
shells, soap, saxifage, burdock seeds and a few other common vegetable extracts [Joly, 1931 
cited by 63]. 
The development of renal surgery for stone was continued through the 18th and 19th 
century. The application of anaethesia and antiseptics by the late 19th century resulted in a 
decrease inmortality as a result of nephrectomy from 80 % to 8 % [66]. In modem-day 
medicine, numerous treatments to remove kidney stones are performed. Despite the existence 
of these procedures and the progress in the concepts of calculogenesis, many aspects 
concerning the cause and prevention of urinary lithiasis remain a mystery. 
1.4.2 Epidemiology of Stone Formation 
Urinary lithiasis is a world-wide [67], multi-factorial disease [68], the incidence of which 
has increased dramatically in wealthy industrialised communities during the last century [69]. 
Renal stone as it occurs in developed countries is twice as prevalent in males than in females, 
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although the ratio of incidence approaches unity in the earlier and again later decades [70, 71 ]. 
The incidence of the disease is influenced by a diverse range of external factors which include 
geography, climate, environment and nutrition [70]. 
Table 1.6 shows these and other factors which may influence the formation of urinary 
calculi [65]. Renal calculi can seldom be attributed to one factor on its own, but rather a 
combination of these. Inspite of these factors, the cyause of urinary lithiasis has not been 
identified, although the factors shown in Table 1.6 have set the scene into which all hypotheses 
of causation of the condition may eventually fit [70]. 
Table 1.6 Factors influencing urinary stone disease. 
Geography Drinking Water 
Climate Drugs and Medication 
Occupation Infection 
Race Metabolic Disorders 
Diet Genetics 
"Stone belts" have been known to exist inparticular areas of the same country. In these 
regions the- incidence of stone disease is higher per capita than anywhere else in the country 
[72]. One of the contributory factors in-regions where this occurs, such as the south east of 
the United States, could be climate. In exceedingly hot areas, dehydration occurs more 
frequently; if people do not adequately replenish the loss of liquid by increasing their fluid 
intake [65], stone formation may occur. In hot climates, there is enhanced loss of liquids due 
to perspiration [73]. This results in a decrease in urinary volume and increase in urinary pH, 
together with high urine osmolality, higher concentrations of calcium and oxalate and other 
stone forming urinary constituents [74]. These features contribute to an increased likelihood 
of stone formation. Exposure to the ultra-violet (UV) portion of the sun's rays promotes the-
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formation of vitamin D3 which increases the intestinal absorption of calcium, calciuria and , 
stone frequency [73, 74]. Climatic effects can however be controlled. A diminished incidence 
of stone disease was found in populations which had been instructed on the importance of 
hydration in a hot climate [75]. Indigenous populations of hot desert areas tended to have 
higher fluid intake and fluid output than immigrants. In geographical considerations of the 
disease, Anderson (1972) [cited by 70] related the differences in incidence to the development 
and economy of the countries and communities. 
Community surveys in technically developed countries indicate that stone disease is more 
prevalent in certain occupation groups than in others [70]. Professional groups and sedentary 
working environments seem to have a higher incidence of stone disease than persons in more 
active jobs, presumably because the daily routine of the former requires less physical effort 
[65]. Blacklock showed in 1969 [76] that within the Royal Navy, offic~rs a1_1d personnel with 
predominantly sedentary work showed a higher incidence of stone disease than in the British 
naval seamen. 
Numerous investigators have shown that a non-physiological dietary regimen in the form 
of insufficient fluid intake [73] and the excessive consumption of foodstuffs containing 
lithogenic substances may play a crucial role in calculi formation [68]. Anderson has been 
able to establish that a general relationship exists between economic and cultural development 
of a country and the type of stone incidence [Anderson, 1967, cited by 63]. A deficiency in 
animal protein is known to increase the incidence of stone disease. Anderson (1972) [cited by 
70] reported a virtual disappearance of this condition in populations with a high incidence of 
stone disease after the introduction of sufficient animal protein into the diet. From the same 
source, although not specifically remarked on by Anderson, is that in areas of high sugar 
consumption per capita, upper urinary tract stone is more common. There are a number of 
possible links between refined carbohydrate intake and urolithiasis [70]. Hypercalciuria and 
raised oxalate levels are known to increase the possibility of urolithiasis since calcium oxalate 
crystals commonly occur in the disease. Lemann et al. [77] have shown that an increased 
intake of glucose or sucrose resulted in an increase in urinary calcium levels in both normal and 
stone forming subjects, but the calcium excretion levels increased to a much greater extent in 
the stone forming patients. Increased intestinal absorbance of calcium may also account for an 
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increased oxalate excretion in the urine since there will be less calcium available for oxalate 
binding. Increased dietary oxalate may increase excretion of oxalate (5]. As a result patients 
are advised to avoid foods rich in oxalate (65] (Table 1.3). 
The chemical composition of drinking water may also play a vital role in stone formation. 
"Soft" water is deficient in magnesium, a natural inhibitor of stone formation. It is therefore 
expected that regions in which water is "soft" may have a higher incidence of urolithiasis. 
Research has shown that in regions where drinking water is "hard", the incidence of urolithiasis 
is reduced [78, 79]. Magnesium competes successfully with calcium for free urinary oxalate 
resulting in the formation of soluble magnesium oxalate rather than insoluble calcium oxalate. 
Magnesium oxalate is passed in urine with no harmful effects (65]. Some researchers suggest 
that the chemical composition of water has no effect on urolithiasis [80]. However, there are 
reports that dietary t:1ctors in combination with "water softness" may play a role in stone 
formation (81 ]. 
Certain drugs and medications have side effects which are well known in urinary 
disorders. Antacid tablets, taken for peptic ulcers, contain silica and many a case has been 
reported where patients on antacid treatment (magnesium trisilicate oral compound BP) for 
many years have formed pure silica stones [82, 83, 84]. 
Urinary infection accounts for 15- 28 % t of all stone types [65]. Infection stones occur 
more frequently in females (85] since they are more susceptible to urinary tract infection. 
Westbury [85] has shown that the typical "male" stone is made up of calcium oxalate and the 
typical "female" stone conforms to the triple phosphate or carbon-apatite pattern, frequently 
staghorn in appearance. 
Certain ethnic groups such as South African blacks, Indians of Mexico and Peru and 
Eskimos appear to be immune to stone formation. Although diet appears to play an important 
role in these findings, physiological conditions present in particular race groups cannot be ruled 
out [65]. Despite the cases which show the genetic predisposition to stone formation in the 
ethnic groups (86], findings in general detract from the importance of genetic and heredity 
t An examiner highlighted that a recent series of more then 4500 stones revealed that approximately 10 % 
were a result of urinary infection (Wilson D.M., J. Urol., 1989, 141:770-774). 
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influences and indicate more the involvement of environmental factors including dietary 
customs [70]. 
1.4.3 Physico-Chemical Factors Governing Stone Formation 
According to Finlayson [87], the known physico-chemical features of urolithiasis can 
essentially be divided into four interrelated processes which include the supersaturation of the 
urine, nucleation, crystal and particle growth and crystal aggregation. 
The thermodynamic driving force for stone formation arises from supersaturation of 
urine with respect to urinary salts that stones consist of [87]. Ordinarily, urine is 
supersaturated with respect to calcium oxalate hydrates and calcium phosphate phases [88]. 
The three hydrates of calcium oxalates, in order of increasing solubility, are monoclinic 
monohydrate (COM), tetragonal dihydrate (COD) and triclinic trihydrate (COT) [89]. The 
less stable COT and COD crystals may precipitate and dissolve transiently, acting as precursors 
for the more thermodynamically stable COM crystals [88]. If stone formation is an extra-
cellular process, the level of saturation of the urine will determine whether crystal nucleation, 
growth and aggregation can actually occur [90]. New crystals do not form in just saturated 
solutions; in fact a high degree of supersaturation is necessary in order for spontaneous 




















Figure 1.4 The saturation zones of the urine in relation to the solubility and formation 
of the salts concerned [90]. 
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The driving force for stone formation is expressed in terms of free energy and the 
activities of the unionised salt species (A/Ao) in solution ·at any given condition and at 
equilibrium, respectively [91]. · In order for stones to grow, free energy is required since phase 
transitions, crystal growth and particle aggregation require free energy [16]. Below the 
solubility product, the urine is undersaturated and will dissolve crystals of the salt concerned 
(i.e. the free energy of formation is below zero) [90]. In this case the ratio of the activities of 
the unionised salt species (A/Ao) is less than one [87]. 
For a given stone sal~, saturation of a urine is defined as a driving force equal to one. In 
such cases, old stones will not dissolve and new stones will not form. However, aggregation 
of the existing stones can occur, resulting in growth [87]. 
If the energy of formation is greater than one, the urine is said to be supersaturated. 
Despite supersaturation, precipitation of stone crystals will not occur if crystals are not already 
present unless the ratio of the activities of the salts exceed an experimentally determined limit 
called the "metastable limit" [87]. The metastable zone may thus exist without spontaneous 
precipitation taking place [90]. If however, some nucleating material is added to a metastable 
- . 
solution, heterogeneous nucleation followed by crystal growth can occur at levels well below 
the formation product [90]. It is possible for new stones to form spontaneously and old stones 
to grow above the metastable limit [87]. 
The three extra-cellular models of stone initiation (Section 1.4.4) require urine to be 
supersaturated. However, in the case of the "matrix" hypothesis, the level of metastable 
supersaturation required for crystal growth is considerably lower than in the "inhibitor" and 
"crystallization" theories, which require a higher levels of supersaturation in order to exceed 
the level of spontaneous precipitation of the salt concerned. In each cases, once precipitation 
?as occurred, growth and aggregation can take place in the metastable zone [90]. 
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Figure 1.5 The saturation of urine with calcium oxalate (CaOx) in relation to urinary 
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Calcium oxalate supersaturation is essentially determined by the urinary concentrations 
-
of calcium arid oxalate [90]. The relative effects of increasing urinary calcium and oxalate 
concentrations indicate that oxalate is potentially more important than calcium in causing 
spontaneous crystalluria [90] since more than 50 % of urines in the upper half of the normal 
range of oxalate concentrations are above the formation product, whereas only small fractions 
of urines with high calcium concentrations exceed the formation product (Figure 1.5). When 
the effects of volume are considered, it can be seen that it is very difficult to achieve a urine 
which is undersaturated with respect to calcium oxalate [90]. 
Experimental evidence shows that urine of stone formers is supersaturated with respect 
to the salts from which their stones are formed [22]. However, it has also been shown that the 
urine of normal subjects is often supersaturated and yet stone formation does not occur. The 
essential difference must lie in the boundary conditions, the stochastic nature of the process or 
urinary inhibitors of nucleation, crystal growth and aggregation, or by some as yet 
undiscovered principle [87]. According to Robertson et a/. [90], there appear to be two 
prerequisites for stone formation : 
• 
• 
a critical period of oversaturation and crystalluria during which crystals are formed and 
retained in the urinary tract and 
a period of metastable supersaturation during which trapped crystals can grow and 
aggregate into stones. 
Nucleation reconciles the increase in free energy when a new surface is formed with the 
free energy that is lost when a material leaves solution [16]. It is described as the initial event 
in phase formation and in urolithiasis would correspond specifically with stone salt 
precipitation [87]. A review of the physical chemistry of nucleation in liquids and solids by 
.. 
Walton [92] develops points of view which have been neglected in theJiterature of urolithiasis, 
but according to Finlayson [87] should be pursued in stone research. Nucleation may occur in 
a number of ways, some of which are listed below [92] : 
• classical homogenous nucleation; 
• classical heterogeneous nucleation; 
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• classical coherent and non-coherent nucleation; 
• non classical nucleation including 
* spinodal decomposition 
* secondary nucleation. 
The initial nucleation process, which determines the size, number and morphology of the 
precipitating crystals, may occur spontaneously [88]. This is homogenous nucleation, and it 
occurs when the nucleus consists of a pure substance which is presumably crystalline in nature. 
Heterogenous nucleation occurs when some foreign material trapped in the urinary tract results 
in the metastable region being narrowed [16]. Heterogenous nucleation on a particle or 
substrate surface will generally require a lower .~upersaturation than ·that required for the 
induction of homogenous nucleation [88]. 
Secondary nucleation or the production of· additional nuclei in the presence of seed 
crystals [93] may also be important in the formation of urinary calculi. Secondary nuclei may 
result from (1) collision breeding, (2) needle breeding, (3) initial breeding, ( 4) fluid shear which 
results in particles of existing crystals breaking off due to the movement of solution, or (5) 
impurity concentration gradients at the surface of the crystals. A comprehensive explanation 
of these facets are provided by Nancollas [88]. The rate of secondary nucleation is probably 
governed by the degree of supersaturation since the latter determines the size of the critical 
nucleus. This allows different proportions of the original nuclei to survive and grow [88]. 
The size of crystals in the urine of stone formers is significantly greater than the size of 
crystals in the urine of normal subjects. Additional oxalate in the diet increases the size of the 
crystals in both groups [90]. Robertsorret a/. [90] established that while normal subjects pass 
crystals of consistently small size, stone formers' urine contain large octahedral crystals of 
calcium oxalate dihydrate which are often fused in large aggregates of 40 - 50 f..tm and 
occasionally these aggregates grow to 200 - 300 f..tm. Other studies have shown that the 
formation and retention of these aggregates in the kidneys plays a vital role in the triggering 
phase of calcium oxalate stone formation [90]. According to these workers (90], there are two 
basic differences between the urines of stone formers and those of normal subjects : 
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• there is a greater degree of calcium oxalate crystalluria in stone formers urine due to 
higher calcium oxalate supersaturation; 
• there exists a difference in the size and type of calcium o:xalate crystals between the two 
groups. 
The question now arises as to why there is a difference in crystal size. Chemically, the 
more saturated a solution, the faster the crystal growth and aggregation rates; hence in the 
supersaturated urine of stone formers, a faster rate of crystal growth can be expected [90]. 
However, this is not the only reason for higher crystal growth rate in stone formers. Normal 
' 
subjects probably excrete some substances in their urine which prevent the growth of large 
crystals and aggregates. These inhibiting substances are probably deficient in the urine of stone 
formers [90]. It has been established that stone formers do exhibit less inhibitory activity than 
normal subjects [19, 88, 94]. Inhibitors of growth and aggregation of crystals in the urine of -
normal subjects prevent the crystals from reaching a size which may become trapped in the 
urinary tract. In the absence of these inhibitors, crystals form spontaneously once the 
formation product of the salts has been exceeded. Crystal growth and aggregation then occur, 
resulting in the formation of particles which may indeed be large enough to become trapped in 
the urinary tract. The particle will continue to grow even if the urine saturation falls to within 
saturation levels of the metastable limit. The factors which will influence the growth of a stone 
lie in the balance of the precipitability of the stone components and the inhibitory activity of the 
urine [90]. 
Growth history of stones can be speculated from studies of particle growth in urine. 
Conventional crystal growth experiments involve metastable supersaturated solutions of 
calcium oxalate or phosphate being dosed with seed crystals and the rate of the reaction 
determined by measuring the decrease in concentration of lattice ions as a function of time _ 
[88]. Since the different calcium oxalate phases may form over a wide range of 
supersaturations resulting in formation and dissolution of crystal phases during the reaction, it 
is impossible to quantify the kinetics of mineralisation [88]. In particle growth studies it is 
necessary to distinguish between crystal growth and crystal aggregation [87]. 
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Flocculation refers to the tendency for small suspended particles in a liquid to form 
aggregates oi ·agglomerates [88]. Aggregates are considered to be groups of primary particles 
joined at their faces and having considerably less surface area than the constituent particles. 
Aggregation may be a very rapid process depending on the size and morphology of the 
crystallites [88]. Agglomeration is regarded as the joining of particles at the edges and 
comers, resulting in the surface area of the resulting particles being similar to the constituent 
particles. 
Aggregation is important in urolithiasis [87] since it was observed that normal subjects 
frequently passed single crystals whereas stone formers passed large crystal aggregates. 
However, relatively little work has been carried out on this aspect of urinary crystallization 
[88]. Finlayson [87] outlines aggregation as it pertains to urolithiasis in the following way.-
Particles of large diameter (1 em or more) are more susceptible to the force of gravity than to 
forces of adhesion. However, as the size of the particles diminishes, adhesion becomes more 
prevalent than gravitation. The susceptibility of adhesional forces in particles of diameter 1 f.tm 
is approximately one million times higher than the gravitational force on such particles [Rumpf 
et al. 1977, cited by 87]. ·-Thus when dealing with fine particles it is essential that forces of 
adhesion be taken into account. In crystallization studies it becomes necessary to consider 
both particle-particle and particle-membrane adhesion [Finlayson, 1976, cited by 87]. The 
stability of minute crystalluria in urines is determined by the nature of the forces which are 
effective only at short distances of separation. When the surfaces are brought close together, 
London forces or VanDer Waals forces predominate, resulting in overall attraction and natural 
flocculation. Surface charges do play an important role and suspensions are rendered stable by 
repulsive electrostatic forces [88]. 
.. 
1.4.4 Mechanism of Stone Formation 
As stated earlier, calcium oxalate stone formation is related to crystallization processes in 
the urine [95] which can be subdivided into four stages [96]. Firstly, there must be a period of 
high supersaturation [87, 96] which results in crystal nucleation (increase in crystal number). 
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This is followed by a period of rapid crystal growth and aggregation in which the primary 
particles increase in size [95, 96]. 
Numerous hypotheses have been put forward in an attempt to explain the formation of 
stones in the renal tract. Robertson et al. [90] have suggested that any hypothesis should 
account for the formation and retention of some critical nucleus and its subsequent growth. 
Stone growth arises as a result of an imbalance betw~en saturation of the urine with stone 
forming substances and the activity of crystal inhibitors [94]. The hypotheses which have 
emerged may be subdivided into two groups : firstly, those which describe the formation and 
retention of the stone nucleus as an intracellular process [97] and secondly, those which define 
stone formation as taking place entirely within the lumen of the urinary tract (i.e. an 
extracellular phenomenon) [90]. The latter group comprises three possible theories which can 
be summed up as follows : 
• matrix hypothesis; 
• crystallization inhibitor hypothesis; 
• excessive supersaturation of the urine leading to spontaneous precipitation hypothesis . 
The matrix hypothesis invokes the active role of non-crystalline, organic material which 
provides structural rigidity and hence provides a framework for mineralisation [98, 99]. Stone 
development is initiated by some chemical or pathological process which promotes the 
precipitation of stone forming salts by secretion of specific crystalline substances into the urine. 
The crystallization inhibitor theory suggests that stone formation and growth may occur 
due to a deficiency or absence of specific ions which may inhibit. the crystallization of stone 
forming salts. The urine of normal subjects contains sufficient of these inhibitors whereas 
'stone formers urine is deficient in these protective substances [100, lQl ]. 
Finally, there is the theory that the urine stream is excessively saturated with one of the 
stone forming salts which may lead to spontaneous precipitation of the salt independent of a 
pre-formed matrix or inhibitors of crystallization. Persistent crystalluria may result in the 
trapping of an aggregate or large crystal in the urinary tract, resulting in stone formation [22, 
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102]. This is known as the free particle theory [96]. Alternatively, the rate of production of 
crystals in the narrow tubules may cause a blockage due to crystal overload [90], resulting in a 
primary particle becoming attached to the walls of the renal system through the participation of 
some gluing substance [96]. This is the fixed particle theory [96]. Subsequent growth of the 
trapped particles occurs due to aggregation of the passing materials. Together with the 
adsorption of protein on the growing crystal faces, this process may produce a fully-developed 
calculus [90]. In both theories a nidus forms which constitutes the centre around which a 
stone will form by the continued processes of crystal growth and adhesion [96]. 
1.4.5 Urinary Risk Factors of Calcium Nephrolithiasis 
Calcium renal stone formation occurs as a combined result of a number of individual 
determinate factors in urine [7]. In recent years the term risk factor has been associated with 
the phenomenon. It has emerged that a number of the urinary risk factors contribute to the 
increased likelihood of precipitation of calcium oxalate and calcium phosphate stones. The 
urinary risk factors as summed up by Ryall et al. [7] can be considered as those determining 
the degree of calcium oxalate saturation in the urine and those which, once the crystal 
nucleation has been initiated, actually allow for crystals to enlarge and aggregate [7]. 
According to Robertson eta!. [73], the 6 main risk factors are high pH and low urinary 
volume, raised oxalate and calcium renal output, the absence of substances which retard crystal 
growth (inhibitors) and an increase in uric acid excretion. These risk factors, together with 
other pertinent factors regarding stone growth, are listed in Table 1. 7. 
The solubility's of calcium oxalate and calcium phosphate are related to the pH [7]. 
However, there is controversy in the literature as to the significance of urinary pH on stone _ 
formation. Although studies which compare the urinary pH in normal controls and stone 
formers are few [7], most agree that there is no noticeable difference in the pH of each group 
[22, 23, 103, 104]. In contrast, Robertson et al. [19] show that there is a difference in urinary 
pH between stone formers and normal controls and hence conclude that urinary pH is a risk 
factor in calcium oxalate urolithiasis. Although there is undoubtedly an effect of urinary pH on 
the solubility of calcium stone salts, the conflicting opinions in the literature indicate that 
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caution must be carefully exercised when classifying urinary pH as a risk factor in stone 
disease [7] . · 




hypercalci uri a 
hyperuricosuria 
inhibitors 
An increase in urinary volume results in a lower concentration of stone constituents, 
thereby reducing the probability of stone formation. However, the increase in volume also 
results in the dilution of urinary inhibitors [7]. It is thus not a simple matter to ascertain the 
effects of volume on urolithiasis. There is evidence which indicates that stone formation is 
significantly lower in a population whose average urinary output was a third higher than in a 
second control population [75]. Volume is thus influential in calcium urolithiasis, but stone 
formers do not necessarily exhibit a lower urinary output than do .normal individuals [22, 23, 
104]. This is not to say that urinary volume is not a risk factor in calculi formation, "theory 
and common sense indicate that it is" [7], but that there isn't anything to be gained by volume 
measurement between stone formers and control subjects. Urinary volume was not one of the 
origi_nal lis! of risk factors [19] but was included later [18]. Possibly the most pragmatic 
approach to urinary volume is to let _common sense prevail : the higher the fluid intake,- the 
greater the dilution of the urine and hence the lower the chance of stone formation [7]. 
Urinary inhibitors are naturally occurring components of the urine which have been 
shown in model crystallization systems to prevent or retard the nucleation, growth or 
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aggregation of calcium oxalate crystals [7]. Stone formation may occur as a result of the 
absence of natural inhibitors, which in normal subjects, prevent the formation of crystalluria 
[88]. The studies as summarised by Robertson et al. [94] have centred around the effect of 
inhibitors of new crystals in the urine, rather than on the growth and aggregation of pre-
existing ones. According to Ryall et al. [104], if inhibitors do affect crystal aggregation, they 
may exert an indirect influence on the growth of crystals by reducing the amount of surface 
area available for the deposition of new material. Robertson et al. [96] also state that the urine 
of controls as well as stone formers can attain high levels of supersaturation in which the 
inhibitors have little or no effect on the spontaneous formation of new crystals. Thus inhibitors 
may not prevent the nucleation of crystals [Fleisch et al. 1965 cited by 94, 105] but rather 
prevent the growth and aggregation of existing crystals. Since growth and aggregation occur 
in the urines of stone formers, it is suggested that these urines are deficient in such substances 
[94]. 
In order to determine the importance of urinary components in preventing mineralisation, 
studies have been made in conventional crystallization experiments. A number of low 
molecular weight urinary components such as magnesium, citrate and pyrophosphat~ as well as 
higher molecular weight compounds such as glycosaminoglycans (GAGS) have been shown to 
play roles as effective inhibitors of nucleation and crystallization [7, 106, 107]. 
Pyrophosphate was the first urinary inhibitor to be isolated from urine and identified 
[100]. The effect which pyrophosphate was observed to have on preventing calcification 
indicated its possible inhibitory role [7]. A dichotomy of opinion exists in the literature as to 
the potential of pyrophosphate as an inhibitor in human urine [101, 108, 109, 110]. Once 
again, the conflict in the literature indicates that although pyrophosphate may not be a major 
determinant in urolithiasis, it does play a minor role in calcium oxalate urolithiasis [7]. 
Citrate has been observed to directly inhibit calcium oxalate crystal growth [111] and 
aggregation [112, 113, 114]. Citrate may influence crystallization properties in a number of 
ways. Complex formation between citrate and calcium ions decrease the ion-activity products 
of both calcium oxalate and calcium phosphate. The resulting change in supersaturation brings 
about a reduction potential of crystal formation and growth [114]. However, the literature 
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depicts conflicting opinions in this regard, with reports indicating that there is no apparent 
difference in citrate excretion of stone formers and normal control subjects [Pak et al. 1978, 
cited by 7, 22]. On the other hand, other investigations have shown that there is an abnormally 
low urinary citrate excretion in the stone forming individuals [115, 116, 117] relative to normal 
controls. Even in situations where a significant reduction in citrate concentrations in stone 
formers was not shown, a decided decrease in the ratio of citrate/calcium excretion was 
observed in the stone forming individuals [118]. Administration with alkaline citrate has 
proven to be effective in correcting low citrate concentrations in stone forming individuals 
[119, 120]. It can therefore be suggested that the urinary excretion of citrate may be 
influential in determining the likelihood of calcium stone f~rmation. 
Magnesium is a known inhibitor of urolithiasis afflictions. The ability of magnesium to 
increase the solubility of calcium oxalate was rerognised in 1929 by Ham~erstan. More recent 
studies on rats [Rushton et al. 1982, cited by 7] and in human urine [121] have shown 
magnesium to reduce calcium oxalate crystal formation. It has several possible modes of 
_ action, the first of which is that high urinary magnesium concentrations form complexes with 
oxalate. AS a result, the ion activity product of calcium oxalate is reduced resulting in a lower 
risk of calcium oxalate precipitation [5]. These effects are attributable to competition by the 
magnesium with calcium for the oxalate ion, resulting in the formation of the more soluble 
magnesium oxalate [7]. If however, magnesium is a critical factor in the formation of urinary 
calculi, it might be expected that abnormally low levels of magnesium would occur in the urine 
of stone forming individuals. This has not been unequivocally demonstrated in the literature. 
Investigations which indicate that magnesium excretion is indistinguishable between stone 
formers and their normal counterparts [22, 122] are more common. 
Presently, evidence indicates that macromolecules are the principle contributors of 
inhibitory activity [123]. The bulk of inhibitory activity of calcium oxalate crystal growth has 
been attributed to GAGS [112, 124] and proteins [Worcester, 1987, cited by 7]. As a result, 
investigations have been carried out in order to establish whether stone formers excrete lower 
concentrations of either of these inhibitory substances. Robertson et al. [19] showed that 
GAG output is lower in the urine of stone formers than in the urine of control subjects which 
was later confirmed in investigations by Baggio et al. [125, 126]. Other studies have indicated 
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that there is no difference in the GAG output between stone formers and control subjects [104, 
127]. Very little data is available on the effects of proteins as urinary inhibitors. Whether 
proteins do or do not play a role in calcium oxalate disease is therefore open to debate [7]. 
Other workers have suggested that the presence of macromolecules in urine [128] 
indicates that they may in fact play a promotory role in stone formation [9]. Indeed this is 
supported by some in vitro studies. However, current evidence is insufficient to state with 
certainty whether macromolecules in human urine play a promotory or inhibitory role [7]. 
It has been found that monosodium urate forms a nidus for calcium oxalate stone 
formation, or growth by means of epitaxy [71 ]. As a result, uric acid is considered to be a risk 
factor in calcium oxalate stone formation. 
A history of stone disease in one or more first degree relatives has been known to 
increase the tendency for stone formation by 25 % in patients with recurrent stone disease 
[71 ]. Dehydration causes urine to become more concentrated and is thus an obvious risk 
factor [71]. 
The nature of urine is complex and hence factors that may have an effect on urine will be 
intricate. All the aforementioned risk factors may result in an increase in the risk of the stone 
forming potential of urine. However, the importance of each factor in urolithiasis is clouded 
by uncertainty and differing opinions. As a result, further investigation is required into the 
intricate network of possible urinary risk factors in order to ascertain the true effects of each 
individual component as a risk in calcium oxalate nephrolithiasis. 
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1.5 Objectives of Research 
The existing investigations of megadose ingestion of ascorbic acid present a conflicting 
picture as to whether ascorbate promotes hyperoxaluria or not and, in so doing, whether it 
increases the risk of calcium oxalate urolithiasis. The possible relationship between ascorbic 
acid ingestion and kidney stone formation is somewhat alarming in today's health conscious 
society where self prescription megadose ingestion of this substance is commonplace in the 
management of a vast range of diseases as diverse as the common cold and cancer [39]. ' 
Although the concentration and excretion ratios of oxalate and ascorbate have been measured . 
in many different studies involving ascorbic acid ingestion, workers have failed to consideca 
host of urinary risk _factors in assessing the role of dietary ascorbic acid but have confined their 
investigations to the effects on urinary oxalate excretion only. The present study is aimed at 
investigating whether there is a significant urinary stone risk associated with megadose 
ingestion of ascorbic acid on a daily basis by focusing attention on many risk factors. 
I 
Many of the reported studies fa!led to take into account the possibility of in vitro 
conversion of ascorbic acid to oxalate, leading to a lack of confidence in reported oxalate 
values. Moreover, investigators have confined themselves to employing only one method of 
ascorbic acid analysis- and have not checked it against others. 
The objectives of the study are as follows : 
• to determine the influence of dietary ascorbic acid on a host of calcium oxalate stone 
formation risk factors; 
• to determine urinary oxalate (and other components) in the presence and absence of an 
EDTA preservative so as to establish realistic values for these components and to assess 
the necessity of a preservative; 
• 
• 
to design, develop and test a flow-injection system for analysis of urinary ascorbic acid; 
to determine urinary ascorbic acid by the aforementioned flow-injection method as well as 
by a manual titration method. 
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Chapter 2. 
General Theory of Techniques 
Many techniques can be applied in the study of crystalline material and hence in the study 
of urinary c~:tlculi. This chapter deals briefly with some of the basic prinCiples of the techniques 
used in the present investigation, including atomic absorption, enzymatic assays of oxalate and 
citrate, turbidiometry and Coulter multisizer. Various techniques for the determination of 
ascorbic acid in biological samples are also discussed. 
2.1 Analytical Visible Spectrophotometry 
Spectrophotometric methods for the determination of elements are based on the 
absorption of visible radiation. Essentially, spectrophotometric methods depend on the 
relationship between the absorption of radiation by a solution and the concentration of the 
coloured species in solution. In the application of spectrophotometric methods, the species 
.. 
analysed is often converted to a coloured complex. In cases where the analytical species is 
colourless, indirect spectrophotometric methods can be used for determination. Alternatively, 
analysis by ultraviolet (UV) spectrophotometry can sometimes be used [1 ]. 
Spectrophotomeric techniques are remarkably versatile, sensitive and precise. 
Application is broad, covering most elements with the exception of the noble gases. A wide 
range of concentrations can- be determined, from macroquantities to traces [1 ]. 
Spectrophotometry is one of the most precise instrumental means of analysis and is probably 
one of the most widely used single procedures in chemical and clinical laboratories world-wide 
[2]. Furthermore, the basic apparatus required, a spectrophotometer, is relatively inexpensive. 
Attempts to use the colour of a complex in analytical analysis dates back to ancient 
times. Some investigators believe the origin of colorimetry to date back to 1852 with the 
formulation of Beer's fundamental laws of colorimetry (spectrophotometry). Some 
colorimetric methods dating back to the 191h century, such as the determination of bromide in 
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natural waters by oxidation and extraction of the resulting bromine with ether, are still in use 
today. Originally colorimetric methods were determined-in colorimetric test-tubes. Towards 
the end of the 19'h century, visual colorimeters with filters were applied and towards the 
1930's, the first photoelectric colorimeters were employed. Since then, photoelectric 
apparatus has been developed and improved [1 ]. 
Originally colorimetric techniques involved the cpmparison of analyte concentration to a 
range of standards in order to determine the analyte concentration. Today, photoelectric 
instruments rely neither on measurement nor comparison of colour, but rather on the fraction 
of incident radiation that is absorbed by the coloured complex. The term spectrophotometry is 
thus more popular than colorimetry [1 ]. 
2.1.1 Absorption Laws 
When a parallel beam of radiation of intensity 10 passes through a layer of coloured 
solution, the intensity of the emergent radiation (I) will always be less than the intensity of the 
incident radiation (10) since of some of the energy (Ia) is absorbed by the particles, some energy 
is transmitted (11) and some is reflected Or) and scattered by the walls of the cuvette [1] 
(Equation 2.1). Since measurements are usually made with respect to reference solutions in 
the same cuvette, the last term can be neglected since it is constant. 
Equation 2.1 
Absorption of the incident beam is dependant on the thickness of the coloured layer (i.e. 
radiation pathlength (b), and the concentration (c), of the absorbing species [2] (Figure 2.1). 
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b 
Absorbing solution 
of concentration, c. 
I 
Figure 2.1 Diagram showing the incident beam passing through an absorbing 
solution [2]. 
-
.Bougner established the relationship between pathlength, b, and concentration, c, of the 
absorbing species in 1729. Lambert formulated this mathematical relationship in a more 
__ accurate manner in 1760. Beer determined the linear relationship between the absorption of 
the radiation and the concentration of the light absorbing component of the solution in 1852 
[1 ]. Despite the mathematical input from Bougner and Lambert, the relationship is commonly 
called Beer's Law. 
T=l/lo 
and, A = - log10· T = log (Io I I) = E b c 
where T = transmittance 
A = absorbance 
10 = intensity of incidence radiation 




c = concentration 
E = absorptivity 
b = pathlength 
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Thus if the concentration, c, of the absorbing species is doubled and the pathlength is 
reduced by a factor of 2, and assuming the total number of absorbing species remains constant, 
the absorbance will remain constant. 
If a solution contains more than one absorbing species, the total absorbance (A1) is equal 
to the sum of the component absorbances (Equation 2.4). Provided the pathlength remains 
constant and there is no interaction between absorbing species, the law of additivity holds [2]. 
Equation 2.4 
Deviations from Beer's Law do occur. It is important that the system is tested to ensure 
thatBeer's Law holds. A coloured species obeys the Law ifa straight line P.assing through the 
origin is obfained for a plot of absorbance versus concentration. The linear range in which the 
absorbing species obeys Beer's Law can then be determined visually from the plot. 
2.1.2 Deviations from Beer's Law 
In theory, the relationship between concentration and absorbance is linear (Figure 2.2). 
In practise, however, positive and negative deviations from linearity do occur which may be 
physical, chemical or instrumental in nature [2]. 
Chemical deviations from Beer's Law may occur due to chemical changes associated 
with concentration of the absorbing species or due to interaction of the absorbing species with 
the solvent solution. Beer's Law only applies in dilute solutions, which places restrictions on 
analysis. This a result of the electrostatic nature of concentrated ions which affects the 
absorptivity and causes departures from Beer's Law. Some deviations are fundamental (e.g. 
stepwise formation of complexes). Homogenous solutions are essential since turbid solutions 
will give rise to light scattering [1 ]. 
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~ (4) ~ ..cs 
~ 
Concentration, c 
Figure 2.2 Graph showing the linear relationship of Beer's Law (2) and the positive (1) 
and negative (3) deviations from the Law and deviation independent of concentration (4). 
Physic~} and instrumental factors result in departure from Beer's Law, since the law only 
applies in conditions of monochromatic light. Polychromatic light sources, in conjunction with 
filters and gratings, are commonly employed in routine chemical analysis to ensure 
monochromaticity. In these conditions, deviation from Beer's Law is not appreciable [1, 2]. 
Poor quality absorptometers result in deviation from Beer's Law due to failure of a light 
sensitive element to respond in a linear fashion to incident radiation. Stray light due to 
scattering from imperfections in instrumental optical components such as prisms, lenses and 
filters also result in departure from Beer's Law. In cases where scattered light is of the order 
of the incident radiation, there is a marked decrease of absorbance, however this is only likely 
to occur at high absorbances [1, 2]. Despite potential areas in which it could occur, deviation 
from Beer's Law is rare. Correction factors may be used to accommodate deviations, however 
this is undesirable. 
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2.1.3 Photoelectric Apparatus 
The fundamental apparatus used for measuring the absorbance of coloured solutions 
includes spectrophotometers and photoelectric colorimeters with filters. The basis of 
operation for both types is provided by the photoelectric effect [1]. A block diagram of a 





















Figure 2.3 Block diagram of a photoelectric effect-based detector [1]. 
-
The simplest, most common spectrophotometer is a single beam spectrophotometer in 
which the reference and sample solutions are analysed in the same light path successively. 
Radiation sources ideally give a continuous spectrum over the widest possible wavelength 
range. Spectrophotometers are fitted with a monochromator capable of isolating a· radiation 
band that for practical purposes is monochromatic (0.1- 2 nm band width). A monochromator 
is fitted with an element to disperse light e.g. a prism or diffraction grati!lg and two narrow 
slits. A source of white light is focused on the entrance slit of a monochromator so that a 
narrow band of light at the specific wavelength is selected. Light is passed through the second 
slit. The single wavelength light then passes through the sample in the cuvette (flowcell in 
FIA) to the detecting device. The absorbance of the sample is subsequently obtained and 
recorded [1]. 
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2.1.4 Spectrophotometric Techniques 
There are a wide variety of spectrophotometric techniques available for application to 
any number of chemical systems [1 ]. Three such techniques have been applied in this 
investigation : 
• Standard curve technique : By applying Beer's Law, the linear relationship between the 
absorbance and concentration of a species is expressed graphically to be the standard curve 
for the chemical species. Sample absorbance is then translated into concentration by means 
of the standard curve. 
• Flow-injection analysis : Flow-injection is a technique based on injection of a sample into 
a continuously flowing reagent stream. Application of flow-injection analysis with 
spectrophotometry yields a fast, precise and versatile means of analysis and detection. 
Flow-injection analysis is capable of handling microlitre analyte volumes (10- 200 f.tl). 
• Turbidiometry Spectrophotometric methods involve the measurement of the light 
absorption (or scatter) by suspensions of sparingly soluble solids. 
2.1.5 Quantitative Visible Spectrophotometery 
UV -visible absorption spectrophotometry is one of the most useful techniques of analysis 
available for quantitative analysis [2]. The important characteristics of spectrophotometric and 
photometric methods are outlined below : 
-
• Wide applicability -: An extensive range of chemical compounds and elements, both 
organic and inorganic, absorb UV and visible radiation, and hence are amenable to 
direct quantitative determination. Many non-absorbing species can be manipulated into 
an absorbing derivative and this technique employed. 
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Moderate to high selectivity : Often a wavelength can be identified at which only the 
analyte absorbs, thus avoiding preliminary separations. Use of additional wavelengths in 
cases where overlapping absorption bands occur can overcome the need to separate 
analytes. 
High accuracy· Relative errors associated with this method of detection are usually in 
the range 1 - 5 %. These errors can be reduced further by applying special precautions. 
Ease and convenience : Spectrophotometric and photometric measurements are easily 
and rapidly performed with modem instruments. In addition, the methods lend 
themselves to automation. 
2.2 Turbidiometry 
Turbidity is the expression of an optical property which causes the light to be scattered 
and absorbed rather than transmitted in straight lines through the sample [3]. It is difficult to 
correlate the turbidity of a solution with the weight concentration of the suspended matter due 
to limiting factors such as particle size, shape and the refractive index, all of which affect the 
light scattering properties of the suspension [3]. 
2.2.1 History of Turbidiometry 
The measurement of turbidity was initiated by Whipple and Jackson in 1900 [ 4]. The 
investigation led to the development of a seri.es of standard suspensions prepared from 
diatomaceous earth and the scale derived in parts per million (ppm) . is still used in the 
calibration of turbidimeters today. One of the earliest turbidimeters was the Diaphanometer 
which consisted of a graduated glass tube with a cross shaped window at the bottom. The 
• Accuracy is the closeness of the measured analyte concentration to the true concentration of the analyte. 
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sample was slowly poured into the glass tube while observing the image of the cross from the 
top. As the cross disappeared into a uniform glow, the sample was no longer poured into the 
glass tube and the turbidity reading was taken from the graduated scale of the glass tube. The 
candle turbidimeter developed by Jackson and still employed today, used a candle as a light 
source in place of the cross window, but the extinction principle is the same [4]. Low range 
turbidimeters for continuous measurement were not available until after 1958. The 
development of low range turbidimeters resulted in a stimulus for rapid rate filtration and is 
very useful in the water industry as a means for determining the dosage rate of clarification 
chemicals in water, resulting in less chemical waste [3]. 
2.2.2 Jackson's Candle Turbidimeter 
· Turbidity measurements by the candle turbidimeter are based on the light path through a 
suspension that just causes the image of the flame to become indistinguishable against the 
general background illumination when the flame is viewed through the suspension. The longer 
the light path, the lower the turbidity. 
The candle turbidimeter consists of a glass tube calibrated according the light path (em) 
and Jackson Turbidity Units (JTU) (Appendix B), a standard candle and a support which aligns 
the tube and the candle in a vertical manner. The candle is supported by a spring loaded 
system which is designed to ensure that as the candle bums away, it is pushed up to the top of 
the support. The top of the support for the candle is 7.6 em from the bottom of the glass tube. 
The bottom of the . glass tube is flat, of highly polished optical glass and conforms to 
specifications for Nessler tubes. It is graduated to read directly in JTU. The glass tube is 
enclosed in metal during readings to prevent breakage, but more importantly to exclude 
,extraneous light. To ensure uniform results, the flame should be kept at a constant size and 
distance from the bottom of the glass tube. This is achieved by frequent trimming of the wick 
and ensuring that the candle is continuously pushed to the top of its support. Conditions should 
be draft free to ensure that there is no flickering of the flame. The candle should also not be 
burnt for more than a few minutes at a time since this leads to an increase in flame size [3]. 
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2.2.3 Nephelometric Turbidimeters 
The nephelometric method is based on comparison of the intensity of light scattered by a 
sample under defined conditions with the intensity of light scattered by a standard reference 
suspension under the same conditions. The higher the intensity of scattered light, the higher is 
the ·turbidity. Formazin polymers are generally employed as normal reference turbidity 
standards. They are easy to prepare and give reproducible light scattering properties [3]. 
Nephelometric instruments consist of a turbidimeter which has a light source for 
illuminating the sample and one or more photoelectric ,detectors with a readout device to 
indicate the intensity of the scattered light at 90° to the path of incident light. It is important to 
note that differences in design from one instrument to the next result in variances in measured 
values for turbidity even though the same suspension is used for the calibration [3]. 
Commercial turbidimeters for the determinatipn of low turbidities generally give a good 
indication of light scattering in one particular direction, usually at right angles to the incident 
beam. These turbidimeters (or nephelometers) are relatively unaffected by small changes in 
design parameters and hence are specified as standard instruments for measuring low 
turbidities. Non-standard nephelometers are more sensitive to larger particles and are useful 
for process monitoring [3]. 
Standard Methods (131b Edition) [4] gives preference to nephelometric photoelectrical 
instrumental methods as standard methods of turbidity determination, although the Jackson's 
candle visual method remains as an alternative standard of turbidity measurement [4]. 
There are two basic types of photoelectric turbidimeters : (1) nephelometers and (2) 
absorptometers. The differences between the two turbidimeters are detailed in Table 2.1. 
61 
• 
Ascorbic Acid and Calcium Oxalate Kidney Stone Formation __ 
Table 2.1 The differences between nephelometers and absorptometers [4]. 
N ephelometers Absorptometers 
Can be highly sensitive for measuring Not sensitive to small turbidities 
small turbidities 
Zero signal at zero turbidity Maximum signal at zero turbidity 
Direct response- signal increases with Negative response- signal decreases with 
increasing turbidity increasing turbidity 
Linear response at low turbidities and Disobeys Beers Law giving a non - linear 
possible linear response at higher turbidities response, even in moderate ranges 
Dissolved colour does not register as Dissolved colour registers as turbidity 
turbidity although some colours may give a 
negative error 
2.2.4 Limitations of Turbidimeters 
The standard method to determine turbidity is based on Jackson's candle turbidimeter. 
The Jackson's candle can handle a wide range of samples and, as yet, no turbidimeter is able to 
replicate this for all samples [3]. However, limitations do exist. A candle flame is used and 
light in the yellow-red range wavelength is radiated. Very fine particles do not scatter or 
reflect light in this range with the result that fine particle suspensions cannot be measured using 
a Jackson's candle turbidimeter [4]. The lowest turbidity value which can be measured is 
25 units [4], which is often too high for experimental use in the study of solution suspensions · 
'such as water and calcium oxalate crystal nuCleation and growth. Fine suspensions can be 
measured by means of a photoelectric turbidimeter in which an incandescent light source is 
employed. Furthermore, Jackson's turbidimeter cannot measure black particles since the 
absorption of light is so great compared to the scattering of light that the field of view becomes 
dark before sufficient sample is poured into the tube to reach an image extinction point. 
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Interferences occur in nephelometric instruments and Jackson's candle turbidimeters due 
to dirty glassware, air bubbles and the effect of vibrations that disturb surface visibility of the 
sample solution [3]. 
2.2.5 Units of Turbidiometry 
There have been numerous changes over the years regarding the unit of measurement 
and the expression of turbidity. Initially turbidity units were expressed as parts per million 
(ppm) turbidity (1946). However, by 1955 the term "ppm" was discarded since turbidity was 
described as an expression of the "optical property of a sample which causes light rays to be 
scattered and absorbed rather than transmitted as straight lines through the sample" [ 4]. The 
unit term for turbidity thus simply became turbidity units (TU). In the water industry, the units 
are referred to as Jackson's turbidity units (JTU) [4]. In the case where formazin is used in 
standardisation of the turbidimeter, the units are referred to as formazin turbidity units (FTU) 
[4] and in nephelometric measurements the units are called nephelometric turbidity units 
(NTU) [3].' 
2.2.6 Standards and Standard Development 
Standard suspensions for turbidity measurements were initially prepared using materials 
in nature,· such as diatamaceous earth useq by Whipple and Jackson in 1900, and later 
supplemented by Fuller's earth, kaolin and sediment from stream beds. Standards were 
prepared by addition of the material to distilled water. The turbidity was then determined by 
Jackson's turbidimeter and further standards were then prepared from__the stock solution by 
appropriate dilution. Formazin, developed in 1926, was found to be an almost ideal turbidity 
material and is now adopted by the water industry and Standard Methods (131h Edition) as the 
standard turbidity material [ 4]. 
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2.2. 7 Shortcomings of Turbidiometry 
The most serious disadvantage of photoelectric turbidity measurements concerns stray 
light. Any scratches or imperfections in the glass window, any dirt, film or condensation on 
the glass will cause light to scatter. Some of this light reaches the photocell, with the result 
that positive deviation to turbidity measurements is observed [4]. This is a serious problem, 
particularly when measuring low turbidity values. The problem of dirty glass windows has 
been overcome by pouring molten glass directly onto a molten metal surface when the window 
is manufactured. The effect is superior polished glass surfaces on both sides of the window, 
which does not normally occur in routine glass manufactu're. If the light source enters through 
the upper surface of a water sample in the nephelometer, the problem of scattered light is 
overcome. The adoption of this principle resulted in turbidimeters which could read very low 
and very high turbidities [4]. 
There is a misunderstanding concerning the natural desire to relate the concentration of 
suspended matter with the measured turbidity of the sample. It is only possible to compare 
samples of the same material, measured on the same instrument. Even then, a linear 
relationship is not always observed between the concentration of suspended matter and FTU 
turbidity measurements. An example of this is the turbidity of a natural sample which measures 
500 FTU, but after 1 + 4 dilution with distilled water, may read more than the expected 
100 FTU. A l'ossible explanation is that on dilution of some types of solutions, particles may 
sub-divide into a larger number of smaller particles resulting in higher turbidity readings [4]. 
There is very little correlation between turbidity -measurements obtained with different 
types of turbidimeters and- Jackson's instrument [4]. Indirect secondary methods are 
sometimes required to estimate turbidity. Optical systems have fundamental differences and 
hence employ different types of secondary instruments. Turbidities will thus vary from one 
instrument to another despite their being pre-calibrated against the candle turbidimeter [3]. 
Further discrepancies occur in turbidity analysis due to the use of different suspensions for the 
preparation of instrumental calibration curves. A standard reference suspension which has 
reproducible light scattering properties is needed for turbidimeter calibration. Even then, when 
two or more turbidimeters are standardised using the same turbidity standard (e.g. formazin), 
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they will usually give very different readings for the turbidity of a sample containing some 
other turbidity substance. Variations under these circumstances can be as much as 500% [4]. 
2.3 The Coulter Multisizer 
The Coulter multisizer is a flexible, multichannel, particle size analyser developed by 
Coulter in 1956 [5]. It is designed to give high resolution and precision over a wide range of 
sample sizes and materials [5]. The basic principle of operation allows the determination of the 
number and size of particles suspended in a conductive liquid. This is achieved by monitoring 
the electronic current between two electrodes immersed in the conductive liquid on either side 
of a small aperture, through which the suspension of the particles is forced to flow [6]. As 
each particle is drawn into the aperture, it displaces its own volume of electrolyte solution and 
its presence is detected by modulation of the current path [7] (i.e. the changes in resistance as 
particles pass through the orifice generate voltages, the amplitudes of which are proportional 
to the volumes of the particles [8]). The series of pulses is electronically scaled, counted and 
accumulated in a series of size related channels which, when displayed, produce a size 
distribution curve. The instrument is designed to provide accurate particle size distribution 
curves over a wide range of either diameter or volume. 
The technique was originally applied to blood cell counting and later modified to allow 
counting of bacterial cells [8]. Kubitschek [cited by 8] showed that Coulter methods could be 
used in the measurement of cell-volume distributions as well as number counting. Modified 
instruments were soon developed with which particles could be sized as well as counted [8]. 
Robertson [9] initiated the use of an electronic particle counter for counting and sizing calcium 
crystals in urine. Calcium crystalluria may be expressed as either the number or the volume of 
crystals excreted per unit volume of urine when using this technique. In addition, number-size 
and volume-size distributions of the crystals may be obtained [9]. The method was found to be 
reproducible and capable of counting all calcium crystals present in a urine sample. Coulter 
multisizer techniques have been applied extensively in research related to crystalluria [10, 11, 
12, 13, 14, 15], This_ technique provides a ~eans of studying both particle growth and particle -
65 
Ascorbic Acid and Calcium Oxalate Kidney Stone Formation 
aggregation mechanisms which cannot be distinguished by other techniques. 
2.3.1 Basic Principles of Operation 
The operating principle of the Coulter multisizer can be followed by referring to 
Figure 2;4. A controlled vacuum initiates flow through an orifice in a glass tube which 
unbalances a mercury siphon. The system is then isolated from the vacuum source by closing a 
tap. Flow continues due to the balancing action of the mercury siphon. The advancing column 
of mercury activates the counter by means of start and stpp probes, placed such that a known 
volume of electrolyte passes through the orifice (500 f.tl in the present study). Resistance 
across the orifice is monitored by means of immersed electrodes . on either side. As each 
particle passes through the orifice it changes resistance, generating a voltage pulse which is 
amplified, sized and counted. The size distribution of the suspended phase is determined (8] 
from the derived data. 
The amplified voltage pulses are fed to a threshold circuit which has an adjustable 
threshold level. All pulses above the threshold level are counted and this count represents the 
number of particles larger than a determinable volume proportional to the appropriate 
threshold setting. Some instruments have upper and lower threshold circuits which permit 
sizing between two determinable volumes (i.e. a relative-frequency distribution). By taking a 
series of set amplifications and threshold settings, data are obtained directly for determining 
number frequency against volume [8]. 
The instrument offers a wide range of operating modes which can be selected to obtain 
optimum results from the samples to be analysed. In order to minimise operator involvement, 
the machine is equipped with several automated calibration procedures for standard orifice . . . 
tube sizes. Furthermor~, the more usual modes of operation are set into the instrument's 
memory and are recalled when the "automatic" mode of operation is selected as opposed to the 
more flexible "manual" mode. Calibration const~nts and automatic operations can be set in the 
memory, and this new data can then be accessed in.the "automatic" mode [8]. 
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Figure 2.4 Schematic diagram of the well known electrical sensing zone, or Coulter 
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2.4 Calcium Oxalate Crystal Sedimentation in Urine 
In principle, kidney stone formation can be due to either crystal growth or aggregation, 
or by the combined growth and aggregation of small crystals into large particles of clinically 
significant size [16]. It is difficult to distinguish between crystal growth and aggregation and 
hence techniques to determine each individually are difficult to effect. 
Hess et a/. [17] developed a method to measure aggregation of calcium oxalate 
monohydrate (COM) crystals in the absence of COM crystal growth, based on the terminal 
sedimentation velocity of COM crystal aggregates produced by slow stirring of an equilibrated 
COM crystal suspension [Biomen, 1982 PhD thesis, cited by 17]. COM crystal slurries were 
prepared in which crystals and their bathing solutions were allowed to come to equilibrium, so 
that crystals no longer grew or dissolved. The outer diametert (OD) of the COM crystals was 
determined at a wavelength of 620 nm (OD620). A 2 cm
3 aliquot of the s~Iution was 
transferred to a 1 em light path quartz cuvette in a cell holder thermostated at 37 °C by a 
constant temperature waterbath. In order to show the stability of the slurries, absorbance was 
measured for a period of 10 seconds to obtain a stable baseline value. Crystal aggregation was 
induced by slow magnetic stirring using a teflon-coated magnetic stirrer bar at a stirring rate of 
500 rpm [17]. 
During the stirring at 500 rpm, the number of particles forced down by gravitational 
forces on the system equal the number of particles forced upwards by the stirrer [Blomen, 
1982, PhD thesis cited by 17]. However, the OD620 initially decreased in a hyperbolic fashion, 
only stabilising after 180 s (Figure 3.5). The decrease in OD620 in the first 180 s can only be 
due to crystal aggregation since the equilibrium solution does not allow for crystal growth or 
dissolution. At 180 s, stirring was stopped and spontaneous sedimentation of particles in the 
suspension was monitored for 300 s. After the stirring was stopped, the OD620 decreased. 
tOuter diameter (OD) is the term of measurement employed by Hess et al. (17]. 00 is equivalent to 
absorbance, the units of which are absorbance units (AU). However, the theory discussed in this study has 
confonued with the fom1at of the original reference. 
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This decrease is interpreted as being due to particle ·settling, which is controlled by particle 
size. 
The theoretical approach for interpreting the data was presented by Hess et al. [17] as 
follows. Assume a system of evenly distributed, free falling spheres of identical size; the 
constant terminal velocity (v1) will be equal to the rate of sedimentation. 
Equation 2.5 
where l is the sedimentation distance in the fluid column and t is the time required for all 
fhe particles to reach the bottom. 
In the system developed by Hess et al. [17], OD620 decreased progressively and fell 
linearly at its maximum rate, between 50 and 150 s after the start of the sedimentation 
(Figure 3.5). The linear portion of the curve has a turbidity slope (ts) equal to OD' Ito where 
OD' is OD620 at the beginning of the linear portion of the curve and to is the time in which 
OD620 would fall from OD' to 0 if particles settled at a maximal constant rate. In other words, 
to is obtained as the x-intercept of the graphical extrapolation of the linear portion of the curve 
to OD6zo = 0, minus the time at the start of the linear portion, t'. Thus if t (Equation 2.5) is 
substituted by OD' Its then, 
Equation 2.6 
In ideal spheres the terminal velocity is equal to (2/9)( 1/rJ)( 01 - o2) r 2 g at low 
sedimentation rates where rJ is the viscosity of the solution, 01 and l)z are the densities of the 
particles and fluid respectively, r is the particle radius and g is gravitational acceleration Thus, 
Equation 2.7 
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Since t5 is a function of r
2 in a given solution, the greater the value of t5, the larger the 
COM crystal aggregates. Terminal velocity is thus determined from the turbidity slope of a 
plot of OD620 vs time (Equation 2.6) together with the particle sedimentation distance derived 
form the cuvette used. Particle radius can be determined from Equation 2. 7, while the density 
and viscosity values were determined by Hess et al. [17] from the supernatant of a COM 
crystal slurry. The published density value for COM crystals [18] was used in the calculations 
of the work carried out in [17]. 
2.5 Methods for Ascorbic Acid Analysis 
The analysis of ascorbic acid presents numerous difficulties. .A routine method of 
analysis which is free from interferences does-not exist [19]. Techniques _for ascorbic acid 
analysis should ideally allow for the vitamins many oxidative products to be distinguished so 
that accurate determination of the compound can be achieved. At the very least they should 
-- allow for simultaneous determination of ascorbic acid and its oxidative products with a 
minimum of sample preparation and interference from any other chemical species which may 
be present. The situation is further complicated since ascorbic acid generally co-exists in plant 
and animal tissues with numerous other organic compounds from which it has to be separated. 
Separation procedures can be bypassed if a unique property of the ascorbic acid can be 
measured. L-ascorbic acid exhibits redox behaviour, a property which is used extensively in 
the analytical determination of the compound [19]. 
2.5.1 Titrimetric and Colorimetric Methods of Analysis. 
Titrimetric analyses of L-ascorbic acid are based on the reducing properties of the 1,2-_ 
enediol group [20]. Since 1927 [19], the technique which has been extensively employed is 
oxidation using 2,6 dichlorophenolindophenol (2,6 DCPIP) [20], a dye which is blue in neutral 
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The procedure developed by Tillman et a/. [cited by 21] and outlined by Harris et a/. 
[21] involves adjustment of a test solution to near neutrality using sodium acetate followed by 
titration with the indicator until reduction is complete. The specificity of the method has been 
found to diminish in the presence of other reducing substances and unsatisfactory results are 
obtained if the analysis is carried out in neutral solution [21 ]. A method using the same 
indiCator was eventually modified by Harris et a/. [21] which, when tested against naturally 
occurring reducing substances such as glutathione and pyrogallol, showed consistently 
negative results. The solution to be analysed was first acidified to pH 2.5 by the addition of 
concentrated acetic acid. The indicator was then added to a suitable volume of the analyte 
until it was no longer reduced. The technique is more' precise if a specific volume of the 
indicator is placed into a titration vessel and a volume of the unknown titrated against the fixed 
I 
volume of the indicator, as is carried out by Gowenlock eta/. [22]. 
Redox titration of ascorbic acid with 2,6 DCPIP in an acid solution allows for the 
reduction of the dye to a colourless leucobase while the ascorbate is oxidised to 
dehydroascorbate [22] (Figure 2.5). If dehydroascorbate is already present in the solution, it is 
necessary to reduce it to ascorbic acid in acid solution by the addition of hydrogen sulphide. 
Any other reducing substances which may be .present in urine, may reduce the specificity of this 
technique. This method is widely used in titrimetric analysis to determine urinary ascorbic acid 
·concentration. It is applied in university chemistry laboratories and in research laboratories. 
The method is employed at a number of the South African Hospitals, including Groote Schuur 
Hospital and Red Cross Childrens Hospital, Cape Town. 
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Numerous other methods, which employ the strong reducing properties of ascorbic acid, 
exist to determine ascorbic acid concentration in substances. Other techniques require time 
consuming laboratory preparations of the samples and the analysis itself is time consuming. As 
a result, the method usually used to determine ascorbic acid is that originally developed by 
Tillman et al. [cited by 21] previously described. The method is relatively simple and can be 
employed in conditions in which there is a high concentration of ascorbic acid [19]. In most 
cases, the end point is easily detected. However, there are disadvantages to the technique. It 
is susceptible to the interference of other reducing agents such as cysteine and glutathione 
which are frequently present in biological fluids, iron (II) which is commonly present in food 
stuffs and sulphites which are added as preservatives to soft drinks [20]. As a result, the 
technique lacks specificity. There are treatments for some of the reducing substances in 
individual cases but there is no single application which can remove all reducing substances in 
an analyte solution. A further disadvantage of the technique occurs in coloured solutions, such 
as urine, in which the endpoint can be masked. As a result, the endpoint is more difficult to 
ascertain, resulting in instrumental means of detection such as polarography being utilised [19]. 
Another titrimetric method employs chloramine-T (MeC,H4S02NNaCl) as a stable titrant 
for ascorbic acid determination [20]. The reagent is used with either acidified potassium-
iodide and starch or in the presence of acidified potassium-bromide and methyl red. Iron(II) 
does not interfere in either method. However, interference due to sulphites and sulphydryls 
occurs and can be overcome in both cases by pre-reaction with acrylonitrile. Both reactions 
allow for the determination of ascorbic acid (without dehydroascorbic acid) in the presence of 
iron, sulphites and sulphydryls without interference after the pre-treatment of samples with 
acrylonitrile. 
Other indicators have been empioyed in titrimetric analysis of ascorbic acid. These 
include the use of ferrozine a,a' dipyridine, 2,4,6-tripyridyl-s-triazine [19] or 2,4-, 
dinitrophenylhydrazine [22, 24]. Another titrimetric determination of ascorbic acid involves 
the use of cerium(IV) in a phosphoric acid medium using a ferroin sulphate indicator [25]. The 
kinetics and mechanism of the oxidation reaction of ascorbic acid with cerium(IV) in sulphuric 
acid solution has also been investigated [26]. 
73 
• 
Ascorbic Acid and Calcium Oxalate Kidney Stone Formation . 
Dehydroascorbic acid is often assumed to be the only product of the redox analysis. 
However, further products of oxidation do exist in the solution. A method to determine the 
concentration of L-ascorbic acid as well as dehydroascorbic acid and all further oxidation 
products in a manner which is unambiguous, accurate, sensitive and precise still eludes 
investigators [19]. 
2.5.2 Enzymatic Colorimetric Analysis 
Boehringer Mannheim have developed an enzymatic kit (Cat. No. 409 677) for the 
analysis of ascorbic acid in foodstuffs and other materials [27] based on the reaction developed 
and described by Beutler [28]. 
-
L-ascorbic acid and some reducing substances (x-H2) reduce the tetrazolium salt, 3-( 4,5- -
dimethylthiazolyl:.2)-2,5-diphenyltetrazolium bromide (MIT), in the presence of the electron 
carrier, 5-methylphenazinium methyl sulphate (PMS), at a pH of 3.5, to a formazan. 
Equation 2.8 shows the reaction taking place in the cuvette in which the sum of the reducing 
substances is measured [27]. 
L-ascorbate(x-H) +MIT PMs ) dehydroascorbate(x) 
+ MIT ~formazan- + H+ Equation 2.8 
A sample blank is necessary for the analysis of ascorbic acid concentrations when using 
this technique. In order to prepare a sample blank, it is necessary to remove any L-ascorbate 
:which may be present in the sample. Oxidative removal of L-ascorbate is achieved using -
ascorbate oxidase (AAO) [27] (Equation 2.9). Other oxidative products, such as 
dehydroascorbic acid, do not react with MTT/PMS and it is unnecessary to remove them in the 
development of a suitable sample blank [27]. 
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L-ascorbate + 0.5 0 2 
AAO ) dehydroascorbate + H2 0 Equation 2.9 
The absorbance difference of the sample minus the absorbance difference of the sample 
blank is equivalent to· the quantity of L-ascorbate in the sample. The MTT-formazan is the 
measuring parameter and is determined by means of its absorbance in the visible range at 
578 nm[27]. 
2.5.3 Spectrophotometeric Analysis 
Aqueous ascorbic acid is colourless and hence there is no significant absorption in the 
visible spectrum. However, neutral solutions of ascorbic acid do have a strong absorbance at 
265 nm which allows for direct spectrophotometric analysis. Ascorbic acid is usually present 
in solutions which contain other substances which absorb in this range, and subsequently this 
technique is limited [19]. 
The molar absorptivity of ascorbic acid at 265 nm varies considerably because it 
undergoes rapid atmospheric oxidation. Thus, it is essential that anaerobic conditions are 
maintained, otherwise there may be significant differences in the absorptions at this 
wavelength. These difficulties are exacerbated by the presence of several transition metal ions, 
such as copper(ll), which catalyse the oxidation. EDTA can be used as a chelating agent in 
solutions which contain transition metal ions. 
In an attempt to overcome the problem of interferences from biological solutions which 
contain ascorbic acid, specific colour reactions have been used to determine L-ascorbic acid 
and/or its oxidation products. The titrimetric analysis of ascorbic acid using 2,6 DCPIP dye is 
one reaction which has been adapted for colorimetric determination.· .. Other compounds and 
indicators have been used for colorimetric analysis, but the specifics have not been detailed in 
this study. 
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2.5.4 Electrochemical Methods 
Electrochemical techniques offer selectivity, precision and accuracy as well as simple 
operative mechanisms. Methods have been devised [29], but further development of work is 
required. These methods of analysis have not been widely adopted. 
2.5.5 Chromatographic Techniques 
It is not yet possible to determine small amounts of ~corbic acid in a sample solution, or 
infact to distinguish between its other oxidative products. Chromatography is used to separate 
analytes from one another in solution and thus allows for this specificity [19]. 
Gas-liquid chromatography is the most common chromatographic method in general use. 
However, it is not suitable for ascorbic acid analysis, since the vitamin is not volatile. Sample 
work-up in order to convert ascorbic acid to its more volatile tri-ether is laborious. The 
method does deliver accurate, reproducible results, but is time consuming. 
High performance liquid chromatography (HPLC) is a more convenient method of 
analysis and has been applied in the determination of catecholamines, of which ascorbic acid is 
one [29]. Despite its successful determinations of organic and inorganic compounds as well as 
some vitamins~ it is not ideal for ascorbic acid analysis. Numerous problems remain and it 
cannot be used in all circumstances with equal ease, for a variety of matrices and for very low 
concentrations. Detection of ascorbic acid in HJ>LC depends very much on a physical property 
specific to ascorbic acid and its oxidative products. Absorption in the UV-visible range has 
been used, but is much less sensitive to dehydroascorbic acid due to its low molar absorptivity. 
2.5.6 Flow-Injection Analysis 
Numerous conventional methods, which are described above, have been used in the 
determination of ascorbic acid, each of which has its own advantages and limitations [30]. 
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Flow-injection analysis (FIA) has been applied twice in the determination of ascorbic acid 
using electro-analytical detection [30]. Strohl et al. [31] used a reticulated glassy carbon 
electrode to carry out the coulometric and amperometric determination of ascorbic acid. The 
coulometric determination allowed for the ascorbic acid to be completely electrolysed, enabling 
it to be determined without a calibration graph. The sampling frequency decreased with 
respect to the amperometric method. Bradberry et al. [32] were successful with an 
amperometric method using enzymatic reactors to determine the vitamin in the tissues of the 
brain. 
A photometric flow-injection technique was developed by Lazaro et al. [30] using 
reagents detailed by Verma et al. [20] in the manual titration of this method. This technique 
was then specifically applied to the determination of ascorbic acid in urine [33]. The principles 
and chemistry of the starch-potassium iodide flow-injection system developed by Lazaro et al. 
[33] were applied to the system in the following manner. The ascorbic acid sample, dissolved 
in an acidic medium, is injected into a chloramine-T carrier stream after merging with a starch-
iodide stream. Iodide forms HI in an acidic medium, which subsequently reacts with 
chloramine-T resulting in the formation of iodine (Equation 2.10). 
The iodine formed oxidises the ascorbic acid. Once the ascorbic acid has been fully 
oxidised, the iodine binds with the starch which constitutes the indicator reaction. Sulphuric 
acid can be considered the blank in the reaction since sample preparation is carried out in a 
sulphuric acid medium to prevent the precipitation of the reagent when the sample is injected. 
The absorbance is at a maximum for sulphuric acid in the absence of ascorbic acid. The -
presence of ascorbic acid reduces the analytical signal proportional to its concentration [33]. 
Very recent documentations on flow-injection analysis methods include the assay of 
ascorbic acid using cerium(IV) [34]. An ascorbic acid solution was injected into a carrier 
stream of cerium(IV)' prepared in sulphuric-acid. A mixing chamber was employed for the 
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resultant solution which was then propelled through a flow cell and detected by means of a 
spectrophotometer at a wavelength of 410 nm. Recently Sultan et at. [35] have developed a 
new method of analysis for ascorbic acid. A simple colorimetric flow-injection method was . 
developed for the assay of ascorbic acid in drug formulations [35]. Ascorbic acid was injected 
into a flowing stream of iron(III) and then mixed with 1,10-phenanthroline in sulphuric acid 
media. ~he mixture was allowed to react in a reaction coil and the resulting colour of the 
1,10-phenanthroline-iron(II) complex was monitored at 510 nm. 
2.5.7 Closing Comments 
Ideally an accurate and reliable method to determine the concentration of ascorbic acid 
excreted in urine is required. Documentation of a reliable and_ efficient means to carry out this 
determination is limited. As mentioned earlier, investigation into the methods used in some of 
the South African hospitals indicate the most popular method remains the m~nual titration of a 
urine sample with 2,6 DCPIP. The method is employed in other institutions internationally 
(University--College Hospitals, London). The method however is laborious and time 
consuming and in conditions where ascorbic acid is present in the urine in low concentrations, 
the end point of the titration is exceedingly difficult to ascertain by human eye. Automation of 
this method using an analytical means of detection (e.g. visible spectrophotometry), would 
therefore be advantageous. 
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Chapter 3. 
' 
Materials and Methods 
This chapter explains the experimental procedure and apparatus used in the study. The 
ascorbic acid protocol and the urine collection procedure are discussed. Details of the urinary 
component analysis, crystallization experiments and risk ratio indices are given. Finally, the 
method of statistical evaluation of the results obtained in the study is described. 
3.1 Participants and Protocols 
A survey of the literature regarding ascorbic acid doses that have beeh administered in 
previous studies led to !he selection of a protocol followed by Hatch et a!. [1 ]. In private 
correspondence with these workers, it was ascertained that the most severe side effect 
experienced by participants in the original study was laxative action, which is common in 
megadose ingestion of ascorbic acid. 
"Scorbex" (Lennon Ltd., South Africa) ascorbic acid tablets were used in the present 
study. The manufacturers confirmed that this product contained only pure ascorbic acid and 
binding agents and that tartaric acid and sucrose were not present. 
3.1.1 Ascorbic Acid Protocol 
The protocol initially decided upon involved the ingestion of 8 g ascorbic acid per day 
for 9 consecutive days. However, the first participant in this protocol developed haematuria 
after 8 days. A full description of this particular case is presented in Chapter 5. 
Following the detection of haematuria in the first participant of the investigation, the 
ascorbic acid protocol was revised. Each participant was required to ingest 4 g of ascorbic 
acid daily for a period of five days. 
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Participants were all post-graduate students in the Department of Chemistry at the 
University of Cape Town (U.C.T), in the age group 20 to 30 years. None had a history of 
stone formation. Participants were required to ingest 1 g ascorbic acid four times daily : at 
breakfast, lunch, early evening and approximately one hour before retiring. They were 
encouraged to maintain a high fluid intake and to pass urine regularly throughout the protocol. 
Each participant provided two consecutive 24 hour specimens immediately prior to 
ascorbic acid ingestion which served as control samples (samples 1 and 2). After commencing 
the ascorbic acid protocol, participants collected 24 hour urine samples during the first, third 
and fifth day of the ingestion period (samples 3, 4 and 5 respectively). After five days, 
ingestion of ascorbic acid was stopped but participants continued to collect 24 hour urine 
samples on alternate days during the following five days (samples 6, 7 and 8 respectively). 
3.2 Urine Collection Procedure 
All urine samples were ~9llected over a period of 24 hours. Participants were required 
to collect each voiding in a clean glass beaker and to pipette 10 cm3 thereof into a small glass 
bottle containing 0.38 g EDTA. The final concentration of EDTA was 10 mmol.dm-3 [2]. The 
EDTA acts as a preservative to minimise the in vitro conversion of ascorbic acid to oxalate 
during the collection period [2, 3]. Participants was also required to pipette a further 10 
cm3 of urine into a second glass bottle, but no preservative was present. These samples will 
henceforth be referred to as the "24 hour representative samples with ( +) or without (-) 
EDTA". 
In addition, participants were requ-ired to add 45 cm3 of the freshly voided urine into a 
~lean glass bottle containing 5 cm3 glacial acetic acid for immediate ascorbic acid analysis [4]. 
These samples were analysed within a few hours of voiding. Three such aliquots were effected 
during the 24 hour collection period : at the second, "x", and fourth, "y", voidings of the day 
and at the first, "z", voiding of the following morning (Figure 3.1). 
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Figure 3.1 Urine collection procedure followed by each participant. 
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After performing the aforementioned procedures, excess urine was poured into a clean 
-2.5 dm3 glass bottle which contained no preservative. This specimen is henceforth referred to 
as the "bulk 24 hour sample". 
The bottles were cleaned by soaking in soapy solution overnight and then thoroughly 
rins_ed with distilled water before being soaked in - 5 % nitric acid for a 24 hour period. Final 
rinsing was achieved with distilled water. The smaller glass bottles, beakers and pipettes were 
washed in hot water and soaked overnight in - 10 % nitric acid. The glassware was then 
thoroughly rinsed with distilled water and allowed to dry before being used for further urine 
collections. 
3.3 Urine Analysis 
Urines were analysed on a daily basis as -follows. The samples were checked for 
infection using Boehringer Mannheim dipsticks (Combur-10-Test). The 24 hour representative 
sample with EDTA was dilut~9 to 100 cm3 with isotonic saline [2] to bring the concentration 
of EDTA to 10 mmol.dm-3• The volume and pH of the bulk urine sample and the two 
representative samples were measured and recorded. 
Aliquots of each sample (representative samples and bulk 24 hour collection) were 
analysed for chloride, phosphate, urate and creatinine by private pathologists. In those cases 
where urine samples contained concentrations of ascorbic acid greater than 1136 t-tmol.dm-3, 
urate could not be determined due to interference [5, 6]. Other methods employed for urate 
analysis such as phosphotungstic acid (PTA) are also subject to interferences by ascorbic 
acid [7]. 
Aliquots of 30 cm3 of the bulk sample and the two representative samples were filtered 
through a 0.74 t-tm sieve to remove all cellular debris and proteinaceous material. A small 
quantity of each was subjected to atomic absorption analysis (VARIAN Techtron Flame 
Atomic Absorption Spectrophotometer 5, 1970) for calcium [8], potassium, magnesium [8] 
and sodium. The remaining volume of each aliquot was used for the determination of oxalate 
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(Sigma Kit, Procedure No. 591) and citrate (Boehringer Mannheim UV method, Cat. No. 
139 076) by enzymatic assay. 
3.4 Metastable Limit Determination 
Nucleation of calcium oxalate (CaOx) crystals can be induced by dosing the urine with 
aqueous sodium oxalate (NaOx). The extent of crystallization can be monitored by several 
different methods, including measurement of the turbidity of the urine [9, 10] or by 
determining crystal number-size distributions with a Coulter multisizer [11, 12, 13, 14, 15, 16]. 
Initially turbidity or crystal numbers increase slowly in response to increasing NaOx 
concentration but when the metastable limit (MSL) is reached, these values increase 
dramatically. Readings of turbidity (or crystal number) are plotted as a function· of the 
concentration of the administered NaOx dose concentration. The minimum amount of oxalate 
necessary to induce nucleation (detected by the sudden increase in particle number or turbidity) 
is taken to be the measured limit of metastability of the urine, determined by interpolation of 
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Figure 3.2 Determination of the practical metastable limit of urine [16). 
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3.4.1 Metastable Limit by Turbidiometry 
A volume of 800 cm3 of the bulk urine was filtered through Sartorius glassfibre prefilters 
followed by filtration through Sartorius cellulose acetate filters (0.45 ~-tm) to remove all 
crystalline and non-crystalline matter. Aliquots of 30 cm3 of this filtered urine were pipetted 
into each of 12 narrow necked plastic bottles which were then incubated for a period of 
30 minutes in a MEMMERT oven at a temperature of 37 °C. 
Aliquots were dosed pairwise at five minute intervals with 0.3 cm3 of aqueous sodium 
oxalate (NaOx) solution of increasing concentration .(range 0.01 - 0.2 mol.dm"3 (M); 
Appendix C) and incubated for a further 30 minutes. ·After this period, the aliquots from the 
first two bottles in the series were transferred into HACH screw-top glass cells containing a 
teflon-coated magnetic stirrer bar and the turbidity in each was recorded during gentle stirring. 
The turbidity in each of the other bottles was measured in sequence at five minute intervals. 
The turbidity of each sample was plotted as a function of the administered NaOx dosing 
concentrations and the MSL was determined as shown in Figure 3.2. The computer program 
MSL [17] w'as used for this purpose. 
3.4.2 Metastable Limit by Coulter Multisizer 
Aliquots of 10 cm3 of filtered urine were pipetted into 12 cups specifically designed for 
use in Coulter multisizer analysis and were then incubated for 20 minutes at 37 °C. Thereafter 
aliquots were dosed pairwise at 5 minute intervals with 0.1 cm3 NaOx of increasing 
concentration in the same range previously described (Section 3.4.1) and were incubated for a 
further 30 minutes. The number of particles in each aliquot was th~_n measured using the 
Coulter multisizer and plotted as a:· function of the administered NaOJ_C dosing concentration. 
The MSL was determined as shown in Figure 3.2 using the computer program MSL [17]. 
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3.5 Crystallization Kinetics 
Many methods have been used to study CaOx crystallization [18]. These can be divided 
into three categories, depending on how the level of supersaturation changes during the course 
of the experiment [18]. Firstly, existing supersaturation may be allowed to decay. In this case, 
crystallization is induced and allowed to proceed without further additions and the 
supersaturation of the solution decreases as CaOx crystallizes. Secondly, the supersaturation 
may be increased; initially stable, saturated solutions in which CaOx crystallization does not 
occur are concentrated to further increase saturation resulting in CaOx crystallization with the 
' 
aim of reproducing the way in which the kidney brings about supersaturation. In the third 
approach, constant supersaturation is maintained by continuously adding calcium and oxalate 
as crystallization occurs [18]. 
In the present study the supersaturation decay approach was used. The capacity of a 
given urine to inhibit crystal growth was quantified by monitoring the rate of growth of CaOx 
crystals precipitated in response to a fixed oxalate load above its MSL [16]. This was achieved 
by using two methodS : turbidiometry and Coulter multisizer. In the former case,Jurbidity of 
the urine was recorded at 10 minute intervals for a period of 90 minutes. In the latter case, 
particle numbers were measured in the urine over the same time intervals. Plots of turbidity 
versus time and particle number versus time all showed an initial time lag followed by a steeply 
rising linear portion corresponding to increasing crystallization. The gradient of this section 
may be regarded as an index of the crystallization rate [16]. Idealised plots illustrating these 
two cases are shown in Figures 3.3 and 3.4. 
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Figure 3.3 Idealised plot of turbidity as a function of time showing the initial time lag · 
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Figure 3.4 Idealised plot of particle number as a function of time showing the initial 
time lag followed by a steeply rzszng linear portion corresponding to increasing 
crystallization [16]. 
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3.5.1 Crys_tallization Kinetics by Turbidiometry 
A volume of 30 cm3 of filtered urine was poured into a clean HACH screw-top cell 
containing a teflon-coated magnetic stirrer bar. The cell was then incubated at 37 °C for 
30 minutes. Thereafter, it was positioned in a HACH RATIO turbidimeter and the turbidity of 
this "blank" specimen was recorded. The reading was determined in duplicate. The sample 
was then dosed with 0.3 cm3 NaOx of concentration corresponding to the MSL of the control 
urine. Thus each urine obtained from a particular participant throughout the ascorbic acid 
protocol received the same NaOx challenge. Because the concentration of the administered 
load was "standard", the response of each urine could effectively be compared. Turbidity was 
determined in duplicate every 10 minutes for a period of 90 minutes. 
Turbidity was then plotted as a function of time and the rate of crystallization of each 
urine sample was determined from the linear portion of the kinetics graph as explained earlier. 
In addition, samples of each urine were given NaOx challenges cor~esponding to the 
concentration just below and just above its own MSL concentrations and the rate of 
crystallization was then monitored as described above. 
3.5.2 Crystallization Kinetics by Coulter Multisizer 
Urine specimens were treated in the same way as for the turbidiometry measurements 
except that the starting volume was 80 cm3 and ~he ·volume of the administered NaOx 
challenge was 0.8 cm3• Coulter counting was done in triplicate. 
The particle count was then plotted as a function of time and the rate of crystallization 
determined from the slope of the linear portion of the kinetics graph as explained earlier. 
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3.6 Sedimentation of Calcium Oxalate in Urine 
In order to simulate the calcium oxalate monohydrate (COM) crystal slurries described 
by Hess et al. [19], urine in the present study was dosed with NaOx of concentration equal to 
that of its MSL. Turbidity was monitored until readings remained constant, suggesting that 
crystal growth had ended and that the CaOx crystals in the urine were in equilibrium. This 
supersaturated CaOx suspension can be equated with the equilibrium slurry described by Hess 
et al. [19]. At this point the magnetic stirrer bar was removed and the sedimentation of the 
crystals monitored by measuring the rate at which turbidity decreased. 
After this approach failed to yield meaningful results, the NaOx dosing COI_Icentration 
was increased to 0.2 M, thereby allowing the solution to become supersaturated more rapidly. 
Once equilibrium conditions had been established, 9 cm3 of the urine was transferred from the 
HACH RATIO screw-cap glass cuvette to a spectrophotometer tube (pathlength = 1 em) as 
rapidly as possible. The tube was placed into an LKB NOV ASPEC spectrophotometer and the 
absorbance of the supersaturated solution determined at 620 nm. Spectrophotometric 
measurements were determined immediately and the resultant absorbance was plotted against 
time. Figure 3.5 shows an idealised plot of the expected results. 
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Figure 3.5 An idealised plot of OD62o versus time to illustrate sedimentation of the 
cqlcium oxalate crystals in a COM suspension [19]. The linear portion of the graph is 
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3.7 Ascorbic Acid Determination 
The three urine aliquots, collected at specific inteiVals during the day, were initially 
analysed using the method developed by Tillman et al. 1932 [cited by 4], improved by Harris et 
al. 1933 [4] and clearly explained by Gowenlock et al. 1988 [20]. The method involved the 
use of 2,6 dichlorophenolindophenol (2,6 DCPIP) dye solution in a manual titration of the 
urine to which glacial acetic acid had been added. After the concentration of ascorbic acid had 
been determined in this way, the sample was analysed by flow-injection analysis. (Chapter 4), 
Where the ascorbic acid concentration exceeded 150 ~g.cm-3, the urine was diluted with acetic 
acid (10 cm3 glacial acetic acid in 100 cm3 distilled water): 
3. 7.1 Titrimetric Determination of Ascorbic Acid with 2,6 DC PIP 
The technique is based on a redox titration of ascorbic acid with 2,6 DCPIP in an acidic 
medium. The dye is reduced to a colourless leucobase (Figure 3.6) while the ascorbate is 
oxidised to dehydroascorbate [20]. If the latter is present, it must first be reduced to ascorbate 









Colourless Leucobase (reduced) 
Figure 3.6 Chemical formulae of 2,6 DCPIP and the reduced colourless leucobase. 
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3. 7.2 Preparation of 2,6 DC PIP Dye and Ascorbic Acid Standards 
A quantity of dye powder (100 mg) was accurately weighed and dissolved in 250 cm3 
distilled water. A fresh solution was prepared every two to three days. The dye solution was 
standardised against a 20 f.tg.cm-3 ascorbic acid solution. This standard solution was prepared 
in the following manner. Acetic acid was prepared in the ratio of 10 cm3 glacial acetic acid in 
100 cm3 distilled water. A 400 f.tg.cm-3 ascorbic acid stock solution was prepared by weighing 
out 40 mg pure ascorbic acid into a 100 cm3 volumetric flask. The flask was made up to 
volume with the prepared acetic acid solution. The 400 f.tg.cm-3 ascorbic acid stock solution 
was diluted with acetic acid to make up a 20 f.tg.cm-3 standard (2.5 cm3 stock solution in 
50 cm3 acetic acid), a 60 f.tg.cm-3 standard (7.5 cm3 stock solution in 50 cm3 acetic acid) and 
a 100 f.tg.cm-3 standard (12.5 cm3 stock sol~tion in 50 cm3 acetic acid). The 20 f.tg.cm-3 
ascorbic acid standard was then titrated against 0.5 cm3 of the blue dye ~oluiion. Since 1 cm3 
-
of 2,6 DCPIP is equivalent to 0.2 mg of ascorbate, the expected volume of the titrant is 5 cm3 
[20]. 
3. 7.3 Technique for the Titration of Urine Samples 
As stated previously, 45 cm3 of fresh urine was pi petted by each participant into a small 
glass bottle containing 5 cm3 glacial acetic acid at three specified times during the 24 hour 
collection period. The samples were analysed within a few hours of collection. 
A volume of 0.5 cm3 2,6 DCPIP dye solution was pipetted into a glass vial using a 
0.1 cm3 GILSON micropipette. The mixture of 9 parts urine to 1 part glacial acetic acid was 
placed in a 10 cm3 burette, graduated at 0.2 cm3 intervals, and titrated directly with the dye. 
The dark blue dye solution turned a brilliant red as the first drop of the acidified urine came. 
into contact with it. As the endpoint of the titration was approached, the solution became a 
paler pink colour, the endpoint being attained when the red colour had been completely 
discharged. The volume of the urine solution required to discharge the red colour of the 
acidified dye solution was then recorded. 
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Equation 3.1 allows for the determination of the concentration of ascorbate present in 
t-he urine sample. 
Urinary ascorbate (f..tg.cm"3) = 111 I urine vol ( cm3) Equation 3.1 
3.8 Tiselius Risk Index 
The Tiselius risk index expresses the biochemical ri~k of calcium oxalate stone formation 
[21 ]. The mathematical expression is given by Equation 3.2. 
(Ca I Cr)0·71 x (Ox I Cit) I (Mg I Cr)0·14 x (Cit I Cr)0'10 Equation 3.2 
where Ca, Ox, Mg, and Cit are the excretions (mmol per 24 hour) of calcium, oxalate, 
magnesium and citrate respect-ively. Creatinine concentrations are expressed in mols per 24 
hours. The higher the value the greater the risk. 
3.9 Calcium Oxalate Relative Supersaturation 
Calculation of relative supersaturation for CaOx was undertaken using the computer 
program EQUIL [22]. Each of the chemical components of the urine was included in the 
-calculation. Samples in which ascorbic acid interference prevented urate concentration from 
being determined, CaOx relative supersaturation values were calculated using a urate 
concentration of zero. ·· 
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3.10 Scanning Electron Microscopy 
Approximately 10 cm3 raw urine and urine preserved with EDTA was poured into a 
clean glass centrifuge tube and centrifuged at 4000 rpm for 20 minutes using a HERAEUS 
SEPATECH LABOFUGE 200. The sedimented samples were then aspirated carefully using a 
clean pasteur pipette and filtered through a 0.22 f..tm Sartorius filter paper placed in a Sartorius 
membrane filter clamp. Thereafter the filter paper with the deposited crystals was pasted onto 
an aluminium stub. These stubs were then coated with approximately 100 nm of Au/Pd in a' 
BLAZER'S vacuum coater. Specimens were examined using a LEICA CAMBRIDGE S440 
sigma scanning electron microscope operating at an acceleration voltage of 10 kV and a probe 
current of 50 pA. 
3.11 Statistical Analysis 
Statistical analysis employed a repeated measures or split plot design [23]. The layout 
for the design for statistical analysis of the 10 participants is shown in Table 3.1 overleaf. 
The analysis of variance, in the split plot design, falls into two parts, the whole plot 
analysis and the subpiot analysis. The data for each fraction for each participant comprises the 
whole plot data. Thus the values a11, a12, •••• , a1a comprise the data for one whole plot with 
total At. The totals At. Bt. Ct. ...... , A10, B10, C10 comprise the whole plot total and give rise 
to the whole plot analysis. The variation between these totals is due to variation between 
participants and to variation between fractions, these being the factors we can identify for the 
whole plots. The remaining variation between the whole plot totals comprise random or error 
variation; specifically whole plot error. The subplots are the values a11, a12, ••• a1a etc. within 
each whole plot. These values, over all whole plots, gives rise to the subplot analysis. Part of 
the variation between the subplots is the interaction between fractions and samples. The 
remaining variation is considered error variation, and this is referred to as subplot error. 
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Table 3.1 Summary of the method for the statistical analysis employed in this study. 
Participants 
1 2 ............. 10 






au bu cu a21 b21 c21 ............. a10,1 b10,1 c10,1 
al2 b12 C12 a22 b22 c22 ............. a10.2 b10.s Cto,s 
. . . . . . . . . . . . . 
. . . . . . . . . . . . . 
a1s bts Cts a2s b28 c2s ............. a10,s b10,s c10,s 
At Bt c1 A2 B2 c2 ............. A10 B10 C10 
: indicates the manner in which the urine was stored when collected (i.e. a = bulk 
urine sample, b =representative sample+ EDTA and c =representative sample 
- EDTA) 
sample no. : indicates the number of the sample in the order it was collected during the 
protocol (1, 2: before ascorbic acid.protocol; 3, 4, 5: during ascorbic acid 
- protocol; 6, 7, 8 : after ascorbic acid protocol) 
A feature of this design is the presence of two sources of error variation. Thus standard 
errors of the fractions are based on the whole plot error and the standard errors of the sample 
and the interaction means are based on the subplot error. 
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Chapter 4. 
Flow-Injection Analysis 
4.1 Introduction and Theory 
Solution analysis in any chemical laboratory requires a number of operations which 
include solution handling, analyte detection, data collection and the computation of results. 
The latter two tasks can be carried out easily with the availability of sophisticated computers 
and detectors. However, a knowledge of several skills is required in solution handling, such as 
qecanting, pipetting, mixing and other volumetric operations. These skills are still performed 
manually, even in advanced chemical laboratories, using apparatus that was designed two 
centuries ago. Recent trends have been to move away from these large volume manipulations 
to smaller volumes. Smaller volumes are economically and environmentally favoured. 
The move to small volumes introduces the concept of "flow operations". The 
mechanical handling of volumetric vessels is replaced by handling micro-volumes of solution in 
closed, small-bore tubes. Flow operations facilitate control in time and space since 
evaporation does not occur. The paths along which the solutions flow are exactly repeatable, 
with the result that the solution mixing and formation of reaction products is highly 
reproducible. In the case of solution spectrophotometry, the standard batch-method detectors 
are readily equipped with flow-through cuvettes (flowcells), to monitor coloured reaction 
products. 
Flow-injection analysis (FIA) [1, 2] has emerged in the last decade as a very powerful 
solution handling and data gathering technique. FIA is based on controlled flow operations. It 
is used in many analytical and research laboratories world-wide. FIA can be applied to many 
existing wet-chemical methods and is an ideal means to automate such analyses. 
FIA belongs to a group of methods involving the injection of a liquid sample into a non-
segmented, continuous carrier stream of suitable liquid. This group of methods comprises 
techniques including chromatography, electrophoresis and field flow fractionation. These 
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different techniques vary in one fundamental aspect - the function of the modulator that alters 
the original square-wave input provided by the sample injection, into a chromatogram, 
electrophogram, fractogram or fiagram respectively, as depicted in Figure 4.1. The modulator, 
or force that occurs within it, is a column for chromatography, an electric field for 





I . . 
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Figure 4.1 Flow scheme (top) and concept (below) of analytical techniques based on 
the injection of the sample analyte into a flowing carrier stream [ 1] 
4.1.1 The PIA manifold 
The simplest flow-injection analyser consists essentially of four components: (1) a pump 
which is used to propel the carrier stream through a narrow tube, (2) an injection port (valve), 
by means of which a well-defined volume of sample solution is injected into the carrier stream 
in a reproducible manner, (3) a reactor in which the sample zone disperses and reacts with the 
components of the carrier stream, and ( 4) a detector that continuously monitors some physical 
parameter (such as absorbance, electrode potential, chemiluminescence, pH, etc.) of the carrier 
stream as it passes through the flowcell. The shape and magnitude of the resulting transient 
102 
Ascorbic Acid and Calcium Oxalate Kidney Stone Formation 
signal reflects the concentration of the injected analyte, along with thermodynamic and kinetic 
information of the processes occurring within the flow stream. Together, the complete FIA 
system is termed a manifold. 
The pump is most often a multi-roller peristaltic pump, accommodating one or more 
pump channels. By variation of individual pump tubing diameters, equal or different 
volumetric pumping rates may be obtained. Pulsing of the flow stream is minimised if pump 
tubing comes into contact with as many of the pump-rollers as possible. 
The injection method used may be one of four types : syringe injection, valve injection, 
' 
hydrodynamic injection and time-based injection. The method of injection in this study was by 
means of a 6-port, rotary injection valve. This valve has two stages of operation, (1) "load" 
and (2) "inject". In the "load" position, the sample loop is filled with sample whilst the_ carrier 
is shunted past the valve, via a bypass, to prevent pressure build up [3]. The valve is switched · 
to the "inject" position with the result that the sample zone is injected into the carrier stream 
and swept towards the detector in the flowing carrier stream. 
The reactor is commonly made of plastic tubing (usually 0.5 - 1.0 mm i.d. *) which can be 
coiled, knitted or knotted [4]. Selection of the reactor is naturally dependent on the chemistry 
of the system. The geometric deformation of the flow path of the sample has an effect on the 
radial and axial mixing of the sample with the carrier stream components. Many other 
reactors, such as immobilised enzymes, ion exchangers, and gas diffusion membranes, can be 
used. 
The final component in a FIA manifold is the detector, and closely associated, the signal 
recording device. Amongst the first methods adapted for FIA were colorimetric methods for 
ammonia and phosphate, where spectrophotometers were readily available. A flow cell allows 
such detection systems to be readily employed in flow-injection analysis without further 
adaptation or capital outlay. The signal recorder (often a chart recorder) is essential in a FIA 
system since it records the detector response from which the result may be determined. The 
i.d. represents the inner diameter of the tubing. 
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response profile enables the monitoring of the systems operational status (e.g. monitoring any 
baseline drift). 
4.1.2 Quantitation in FIA 
Anruysis by means of FIA is unique. The manifold shown in Figure 4.2 is the most 
commonly used single-line manifold. The pump, P, propels the carrier stream to the point at 
which the sample, S, is injected into the carrier stream (C) which contains the reagent. 
Dispersion of the injected sample zone occurs and a reaction takes place. The duration of the 
reaction is controlled by the length of the reaction coil, RC, and the flow rate, F. The 
analytical signal is determined by means of a detector and the resultant signal recorded. 
Typical recorder output has the form of a peak (Figure 4.2)~ the height (H), width (W) and 
area (A) of which may be related to the analyte concentration. 
c 










Figure 4.2 Scheme of the most commonly used single-line manifold shown with the 
typical signal response obtained. 
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The time span from sample injection to peak maximum, is the residence time (T R) during 
which the reaction takes place. Well-designed PIA systems have a short residence time of 
typically 5 to 20 seconds and thus a sample cycle less than 30 seconds. The injection volume is 
usually in the range of 10- 200 ~I. with no more than 0.5 cm3 of sample required to flush the 
injection loop between sample cycles. This makes PIA a very economical technique. 
A variation of PIA is "Reversed PIA" (rFIA). [1 ]. This technique is based on the 
injection of the reagent into a carrier stream of the sample. This approach is common when 
there is an abundance of sample (e.g. analysis of a sea-water sample), or when the reagent is 
very expensive or hazardous. Reversed flow-injection analysis is used in this study, however, 
theoretical and quantitation aspects of flow-based technology apply both to PIA and rFIA. 
4.1.3 Dispersion and Mixing-Processes 
PIA is based on three principles : sample injection, controlled dispersion of the injected 
sample zone and reproducible timing. In contrast to all other techniques, chemical reactions in 
PIA are taking place while the sample reagent is dispersing within the reagent (i.e. while the 
concentration gradient of the sample zone is being formed by dispersion processes). The 
concept of dispersion, controlled within space and time is the foundation-stone of FlA. 
The parameters which characterise the transient signal define the dispersion. The 
sensitivityt of the response is one of the parameters which is a characteristic of the transient 
signal. Sensitivity is influenced by the physical parameters of the manifold such as the flow 
rate, reaction coil length, sample injection volume and the inner diameter of manifold tubing. 
As a result, dispersion is dependent on these same physical parameters [1 ]. 
The sample solution within the cavity of the injection valve prior to injection is 
homogenous and has an original concentration c>. If this sample solution was scanned, it 
would yield a square-wave signal, the height of which would be proportional to the sample 
concentration (Figure 4.3). When the sample zone is injected into a moving carrier stream the 
t the response per unit concentration 
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resultant dispersion depends, amongst others, on the geometry of the reactor and the flow rate. 
The signal is a response curve which has a peak shape that reflects a continuum of 
concentrations, forming a concentration gradient within which no single element has the same 
concentration of sample material as a neighbouring one (Figure 4.3). As a result of dispersion, 
the maximum peak height (C) will not exceed that of the theoretical square-wave response. 
A measure of the extent of dispersion is termed the "Dispersion Coefficient" (D). 
Dispersion in FIA has been defined as the ratio of the original analyte concentration, ~. 
to the concentration of the analyte in the element of fluid which corresponds to the maximum 
of the peak, cmax [5] as shown in Equation 4.1. 
D =CO I cmax · Equation 4.1 
If the analytical response is based on the usual peak height measurement and provided 
- Beer's Law holds, the dispersion equation can be written as Equation 4.2. 
Equation 4.2 
Dispersion is classified as limited (D = 1 to 3), medium (D = 3 to 10) and large (D > 10). 
If one or several reactions resulting in colour formation is to occur, a medium dispersion··of the 
sample zone is required so that the centre of the sample zone is effectively mixed with the 
carrier stream [3]. It is necessary to find a suitable compromise between mixing and reaction 
time on one hand, and keeping zone broadening of the peak to a minimum on the other [3]. 
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Figure 4.3 Dispersion within a FIA manifold. Prior to injection the. sample zone (top 
right) is undiluted and has a concentration C0 • After injection the zone disperses, changing 
the original square-wave form (bottom right) to yield a continuous concentration gradient 
(centre) with maximum concentration cmax at the peak apex. The dispersion coefficient, D, 
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Dispersion for a manifold can be computed using a simple experiment described by 
Ruzicka and Hansen in an excellent monograph on FIA [1 ]. The reagents employed in the 
experiment consist of a 0.02 N borax carrier solution (3.814 g sodium tetraborate decahydrate 
dissolved in 1 dm3 of glass distilled water) and a bromothymol blue dye solution. A 
bromothymol blue stock solution was prepared by dissolving 0.400 g bromothymol blue in 
25 cm3 96 % ethanol. This solution was then made up to 100 cm3 with the borax carrier 
solution. A working solution of bromothymol blue was prepared by 100-fold dilution of the 
stock solution. 
The simplest way to measure dispersion is to· inject a well-defined volume of 
bromothymol blue dye into a colourless carrier stream and continuously monitor the 
absorbance with a spectrophotometer at 620 nm. The height of the recorded peak (H) is 
measured and compared to the distance between the baseline and the signal recorded when the 
flowcell is filled with the undiluted bromothymol blue dye (Hj. Provided Beer's Law holds, 
the dispersion coefficient can be calculated from Equation 4.2. The manifold may be adapted 
in such a way as to control the extent and nature of the dispersion. Dispersion for the 
optimised manifold used in this study was 3.0, and is classified as medium dispersion. 
Mixing processes that take place in FIA comprise convective transport, secondary flow, 
molecular diffusion, and turbulent flow when merging streams. Convective transport in a 
straight tube results in a parabolic velocity profile with the fluid at the centre of the tube having 
twice the average velocity than the fluid at the sides of the tube. Secondary flow arises when 
curvature of the tubing (such as coiling) results in the laminar flow conditions being disrupted. 
This type of flow promotes mixing of the sample zone with the carrier stream. 
Molecular diffusion occurs when concentration gradients are established within the fluid 
~nder the effects of laminar and secondary flow. Molecular diffusion . is the spontaneous 
motion of particles from a region of high concentration to a region of low concentration in ari 
attempt to uniformly distribute all molecules. Axial diffusion occurs in a direction parallel to 
the tube walls, and radial diffusion in a direction orthogonal to the tube walls. Both types of 
diffusion further aid mixing. Finally, turbulent flow arises when the flow streams are disturbed 
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by forces other than those previously mentioned, such as merging streams, stirred mixing 
-chambers, or mini-columns. 
With a knowledge of the underlying theory of FIA, preliminary investigations toward the 
establishment of a FIA method for the determination of ascorbic acid were made. 
4.2 Preliminary Investigations 
Attempts were made to establish a FIA method using chloramine-T and a starch-
, 
potassium iodide (KI) indicator as described by Lazaro et al. [6, 7] (Chapter 2). The system 
was set up using the reported parameters, namely, [chloramine-T] = 5 x 104 mol.dm-3; starch-
KI indicator = 5.25 g soluble starch and 0.50 g KI in 500 cm3 of distilled water; 
flow rate= 2.0 cm3.min-1; injection volume= 96 ~-tl; reactor length =55 em; inner diameter of 






Figure 4.4 Manifold used in the determination of ascorbic acid in urine by the starch-
KI and chloramine-T [6] method. A = starch-Kl, B = Sample, C = chloramine-T, V = 
Injection valve, RC =reaction coil, D =detector, and W = waste. 
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Figure 4.4 shows the manifold used by these investigators. The repeatability and 
reproducibility using the parameters given were very poor. Following this, each of the 
experimental parameters (such as concentration, flow rates, injection volume) were examined. 
Despite extensive effort to find suitable settings of these parameters for the determination of 
ascorbic acid, the repeatability and reproducibility remained unsatisfactory. Further attempts 
to reproduce the FIA system described by Lazaro eta/. [6, 7] were abandoned. An alternate 
FIA system was designed and developed to determine ascorbic acid in urine. 
4.3 The Determination of Ascorbic Acid 
A popular method for the determination of ascorbic acid is the titration using 2,6 DCPIP 
[8] (Section 2.5.1). An objective of this study was to automate the 2,6 DCPIP titration using 
FlA. The· chemistry used in the flow-injection manifold is identical to that employed in the 
manual titration of ascorbic acid using 2,6 DCPIP. The application of FIA to this manual 
titration has not been previously been attempted. 
As discussed previously (Section 2.5.1), the endpoint of this reaction is colourless. After 
preliminary experiments it was decided to using a point other than the colourless end point to 
determine ascorbic acid. This point is referred to as a "pseudo-end point". Although a 
spectrophotometer may be used to monitor disappearance of a colour, the use of a FIA 
titration manifold with measurement of the peak width [1] was undesirable. A measure of the 
peak height for ascorbic acid quantification was preferred. 
A FIA manifold for the determination of ascorbic acid using a wavelength in the visible 
region of the absorption spectrum was used. Although some activity is observed in the UV 
~egion (less than 360 nm), detection in this study is limited to the visible region (Figure 4.5). 
The selection of the pseudo-end point was crucial and careful consideration of accuracy and 
precision was made. 
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4.3.1 Opt~misation of the PIA Manifold 
The aim of optimisation of a manifold is to obtain adequate sensitivity for the analysis 
with high sample throughput, minimum peak widths (and hence peak-tailing) and good 
precision and accuracy. The manifold configuration was optimised by varying physical 
(analytical wavelength, flow rate, injection volume and reaction coil length) and chemical 
(concentrations of the reagent and carrier solutions) parameters of the manifold until a setting 
satisfying the requirements above was found. 
A common approach is to investigate the effect of one parameter at a time until an 
optimum is attained. The next variable is then optimised. Provided minimal interaction 
between variables exists, this method gives an optimised set of conditions without too many 
experiments. The requirement of the method to operate suitably and accurately, not 
necessarily at the optimum sensitivity, was kept in mind throughout the optimisation process. 
4.3.1.1 Analytical Wavelength 
To realise maximum sensitivity, spectrophotometric absorption measurements are made 
at the wavelength corresponding to an absorption maximum since the change in absorbance per 
unit concentration is greatest in this region [9]. It is preferable to avoid determinations which 
correspond to the steep slopes of an absorption curve since minor imprecision in wavelength 
resettability incur large errors. Selection of 3.fl: analytical wavelength was made by scanning the 
absorption spectrum of the absorbing species in the range 350 nm to 650 nm using a PU 8700 
SERIES UV/visible scanning spectrophotometer. 
The absorbance maximum is found at 518 nm (Figure 4.5). Changes in dye (2,6 DCPIP) 
concentrations did not alter the position of this absorbance maximum. Furthermore, the 
maximum did not shift when either ascorbic acid standards or urine samples were analysed. 
Consideration of the wavelength maximum is important since any change thereof (e.g. 
when using different experimental conditions during an optimisation) would affect the resultant 
response by giving a lower response than the true response·. 
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Figure 4.5 Diagram showing the maximum absorbance peak at 518 nm for a 
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4.3.1.2 Flow Rate 
The flow rate of the carrier stream affects the dispersion and mixing of the reagent zone 
with the components of the carrier stream (the sample in rFIA). The regulation of this 
dispersion and mixing may be partially controlled by the flow rate. Low flow rates (less than 
0.5 cm3.min-1) cause peak broadening and very high flow rates (greater than 3 cm3.min-1) often 
result in poor reproducibility. A compromise is essential. 
The careful selection of flow rate is of particular importance in this analysis since the 
residence time (TR) of the species is crucial. A TR that ~s too long will result in the reaction 
going to completion, and a T R that is too short does not permit sufficient mixing between the 
sample and reagent components. In cases where it is desirable to increase the T R, it should be 
noted that it is preferable to increase the reaction coil length (Section 4.~.1.3) rather than 
decreasing the flow rate [3]. 
Factors considered in the optimisation of the flow rate include sensitivity (calibration 
slope) and linearity of this calibration (correlation coefficient). RSD of replicate injections 
(defined here as the precision) is also considered, as is the extent of peak tailing (closely related 
to the peak width). These results are shown in summary in Table 4.1. 
An increase in the flow rate results in (a) increased sensitivity; (b) a decreased peak 
width (and hence less peak tailing and sample carry-over), and (c) an increased sampling 
(injection) rate as a result of (b). A flow rate of 1.99 cm3.min·1 was selected for this work 
based on the high sensitivity, a low RSD for replicate injections, economy of sample and 
reagent solutions, minimal carry-over, little peak tailing and an accompanying high sampling 
rate obtained for at this flow rate. 
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Table 4.1 Factors considered in the optimisation of the flow rate. 
Flow Rate Absorbance RSD Peak Width Slope Corr. 
(<:ril3.1Ilin-1) (AU) a (%) b (mm)c (x 1000) Coeff. 
(AU/!J.g.<:ril-3) (r) 
0.74 0.222 0.87 8.1 -2.22 0.9980 
1.13 0.269 0.68 5.0 -2.33 0.9997 
1.53 0.256 1.89 4.2' -2.36 0.9988 
1.99 0.287 0.37 3.1 -2.57 0.9991 
2.41 0.284 0.78 2.7 -2.70 0.9890 
2.73 0.294 1.23 2.5 -2.65 0.9983. 
a Absorbance for 40 ~g.cm ·3 ascorbic acid 
b. RSD for 5 replicate injections 
c Peak width measured at 50 % of the peak height 
4.3.1.3 Reaction Coil Length 
A reaction coil length that yielded good reproducibility of response, provided an 
adequate, though not too long, residence time, and kept peak tailing to a minimum is essential. 
In addition, a suitable residence time is required to measure the -response at a highly 
. 
reproducible stage of the reaction between 2,6 DCPIP and ascorbic acid. The residence time 
may be conveniently changed at a fixed flow rate by varying the reaction coil length. 
Figure 4.6 shows the effect of the reaction coil length on the calibration slope and 
sensitivity of the reaction. 
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Figure 4.6 A plot of absorbance of (A) a 40 11g.cm-3 ascorbic acid solution and 
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Although maximum sensitivity was observed when using a 50 em reaction coil, the 
reproducibility was poor due to a very short residence time and insufficient mixing of the 
sample zone. At the other extreme, reaction coil lengths longer than 100 em resulted in too . 
long a residence time. The reaction went to completion (colourless) and no response was 
obtained. 
Consideration of the calibration slope and concentration range is important. Too small a 
difference between the response of differing ascorbic acid standard concentrations is 
undesirable, as is a very limited concentration range. Figure 4. 7 shows an increasing 
calibration slope as the reaction coil length increases to a.maximum of 100 em. The response 
is negligible beyond this length, due to reaction completion. The concentration range for a 
reaction coil length of 100 em was 150 ~g.cm·3• A 100 em coil was selected as the optimum 
length for the reaction coil of the system. The reproducibilit¥ for replicate injections (n = 5) 
when using the 100 em reaction coil length was better than 2% for a 40 ~g.cm·3 ascorbic acid 
standard. 
4.3.1.4 Reagent Injection Volume 
A schematic diagram of the injection valve used in this study (Figure 4. 7) shows the 
pump drawing up the reagent (2,6 DCPIP) into the injection loop - the "load" position, while 
the carrier (ascorbic acid standard or urine sample) bypasses the loop. The valve is then 
switched to the "inject" position and the reagent is injected into the urine carrier stream as it 
passes through the loop. Once the maximum absorbance has been reached after the injection, 
the valve is returned to the "load" position. 
A "wash" solution of 50 % nitric acid, followed by distilled water, was used to flush the 
manifold and injection loop between samples. This "wash" prevented build-up of particulate 
matter on the walls of the manifold tubing. 
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Figure 4. 7 Schematic of a 6-port injection valve showing the reagent "load" and 
"inject" positions for a reverse-FIA manifold. The sample forms the carrier stream. 
The effect of the reagent injection volume on the sensitivity and calibration slope is 
recorded in Table 4.2. 
The sensitivity of the system increased with increasing sample injection volumes. 
Coloured zones were observed in the injected reagent zone when larger reagent injection 
volumes were used. This is a result of insufficient mixing and reaction of the sample and 
reagent components in the centre of this zone. Poor reproducibility was found for these larger 
volumes. Calibration slopes were lower when using large injection volumes. 
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Table 4.2 The effect of the reagent injection volume on (1) the response obtained for a 
40 JLg.cm·3 ascorbic acid standard, (2) the calibration slope, and (3) the correlation 
coefficient of the calibration. 
















The smallest sample injection volume {78 f . tl) showed adequate sensitivity and excellent 
reproducibility (RSD = 0.85 %, n = 5). A narrower peak width than those observed in the 
larger injection volumes was observed. Less peak tailing and carry-over and a higher sampling 
rate resulted. The calibration slope for this injection volume was the highest. Consequently, 
78 f . tl was selected as the reagent injection volume. 
4.3.1.5 Reagent Concentration 
Dye solutions of the -following concentrations were used to optimise the reagent 
concentration : (a) 0.98 X 10"3 M, (b) 1.10 X 10"3 M, (c) 1.23 X 10"3 M and (d) 1.35 X 10"3 M 
2,6 DCPIP. A 40 JJ.g.cm·3 ascorbic acid standard was used in this optimisation. 
The dye concentrations were injected into the ascorbic acid carrier stream using different 
pump flow rates. A three dimensional surface plot (Figure 4.8) shows the effect of flow rate 
and dye concentration on the response of the system. 
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Figure 4.8 Three dimensional surface plot showing the effects of 2,6 DCPIP 
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The 3-dimensional surface of the plot clearly indicates an increase in sensitivity as the 
concentration of the dye increases. The flow rates show a slight increase in sensitivity at each 
dye concentration examined. This is accounted for by the extent of zone penetration and 
therefore mixing between the reagent and sample solutions. 
High concentrations of 2,6 DCPIP resulted in the formation of solid particulate matter 
that deposited within the reaction coil. The ~igher the dye concentration, the faster the 
.. 
particulate matter formed. The solid matter caused blockages in the system. In order to 
minimise reagent cost and to reduce the problems caused by formation of solid matter in the 
reaction coil, the system was operated using a lower dye concentration of 1.23 x 10-3 M, 
despite a slight decrease of sensitivity. 
4.3.2 Final Manifold for the 2,6 DC PIP-Ascorbic Acid Method 
Final parameters used in the single line manifold (Figure 4.9) for the flow-injection 
system are listed : C - ascorbic acid carrier streams (varying concentrations); F - flow rate 
.. 
(1.99 cm3• min-1); S- sample injection (78 ~-tl); I -dye injection (1.23 x 10-3 M); RC- reaction 
coil length (100 em, 0.5 mm i.d.); D - spectrophotometer (518 nm); W - waste. All 
experiments were carried out at room temperature. (Detail of the apparatus is tabulated in 
Appendix E.) 
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Figure 4.9 Final manifold and parameters for the determination of ascorbic acid by 
FIA using 2,6 DCPIP. See text for details. 
Once the optimum parameters had been established for the 2,6 DCPIP-ascorbic acid 
FIA, the optimal conditions were tested and the results detailed in the following section. 
4.3.3 Examination of Optimal Conditions 
Optimum conditions were tested with regard to (a) repeatability (i.e. ''within sample" 
precision), (b) reproducibility (i.e. "between sample" precision) and (c) carry-over. 
4.3.3.1 Repeatability 
Within sample precision for the experimental procedure was determined as follows. A 
20 ~g.cm-3 ascorbic acid standard was injected into the system 10 times in order to obtain the 
RSD. The RSD was 0. 71 %. The manifold configuration thus yields highly repeatable results. 
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Standards of higher concentrations (60 f.tg.cm-3 and 100 f.tg.cm-~ were also injected in 
the same manner in order to confirm the repeatability of the experiment. RSD values were 
found to be acceptable in both cases, confirming the repeatability of the manifold. 
4.3.3.~ Reproducibility 
A 20 f.tg.cm-3 ascorbic acid standard was injected 10 times over a period of 5 days. The 
daily variance in absorbance was found to be low considering that fresh solutions for each 
analysis had to be prepared (Table 4.3). 
Table 4.3 Daily variation in absorbance. 
Day Absorbance (AU) 





4.3.3.3 Carry-Over and Sampling Rate 
Alternate injection of the reagent dye into low (20 f.tg.cm-~ and high (100 f.tg.cm-~ 
concentration carrier streams showed that there was no sample carry-over between 
experiments. The sampling rate for the developed method was 40 samples per hour. The 
method may also be readily automated by using computer control of the injection valve and 
adding a selection valve to select either ascorbic acid standard solutions or urine samples. 
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4.4 Expe~imental Procedure and Demonstrative Results 
Ascorbic acid determination by FIA was carried out in conjunction with the manual 
titration method (Chapter 3). The optimised manifold established for the measurement of 
ascorbic acid excreted in urine by FIA enabled measurement of ascorbic acid concentration to 
a maximum of 150 f.tg.cm-3• 
4.4.1 Experimental Procedure 
Individuals participating in the ascorbic acid experiments collected urine directly into 
glacial acetic acid at specific urine voidings {voiding "x", voiding "y" and voiding "z") during 
the 24 hour collection period (Section 3.2). Ascorbic acid excreted in the urine was initially 
determined in each of the aliquots by means of a manual titration. In instances where the 
ascorbic acid concentration exceeded the range of measurement allowed by FIA, the urine was 
suitably diluted using a prepared solution of acetic acid. The urine sample was manually 
titrated to ensure that the ascorbic acid concentration did indeed fall below the maximum 
concentration tolerable by the FIA method. 
The analogue output port of the detector was coupled to a computer data acquisition 
package (FlowTEKrM, Mintek, Randburg, South Africa) to collect and display the peak profiles 
as shown in Figure 4.10. The calibration curve for a range of standards is shown as an inset. 
Some urine sample solutions were also analysed and are shown. 
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Figure 4.10 Typical replicate profiles using the optimised manifold. The numerals 
refer to ascorbic acid concentrations in JA.g.cm-3• Letters correspond to (a) 43.6, (b) 9.6, (c) 
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4.4.2 Demonstrative Results 
The ascorbic acid concentrations determined from a calibration plot, for all the aliquots 
collected by 2 of the 10 participants during the twelve day experimental period are given in 
Table 4.4. The ascorbic acid concentrations determined in the same urine aliquots using the 
2,6 DCPIP manual titration method are also shown. (A full set of results for these analyses are 
given in Chapter 6). 
Table 4.4 Urinary ascorbic acid excretion values determined in the urine of 2 of the 10 
participants during the full twelve day experimental period measured by: (a) manual titration 
(MT) and (b) flow-injection analysis (FIA). 
RG AM 
MT FIA MT FIA 
#1 Vx - 62.8 112.1 137.0 #5vx 
Vy ,.. 5.7 72.8 78.9 Vy 
Vz - 24.2 86.8 178.8 Vz 
#2vx 27.6 57.3 113.4 155.5 #6vx 
Vy 19.9. 43.5 106.7 142.4 Vy 
Vz 10.0 23.4 43.5 79.9 Vz 
#3vx 82.1 122.9 52.6 47.1 #7vx 
Vy 53.4 89.4 84.6 132.9 Vy 
Vz 85.5 146.5 64.6 108.3 Vz 
#4vx 119.0 93.7 89.2 78.2 #8vx 
Vy 93.1 84.8 86.9 80.4 Vy 
" 
Vz 69.25 58.8 48.6 46.8 Vz 
# 1- 8 : sample number (Table 6.1) 
Vx, Vy, Vz : voiding times x, y, and z (Table 6.19) 
RG, AM : participants' initials 
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RG AM 
MT FIA MT FIA 
75.5 67.6 68.8 54.3 
161.6 136.1 58.3 47.3 
87.3 77.4 45.4 45.7 
49.0 49.5 34.7 45.3 
72.0 76.1 69.8 76.1 
96.7 91.7 10.0 7.8 
10.0 29.3 10.0 11.0 
45.3 62.9 10.0 16.6 
25.2 50.8 10.0 19.7 
29.1 60.8 10.0 20.5 
45.2 86~2 10.0 17.7 
10.0 19,.0 10.0 9.41 
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4.4.3 Statistical Evaluation and Analysis of Results 
There are two aspects to be considered in the comparison of the methods : 
(a) How repeatable are the measurements for each method ? 
(b) Are the methods comparable, in other words, do they give the same results ? 
4.4.3.1 Repeatability 
For each method the mean (n = 3) ascorbic acid concentration of the sample was plotted 
' 
against the standard deviation of the sample. The mean and the standard deviation were found 
to be independent for each method. A one-way analysis ofvariance (ANOVA) waS' carried out 
to obtain a measure of the repeatability. The British Standards Institution defines a coefficient 
of repeatability as being twice the standard deviation [10]. The manual titration method had a 
coefficient of 71.0 and FIA had a coefficient of 57.4. The F-test of the variances for each 
method showed that FIA had a significantly smaller variance (F = 1.53, P < 0.05) than does the 
manual titration method. 
It is concluded from this analysis that the repeatability of the flow-injection method is 
superior to that of the manual titration method (i.e. repeated measurements are less variable). 
This is in accordance with the expectations. FIA is inherently highly reproducible due to the 
reproducible ·nature of the sample handling procedure within the manifold tubing. 
Furthermore, the use of a spectrophotometer to monitor the reaction "pseudo-end point" 
removes any bias arising from the monitoring of a colour change during titration by eye. 
4.4.3.2 Comparison of the Methods 
It is desirable to establish whether the methods are comparable with a view to the 
replacement of the more tedious titration by the simple FIA approach. 
The statistical approach was to plot the differences of the sample means for each method 
as a function of the average of the two methods (Appendix F). The values close to zero were 
taken to be zero for the purposes of this plot. Confidence limits at 95 %have been drawn on 
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the plot. Four of the seventy-six points fall out of these limits, which is acceptable since 
statistically five out of a hundred points are expected to do so [10]. The plot enables the 
assessment of the magnitude of any possible disagreement between the methods in terms of 
bias and error. 
There is a significant bias : Ascorbic acid concentrations determined by FIA give 
concentrations that are of the order of 6.5 % higher than those concentrations determined by 
manual titration (t-value = 3; n = 76; p = 0.0021). This probably arises as a result of errors in 
the visual determination of the end point using the manual titration method. As discussed 
previously, the end point is extremely difficult to detect by eye (Section 2.5.1). To ensure that 
all the colour had been discharged from the reaction vessel there was a tendency to over-titrate 
as the endpoint was approached. This would result in lower ascorbic acid concentrations being 
found than when analysed by FlA. 
There is no evidence of a relationship between the differences and the averages 
(correlation, r = -0.1498, n = 76, p = 0.1964) of the two methods, indicating that the accuracy 
of the methods is similar. If this correlation were significant, it would indicate that there was a 
difference in the total variance of the measurements obtained by the two methods. The sample 
means for the· manual titration method have standard deviations of 39.4 (if the values below 
10 f..tg.cm·3 are included in the mean) arid 37.5 (if these low ascorbic acid concentrations a~e 
excluded from the mean) while the standard deviation for the flow-injection technique is 36.8. 
Further validation of the accuracy may be done by using a third method for the 
determination of ascorbic acid involving an enzyme assay (Boehringer Mannheim, Cat. No. 
409 677). 
4.5 Conclusions 
The design and development of a new approach to an existing titrimetric method for the 
determination of ascorbic acid in urine by 2,6 DCPIP has been successfully demonstrated. The 
flow-injection based omethod gives results .statistically similar to the existing manual batch · 
titration. The developed FIA method is more economical, rapid and is easy to implement. 
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Although the methods are similar in accuracy, FIA yields results which are more 
repeatable than those obtained by the manual titration method. The results obtained with the 
manual titration indicate over-titration of the urine which results in lower ascorbic acid 
concentrations being found. Spectrophotometric detection is used in the flow-injection 
method, and therefore the results obtained are more precise than those obtained by manual 
titration since bias associated with the end point detection is removed. 
The specificity of 2,6 DCPIP for ascorbic acid in the manual titration is known to be a 
limiting factor (Section 2.5.1). However, when using FIA and a "pseudo-end point", this 
limitation is sigiiificantly reduced due to the shorter reaction time allowed for any such 
interference to occur prior to analyte detection. Additional dilution in FIA of these interferents 
also increases the specificity. 
Further work is required to validate the accuracy of the method by comparison against 
another technique (e.g. enzyme assay). The use of on-line standard additions would se~e to 
enhance the-validity of the results in the complex urine matrix. It is envisagect that a dedicated 
FIA analyser under computer control, with an autosampler, could be developed and this would 
allow continuous measurement of ascorbic acid in a series of samples. No doubt such an 
analyser, and others like it, will become powerful tools in biochemical and biomedical 
laboratories. 
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Chapter 5. 
Haematuria after Megadose Ingestion of Ascorbic Acid 
- A Case Study 
5.1 Introduction 
A 25 year old, white male with no history of stone formation was the first participant in 
the investigation to determine the effects of ascorbic acid on the risk of kidney stone 
formation. The participant was required to ingest 8 g of ascorbic acid daily [1 ], whilst 
following his normal daily diet, in a protocol which was planned to last 9 days. The 8 g load of 
ascorbic acid was divided into 2 g doses taken four times daily : at breakfast, lunch, dinner and 
just before retiring. 
The participant collected a 24 hour urine prior to commencing the protocol to serve as a 
control. Ingestion of ascorbic acid then commenced and was continued for a further 8 days. 
Twenty-four hour urines were collected on the 1st and 51h days of the protocol to establish the 
short and long term effects of ascorbic acid on urinary oxalate and calcium oxalate 
crystallization. 
5.2 Detection of Haematuria 
Significant haematuria (blood spotting, later confirmed with a Boehringer Mannheim dip 
stick) was detected on the 81h day of the protocol. As a result, further ingestion of ascorbic 
acid was immediately suspended. Fluid intake was increased in order to dilute the urine as 
much as possible. Twenty-four hour urines were collected during the 24 hour period 
immediately following the detection of haematuria and again 5 days after the protocol was 
halted (i.e. during day 1 and day 6 post cessation of ascorbic acid ingestion). 
130 
-
Ascorbic Acid and Calcium Oxalate Kidney Stone Formation 
The 24 hour urine sample collected immediately after cessation of the ascorbic acid 
protocol was tested for the presence of blood using Boehringer Mannheim dip sticks. Aliquots 
were dispatched for full pathological analysis. A small volume of the sample was centrifuged 
and prepared for scanning electron microscopy (SEM). The final voiding of the 24 hour 
period was collected separately and analysed for blood, before being added to the 24 hour 
volume. 
5.3 Protocol Re-Evaluation 
The detection of haematuria in the urine of the first participant indicated the very real 
dangers of a high ingestion of ascorbic acid for an extended period. Although the literature 
shows conflicting opinions regarding the effects of ascorbic acid in calcium oxalate urolithiasis 
[1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 ], the potential danger of the vitamin could have been 
accentuated by the protocol used. 
As a result, the original protocol selected for the present study was altered to the 
ingestion of only 4 g of ascorbic acid for a period of 5 days (Section 3.1.2). 
5.4 Results and Discussion 
The individual in the present study collected 24 hour samples as described previously. In 
order to simplify the presentation of the results and discussion, each collection has been 
designated a sample number. Table 5.1 identifies the day on which each collection was 
effected with the corresponding sample number. 
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Table 5.1 Definition of sample collections. 
Sample 1 = control collection 
Sample 2 = first day ascorbic acid ingestion, 24 hour urine collection 
Sample 3 = fifth day ascorbic acid ingestion, 24 hour urine collection 
Sample 4 = first day post cessation of ascorbic acid ingestion, 24 hour urine collection 
Sample 5 = sixth day post cessation of ascorbic acid ingestion, 24 hour urine collection 
5.4.1 Urinary Components 
The volume, pH and chemical compositio11 of each urine were determined for the 
participant prior to, during and after the ascorbic acid protocol. These data are shown in 
Table 5.2. 
Table 5.2 Urinary excretions (mmol/24 hr), pH and volume (cm3/24 hr) during the 15 
day experimental period. 
# Mg Ca Na K Vol pH Phos Creat Cit Ox Urate CI 
1 3.78 2.13 163 61.6 1760 6.55 30.8 12.7 2.06 0.14 2.43 190 
- 2 5.76 4.50 129 41.9 1340 5.55 30.0 14.7 2.15 0.14 127 
.3 6.15 3.25 76 35.0 1675 5.55 22.4 13.5 2.05 0.34 51 
4 3.23 3.21 87 61.8 1680 5.85 23.5 13.8 2.14 0.20 1.41 111 
5 3.15 2.00 128 56.9 1440 6.35 25.5 14.5 3.14 0.21 3.19 112 
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An immediate increase in urinary magnesium excretion occurs after a 24 hour period of 
ascorbic acid ingestion (sample 2). After 5 days of ascorbic acid ingestion, a further increase in 
magnesium excretion is observed (sample 3) but values return to that of the control after 
cessation of the protocol (samples 4 and 5). Since magnesium is a known inhibitor (12, 13, 
14], the ingestion of ascorbic acid causes a decrease in the stone forming potential of the urine 
with respect to this risk factor. 
A noticeable increase in urinary calcium excretion occurs after the initial ingestion of 8 g 
of ascorbic acid (sample 2). After a prolonged period of ascorbic acid ingestion, urinary 
calcium levels are seen to decrease (sample 3) and continue to do so after the cessation of 
ascorbic acid ingestion (samples 4 and 5). After 5 days in which no ascorbic acid was ingested, 
calcium excretion in the urine was similar to the levels observed for the control collection 
(sample 1). Thus, megadose ingestion of ascorbic acid initially increases the stone formi~g risk 
of the urine, but the effect is not maintained. 
The initial ingestion of ascorbic acid causes a decrease urinary sodium, potassium and 
chloride excretion (sample 2). Urinary sodium, potassium and chloride levels decrease further 
after a prolonged period of ascorbic acid ingestion (sample 3). The excretion of these urinary 
components increased slightly after the interruption of the protocol (sample 4). While 
potassium levels remain consistently low, sodium and chloride excretion increases 5 days after 
the cessation of ascorbic acid ingestion (sample 5), but they do not return to control (sample 1) 
values, suggesting that megadose ingestion of the vitamin has carry-over effects on the 
excretion of these three components. This is particularly significant in the case of potassium 
which has been shown to cause an increase in the urinary excretion of calcium, resulting in an 
increased risk of kidney stone formation [15]. This is consistent with the findings in sample 2, 
as mentioned previously. 
The decrease in urinary pH during the ingestion period of ascorbic acid is expected due 
to the acidic nature of the vitamin. However, after the cessation of the protocol, the pH 
returns to that observed in the control sample. Thus, ascorbic acid ingestion does not have any 
long term effects on the pH of the urine. No particular trend is observed for urinary volume. 
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Previous work has shown that stone formers exhibit lower excretion values of ascorbic 
acid and citrate [16] and that citrate hinders the uptake of ascorbic acid due to competition by 
the two components for the same carrier in the gut [16]. A number of other studies have 
shown that citrate inhibits calcium oxalate growth [17] and aggregation [18, 19, 20]. 
Table 5.2 shows that citrate excretion is unaffected by the ingestion of large doses of ascorbic 
acid. Thus, inhibitory activity and the stone forming potential of the urine are unaffected. 
Urinary creatinine excretion shows no trend during the ascorbic acid protocol nor during 
the period thereafter. Creatinine levels are thus unaffected by megadose ingestion of ascorbic 
acid. 
As discussed in Section 3.3, urate levels could not be determined with confidence in 
conditions of raised ascorbic acid levels due to the masking effect of the vitamin in the analysis. 
Urinary phosphate levels decreased during the ingestion period but started to recover 
after the cessation of the protocol. Hence, ingestion of megadose quantities of ascorbic acid 
resulted in a decrease in urinary phosphate. Previous studies have shown that phosphate 
depletion can increase urinary calcium [21, 22]. In the present study, urinary calcium increased 
significantly with initial ingestion of ascorbic acid but did not remain consistently raised. 
Phosphate depletion can thus be asscociated with an 'initial increase in calcium levels and hence 
an initial increase in the stone forming potential of this individual's urine. The continued 
depletion of urinary phosphate during the protocol is noteworthy since reduced levels have 
been associated with an increased stone risk. 
5.4.2 The Metastable Limit 
The calcium oxalate metastable limits determined by turbidiometry and Coulter multisizer 
methods for each urine are given in Table 5.3. It can be seen that a decrease occurs after the 
initial ingestion of 8 g ascorbic acid. Continued megadose ascorbic acid ingestion for a period 
of 5 days caused a slight increase in the metastable limit but the value is still much lower than 
that for the control urine. Six days post cessation of ascorbic acid ingestion, the metastable 
limit of the urine had returned to its control value. Table 5.2 shows that the trend for the 
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metastable limit, irrespective of the method employed, was the same. This indicates the 
compatibility of the two techniques. 
Thus megadose ascorbic acid ingestion caused a lowering of the calcium oxalate 
metastable limit in this individual. Hence, during the protocol the nucleating potential of the 
urine would have been increased . 
. Table 5.3 Metastable limits determined by turbidiometry and Coulter multisizer. 
Turbidity (mol.dm-3) Coulter Multisizer 
(mol.dm-3) 
Sample 1 0.14 0.11 
Sample2 0.05 0.05 
Sample 3 0.07 0.07 
Sample 4 0.08 0.08 
Sample 5 0.14 0.12 
5.4.3 Urinary Oxalate Excretion · 
Urinary oxalate was determined in the bulk 24 hour sample and in the representative 
sample containing 10 mmol.dm-3 EDTA preservative (Table 5.4). 
Urinary oxalate excretion increased during the 5 day period of ascorbic acid ingestion 
relative to its pre-protocol value. The sudden interruption of the protocol prevented the 
oxalate excretion in the urine being determined after 9 consecutive days of ascorbic acid 
ingestion. The urinary oxalate excretion decreased during the 24 hour period post cessation 
ascorbic acid ingestion, but a further decrease was not observed 6 days later. Thus urinary 
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oxalate remained slightly raised with respect to the control excretion values. The trend 
suggests that ingestion of ascorbic acid results in in vivo conversion of ascorbic acid to oxalic 
acid, thereby increasing the stone forming potential in the urine of this individual. 
Table 5.4 Urinary oxalate excretion (mmol/24 hours) during the 15 day experimental 
period. 
Bulk 24 hr Sample Representative 
Sample + EDTA 
Sample 1 0.141 0.114 
Sample 2 0.140 0.136 
Sample 3 0.340 0.410 
Sample4 0.200 0.210 
Sample 5 0.210 0.200 
It is noted that the representative samples with EDTA are not significantly different to 
unpreserved samples, indicating that this participant's urine did not undergo in vitro 
conversion of ascorbic acid to oxalic acid. However generalisations cannot be made. While 
conversion of ascorbate to oxalate might occur in some urine, its complex nature plays an 
important role in determining the extent to which in vitro conversion occurs. · Thus, the 
conversion occurs to a lesser extent in some urines while in others it does not occur at all. 
5.4.4 Ascorbic Acid Concentration 
Ascorbic acid concentrations were measured using the 2,6 DCPIP manual titration. FIA 
could not be used to determine ascorbic acid concentrations in urines with high ascorbic acid 
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loads since FIA determination of the vitamin concentrations was limited to a maximum 
concentration of 150 J,lg.cm -3• Urines were diluted after the total ascorbic acid concentration 
had been determined in order to compare the results obtained by the two meth~s. 
A noticeable increase in ascorbic acid concentration occurs after the ingestion of 8 g of 
ascorbic acid (Table 5.5). After 5 days of continued ingestion, the concentration of urinary 
ascorbic acid has not increased further and might have reached a plateau value. It has been 
previously recorded that reabsorption of ascorbic acid by the gut is limited to 2.16 cm3.min·l 
[23] and that when the vitamin is presented to the kidney tubules at a rate greater than this, the 
excess ascorbic acid is excreted in the urine. As the dose increases, so the absorption 
decreases and the process eventually attains a level of supersaturation [24]. Unfortunately the 
sudden interruption of ascorbic acid ingestion prevented a third measurement of ascorbic acid 
concentration. This would have permitted investigation of eossible plateau formation in the 
concentration level. However, since an immediate increase in ascorbic acid concentration 
occurred after the initial ingestion of 8 g ascorbic acid and appeared to level pff as the protocol 
proceeded, it is. suggested that this individual probably absorbed only that amount of ascorbic 
acid which his body required while the remainder was excreted. A level of supersaturation was 
thus probably attained with excess ascorbic acid being excreted. 
Table 5.5 shows the mean ascorbic acid concentration (voiding "x", "y" and "z") for the 
participant collected as discussed in Section 3.2. Ascorbic acid concentration in the urine 
decreased considerably in the 24 hour period immediately post ascorbic acid ingestion and that 
a further de<;rease is observed 6 days after the ascorbic acid ingestion was suspended. These 
decreases in concentration are probably due to suspension of ascorbic acid ingestion as well as 
to increased urinary volumes as the participant was instructed to increase his fluid intake 
immediately after haematuria had been detected. 
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Table 5.5 Mean ascorbic acid concentrations for three specified voidings (over 24 













The adult human body accumulates a limited amount of ascorbic acid (normally 2 - 3 g) 
which can rise to a maximum of 4 g [25]. At this point, any intake in excess of the daily rate of 
metabolism is absorbed but promptly excreted unchanged through the kidneys [25]. That 
which is metabolised is broken down in the liver, and to some extent also by the kidney, in a 
series of reactions culminating in oxalic acid, which is excreted in the urine [25]. From a 
dietary point of view, ascorbic acid intake is viewed primarily as being required to prevent 
scurvy with as little as 10 mg daily being effective in this respect. The recommended daily 
allowance (RDA) varies : 30 mg in the United Kingdom [25], 60 mg according to Gowenlock 
et al. [26], and according to laboratory rat ascorl;>ic acid tests, an amount has been calculated 
that is equivalent to 2 g [25]. The daily output of ascorbic acid is approximately half the 
minimum intake, usually about 20 - 30 mg [26]. After 5 days post cessation ascorbic acid 
ingestion urinary ascorbic acid levels had almost returned to the expected daily output levels of 
the vitamin. 
There are a number of problems associated with experimental analysis of urinary ascorbic 
acid. Firstly, analysis must be performed on fresh samples (even if a stabilising preservative 
such as EDTA or glacial acetic acid is present) [26]. Thus, the total amount of ascorbic acid 
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excreted in the urine in a 24 hour period cannot be determined easily. Secondly, the presence 
of the presetvative which is necessary to prevent the conversion to oxalate prevents certain 
other investigations (e.g. crystallization experiments) being performed since chelation of 
urinary calcium by EDTA occurs. The concentrations were averaged for the three ascorbic 
acid samples in each 24 hour collection since this appeared to be the most practical way to 
report the data. 
5.4.5 Tiselius Risk Index and CaOx Relative Supersaturation 
The Tiselius risk index [27] was determined for each 24 hour urine collection. The 
results are presented in Table 5.6. It is noted that the risk index increased after the initial 
ingestion of 8 g ascorbic acid and that a further increase occurred after the participant had 
ingested 8 g ascorbic acid daily for a period of 5 days. During the 24 hour period immediately 
post cessation of ascorbic acid ingestion the value decreased and a further decrease was 
obsetved 6 days later. The trend of the Tiselius biochemical risk index obsetved in this 
individual indicates that prolonged ascorbic acid ingestion caused an increase in the stone 
forming potential of the urine. 
Table 5.6 Tiselius risk index and calcium oxalate relative supersaturation values. 
Tiselius Risk CaOx Relative 
Index Supersaturation . 
Sample 1 114.2 1.097 
Sample2 146.0 3.150 
Sample 3 317.5 5.456 
Sample 4 195.3 3.761 
Sample 5 131.6 1.975 
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The calcium oxalate relative supersaturation values (28] determined for each 24 hour 
sample show the same trend as that observed for the Tiselius risk index (Table 5.6). This 
provides further evidence supporting the observations that prolonged ingestion of megadose 
quantities of ascorbic acid increased the risk of stone formation in this individual. 
5.4.6 Scanning Electron Microscopy 
Scanning electron microscopy (SEM) observations have been summarised in Table 5.7. 
Very few calcium oxalate dihydrate (COD) single crystals or aggregates were observed prior 
to the development of haematuria (samples 1, 2 and 3, Table 5.7). However, varying amounts 
of epithelial debris and organic mucoid material were detected in these samples. In the single 
sample voiding collected 12 hours after the detection of haematuria, numerous single COD 
crystals ( -5 ~m cross section) were noted, together with large, jagged COD crystal aggregates 
(25 ~m to 100 ~m cross section). Typical examples of individual and . aggregated COD 
crystals are -shown in Figures 5.1, 5.2 and 5.3. The sample collected 24 hours after cessation 
of the protocol showed the presence of a few isolated single COD crystals as well as a few 
isolated crystal aggregates. These were much smaller than those observed in the sample 
collected 12 hours after the detection of haematuria and displayed much "cleaner" crystal 
surfaces due to the relative absence of organic mucoid material (Figure 5.4). The sample 
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Table 5.7 A summary of the observations by SEM analysis. 
Single Aggregate Epithelial Organic Blood 
COD's COD's Debris Matter Cells 
Sample 1 a a ~ ~ a 
Sample 2 a a ~ ~ a 
Sample 3 a a ~ ~ a 
12 hrs Post Cessn. 0 (- 5 f.tm) 0 (- 25 - 1 00 f.tm) ~ ~ ~ 
Sample 4 ~ ~ a a a 
Sample 5 a a a a a 
a - not detected 
f3 = small quantities detected 
o (-X f.tm) = substantial visible particulate matter 
Figure 5.1 Single COD crystals (-5 f.tm in cross section) covered in an organic 
mucoid layer observed in urine collected 12 hours after the detection of haematuria. 
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Figure 5.2 COD crystal aggregate (-25 ~-tm m cross section) observed in urzne 
collected 12 hours after the detection of haematuria. 
Figure 5.3 Gigantic COD crystal aggregates (-100 ~-tm in cross section) observed in 
urine collected 12 hours after the detection of haematuria. 
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Figure 5.4 Small, isolated COD crystal aggregates (-25 !J.m zn cross section) 
observed in urine collected 24 hours after cessation of the protocol. 
5.5 Conclusions 
The results of this case study demonstrate that ascorbic acid ingestion induced calcium 
oxalate crystalluria in this individual. The passage of the crystals and aggregates thereof 
probably caused irritation and epithelial injury manifesting as haematuria. Although this 
individual's response to ascorbic acid ingestion is probably rare, it should be brought to the 
attention of stone researchers as high dosage of ascorbic acid by such individuals could have 
undesirable results. 
Within 8 months of these investigations, the individual concerned notified the Kidney 
Stone Research Unit (U.C.T) on further developments related to his health. As a result of 
severe, pulsing lower back pain he consulted a general practitioner. Pathological investigation 
indicated haematuria in the urine. Ultra-sound scans showed significant inflammation of the 
ureter just below the kidney suggesting that the individual had probably passed gravel or a 
small kidney stone(s). The health of the individual will continue to be monitored. 
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Chapter 6. 
Experimental Results 
The 10 participants collected 24 hour samples as described previously. In order to 
simplify the presentation of the results and discussion, each collection has been designated a 
sample number. Table 6.1 describes the collection procedure corresponding to each sample 
number. 
Table 6.1 Description of sample collection procedures followed. 
Sample 1. = control collection 
Sample 2 = control collection 
Sample 3 = first day ascorbic acid ingestion, 24 hour urine collection 
Sample 4. = third day ascorbic acid ingestion, 24 hour urine collection 
Sample 5 = fifth day ascorbic acid ingestion, 24 hour urine collection 
Sample 6 = first day post cessation ascorbic acid, 24 hour urine collection 
Sample 7 = third day post cessation ascorbic acid, 24 hour urine collection 
Sample 8 = fifth day po.st cessation ascorbic acid, 24 hour urine collection 
In the statistical analysis, the samples were grouped into the following categories: 
• samples 1 and 2 : samples collected prior to ascorbic acid ingestion .. 
• samples 3, 4 and 5 samples collected during the period of ascorbic acid ingestion 
• samples 6, 7 and 8 samples collected in the period post cessation ascorbic acid ingestion 
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6.1 Urinary Components 
The volume, pH and chemical composition of each urine were determined for each 
participant prior to, during and after the ascorbic acid experimental period. The total excretion 
(mmol per 24 hours) of each component for respective participants are shown in Appendix D. 
Mean excretions, pH and volumes are shown in Table 6.2. 
·--
Statistical analysis was carried out for each urinary component. Comparisons were made 
between mean excretions prior to, during and after the ascorbic acid experimental period. In 
addition, trends observed during the five day period of ascorbic acid ingestion (samples 3, 4 
and 5) and the five days post cessation of the protocol (samples 6, 7 and 8) were analysed. 
Table 6.2 Mean excretions of the urinary chemical components (mmol/24 hr), pH and 
volume (cm3/24 hr) for the 10 participants at different stages during the 12 day experimental 
period. 
# -Mg Ca Na K Vol pH Phos Creat Cit Urate Cl 
1 3.16 2.73 98.11 60.86 1457 6.23 24.34 12.09 2.17 3.15 126.7 
2 3.04 2.36 95.59 51.83 1506 6.24 26.04 12.29 2.16 3.20 120.1 
3 4.30 2.90 108.74 65.71 1862 6.08 24.48 12.90 2.11 132.3 
4 4.09 2.73 86.30 61.05 1787 6.01 24.40 12.34 2.22 98.1 
5 3.63 2.79 94.75 42.04 1586 6.03 24.94 12.49 2.06 0.72 127.0 
6 3.60 2.86 115.29 44.33 1433 6.12 20.01 11.25 1.91 1.24 124.3 
7 3.01 2.16 61.88 33.38 1620 6.13 20.30 12.28 2.05 2.84 89.3 
8 2.96 2.42 110.86 52.24 1552 6.20 23.18 11.72 2.13 3.04 127.7 
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Probability values for those components in which no significant trends were observed are 
shown in Table 6.3. 
Table 6.3 Tabulation of probability values of urinary components which showed no 
specific changes during the 12 day experimental period. 
Sample No. Creatinine Chloride Citrate Calcium Sodium 
1,2 vs 3,4,5 0.5593 0.7440 0.8651 0.3558 0.9839 
trend 3-4-5 0.6892 0.7900 0.'8632 0.8071 0.4706 
3,4,5 vs 6 0.1165 0.7506 0.3643 0.8869 0.2394 
trend 6-7-8 0.6572 0.8690 0.4678 0.3453- 0.8245 
1,2 vs 6,7,8 0.6393 0.4663 0.4953 0.8150 0.9468 
Probability values of urinary components in which ascorbic acid ingestion resulted in 
significant changes in urinary composition are listed in Table 6.4. Resultant trends observed in 
these components are shown graphically in Figures 6.1 to 6.7. 
Table 6.4 Tabulation of probability values of specific urinary components which 
showed significant changes during the 12 day experimental period. 
Sample No. Magnesium Potassium Phosphate Urate pH Volume 
1,2 vs 3,4,5 0.0050* 0.9913 0.7457 0.0400* 0.0495* 0.0350* 
trend 3-4-5 0.1696 0.0368* 0.8687 - 0.7415 0.1504 
3,4,5 vs 6 0.3016· 0.1924 0.0465* 0.6183 0.5186 0.0482* 
trend 6-7-8 0.2059 0.4920 0.2717 0.0003* 0.5878 0.5463 
1,2 VS 6,7,8 
0
0.7751 0.0759- 0.0292* 0.0060 0.3860 0.6651 
* significantly different at 95 % confidence 
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Urate could not be measured in urines where ascorbic acid concentrations were greater 
than 1136 ~-tmol.dm-3 [1, 2]. Thus in Table 6.4, the first comparison involving urate is between 
the means of samples 1 and 2 versus sample 5 and in the second comparison it is between only 
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Figure 6.1 The trend of magnesium excretion (mmol/24 hr) during the experimental 
procedure. 
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Figure 6.3 The trend of phosphate excretion (mmol/24hr) during the experimental 
procedure. 
151 
Ascorbic Acid and Calcium Oxalate Kidney Stone Formation 
4 














~ 1 ~ ..... 
;::::, 
0 
1 2 3 4 5 6 7 8 
Sample Number 













1 2 3 4 5 6 7 8 
Sample Nu.mber 
Figure 6.5 The trend of pH during the experimental procedure. 
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Figure 6.6 The trend of urinary volume ( cm3 /24hr) during the experimental procedure. 
6.2 Urinary Oxalate 
Table 6.5 describes the manner in which the each of the urine fractions was preserved in 
the case of urinary oxalate analysis for each urine sample collected. 
Table 6.5 Key to the presence and absence of preservative zn the urzne sample 
collections. 
a = bulk 24.hour cotlection (no preservative present) 
b = representative 24 hour collection + EDTA preservative 
c = representative 24 hour collection- EDTA preservative 
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Urinary oxalate excretion values, determined by enzymatic assay, were measured in the 
presence and absence of an EDTA preservative (Chapter 3). Table 6.6 shows the mean 
oxalate excretions for corresponding days in the collection experimental period. Oxalate 
excretions are shown for the bulk 24 hour collection and the two representative sample 
collections, in the presence and absence of EDTA. 
Table 6.6 Mean oxalate excretion (mmols/24 hr) values determined for each sample 
during the experimental period, in the pres(!nce and absence of EDTA. 
Sample Number Bulk Sample Representative Representative . 
Sample + EDTA Sample - EDTA 
1 0.198 - 0.157 0.198 
2 0.182 0.147 0.198 
3 0.222 0.183 0.220 -
4 0.218 0.176 0.251 
5 0.255 0.171 0.292 
6 0.166 - 0.137 0.200 
7 0.204 0.148 0.231 
-
-
8 0.198 0.158 0.224 
Overall Means 0.205 0.106 0.226 
-
Figure 6.7 shows a histogram of the mean urinary oxalate excretion determined for each 
sample during the ascorbic acid experimental period. It is noted that oxalate values in the 
EDT A preserved samples are lower than those recorded in its absence. (This suggests that 
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EDTA prevents the in vitro conversion of ascorbic acid to oxalic acid which is discussed 
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·Figure 6. 7 Histogram showing preservative effects of EDTA on mean urinary oxalate 
values and the trend of oxalate excretion (mmol/24hr) during the experimental period. 
Table 6.7 shows the probability values for the comparison of mean urinary oxalate values 
in the presence and absence of EDTA. Probability values show the comparison between "a" 
and "b", "a" and "c" and "b" and "c" (e.g. probability for the comparison of "a" and "b" is 
0.0015). 
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Table 6. 7 Probability values for the comparison of urinary oxalate values. 
Preservative b c 
a 0.0015 * 0.1565 
b 0.0001* 
* significantly different at 95 % confidence 
a : bulk, b : representative + EDTA, c : representative - EDTA 
The effect of ascorbic acid ingestion on urinary oxalate was determined for the bulk 
sample, the representative sample + EDTA. and the representative sample - EDTA 
(Figure 6.7). Statistical analysis was carried out in each case. Table 6.8 shows the probability 
values obtained :in comparing the oxalate concentrations during the different periods of the 
experimental period. 
Table 6.8 Probability values determined for the comparison of oxalate excretions in 
preserved and unpreserved urines during different periods of the experimental period. 
a b c 
samples 1,2 vs samples 3,4,5 0.0723 0.2873 0.0093 * 
trend 3- 4- 5 0.3587 > 0.050 0.0461 * 
samples 3,4,5 vs sample 8 0.0252 * 0.1764 0.0640 * 
trend 6- 7-8 0.3902 0.5659 0.5128 
samples 1,2 vs samples 6,7,8 0.9777 0.8534 0.3854 
* significantly different at 95 % confidence 
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6.3 Metastable Limits 
The metastable limit for each participant was determined by means of turbidiometry 
[3, 4] and Coulter multisizer [5, 6, 7, 8, 9, 10]. In each case, equal volumes of filtered urine 
were dosed with increasing concentrations of sodium oxalate. The turbidity (or particle 
number) of each consecutive sample was measured and the result plotted against the 
corresponding sodium oxalate concentration. The MSL was determined by interpolation of the 
line to the abscissa [10]. The metastable limits measured for each participant are shown in' 
Tables 6.9 and 6.10. 
Table 6.9 Metastable limits (mol of NaOx. dm-3) determined by turbidiometery. 
# PT ES PR SH MG GV BM cw RG AM 
1 0.10 0.09 0.04 0.04 0.09 0.20 0.15 0.06 0.04 0.04 
2 0.10 0.11 0.07 0.03 0.12 0.18 0.20 0.01 0.20 
3 0.12 0.12 0.10 0.06 0.07 0.11 0.08 0.06 0.05 0.20 
4 0.13 0.08 0.10 0.10 0.07 0.19 0.18 0.01 0.03 0.14 
5 0.10 0.07 0.05 0.05 0.04 0.20 0.04 0.03 0.03 0.20 
6 0.07 0.07 0.06 0.02 0.09 0.20 0.11 0.03 0.04 0.20 
7 0.18 0.09 0.04 0.05 0.10 0.20 0.11 0.05 0.04 0.20 
8 0.11 0.09 0.13 0.04 0.08 0.20 0.04 0.04 0.20 
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Table 6.10 Metastable limits (mol of NaOx. dm-3) determined by Coulter multisizer. 
# PT ES PR SH MG GV BM cw RG AM 
1 0.10 0.03 0.04 0.06 0.20 0.10 0.04 0.04 
2 0.10 0.08 0.01 0.12 0.17 0.20 0.20 
3 0.13 0.09 0.04 0.05 0.11 0.06 0.04 0.18 
4 0.11 0.08 0.08 0.05 0.06 0.20 0.16 0.01 0.03 0.10 
5 0.11 0.04- 0.02 0.20 0.05 0.03 0.02 0.16 
6 0.08 0.05 0.06 0.01 0.07 0.20 0.09 0.03 0.04 0.17 
7 0.17 0.09 0.04 0.07 0.11 0.20 0.05 0.04 0.17 
8 - 0.11 0.04 0.20 0.06 0.04 0.20 
There were a number of cases in which the metastable limit exceeded the highest 
prepared sodium oxalate dosing concentration. As a result, it was necessary to group the 
metastable limit data into three categories in order to carry out a statistical analysis. The 
categories were : 
(i) less than or equal to a sodium oxalate dose concentration of 0.07 M 
(ii) within the range of 0.07 M to 0.20 M 
(iii) greater than or equal to a sodium oxalate dosing concentration of 0.20 M 
The data for turbidiometry and Coulter multisizer were combined_ into two-way tables 
(Tables 6.11 and 6.12 respectively). The hypothesis tested in each two way table was whether 
the proportions of data falling into the three categories of metastable limits was constant over 
the three categories of the samples. Fisher's exact test was employed to test this hypothesis 
[11]. The probabilities from the Fisher exact test (turbidiometry (P = 0.798) and Coulter 
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Table 6.11 Statistical data for the metastable limits determined by turbidiometery. 
MSL Range (M) Samples 1,2 Samples 3,4,5 Samples 6, 7,8 Totals 
~ 0.07 8 (42.1 %) 13 (50.0 %) 13 (44.8 %) 34 (43.6 %) 
0.07 to 0.2 8 (42.1 %) 14 (46.7 %) 10 (34.5 %) 32 (41.0%) 
~0.2 3 (15.8 %) 3 (10.0 %) 6 (20_~7 %) 12 (15.4%) 
Totals 19 (24.4 %) 30 (38.5 %) 29 (37.1 %) 78 
Fisher's Exact Test p = 0.798 
Table 6.12 Statistical data for the metastable limits determined by Coulter multisizer. 
MSL Range (M) Samples 1,2 Samples 3,4,5 Samples 6, 7,8 Totals 
~ 0.07 6 (42.9 %) 13 (50.0 %) 13 (52.0 %) 32 (49.2 %) 
0.07 to 0.2 6 (42.9 %) 11 (42.3 %) 8 (32.0 %) 25 (38.5 %) 
~0.2 2 (14.3 %) 2 (7.70 %) 4 (16.0 %) 8 (123 %) 
Totals 14 (21.5 %) 26 (40.0 %) 25 (38.5 %) 65 
Fisher's Exact Test p = 0.833 
6.4 Kinetics of Crystallization 
Crystal growth and/or aggregation can be measured by dosing a specific volume of urine 
with sodium oxalate of concentration equal to the metastable limit (or formation product) 
concentration and measuring the subsequent increase in turbidity or particle number (volume) 
as a function of time [10]. A plot of the measurement versus time typically shows an initial 
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time lag followed by a rising linear portion (Chapter 3), the slope of which is used as an index 
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Figure 6.8 Typical plot of crystallization determined by means of turbidiometry. The 
linear portion indicated on the J!lot is used as an index of the rate of crystallization. 
Table 6.13 shows the calcium oxalate crystallization rate (gradient) determined by 
turbidiometry for each of the participants at various stages of the experimental period. The 
crystallization rates determined by means of Coulter multisizer are shown in Table 6.14. 
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Table 6.13 Initial calcium oxalate crystallization rates determined at the metastable 
limit by means ofturbidiometry (TU.min-1) 
• 
PT ES PR SH MG GV BM cw RG AM 
1 0.594 0.472 0.423 0.250 0.380 -0 0.568 0.578 0.820 0.298 
2. 0.450 0.675 0.563 0.725 0.417 0.798 0.824 0.737 0.450 1.333 
3 0.901 0.778 0.635 0.308 0.542 0.220 0.009 0.294 0.340 1.025 
4 1.520 0.558 0.115 0.957 0.366 0.443 0.090 0.260 
5 4.836 0.483 0.221 0.002 0.757 0.243 0.003 0.040 0.062 1.307 
6 0.402 0.782 0.019 0.351 0.300 0.002 0.932 0.153 0.123 0.863 
7 1.850 0.583 0.226 0.160 0.103 0.001 0.530 0.278 0.267 1.125 
8 1.030 1.103 0.130 0.383 -0. 0.194 0.460 0.815 
Table 6.14 Initial crystallization rates determined at the metastable limit by means of 
Coulter multisizer (particles.min-1). 
PT ES PR SH MG GV BM cw RG AM 
1 372.2 303.4 206.9 13.5 8.9 298.5 600.7 
2 220.5 169.2 61.6 125.0 346.2 226.0 235.0 
3 234.0 78.6 134.9 104.8 377.3 303.3 269.7 
4 425.6 336.0 92.6 311.1 20.8 391.4 505.3 5.1 522.6 401.1 
5 423.6 291.7 122.6 52.8 342.4 - ... 244.5 398.1 
6 333.6 347.1 334.6 196.4 133.1 18.7 476.9 442.7 306.0 146.5 
7 479.5 387.0 372.4 194.7 8.9 253.9 239.4 266.7 
8 231.9 1.4 323.4 138.7 
161 
Ascorbic Acid and Calcium Oxalate Kidney Stone Formation 
In addition, crystallization rates for each participant were also determined at a 
~·standard"" sodium oxalate dosing· concentration which was maintained constant throughout 
the crystallization experiments for a specific participant. The resultant crystallization rates for 
turbidiometry and Coulter measurements are listed in Table 6.15 and Table 6.16 respectively. 
Data collection by turbidiometry and Coulter multisizer for the "standard" sodium 
oxalate dosing concentrations were incomplete for several reasons. In some cases this was due 
to "overdosing" (denoted o/s) while in others, equipment failure played a role. 
Table 6.15 Initial calcium oxalate crystallization rates determined after administration 
of a "standard, sodium oxalate dosing concentration: turbidiometry data (TU.min-1). 
·-
PT ES PR SH MG GV BM cw RG AM 
1 0.635 0.574 0.250 0.380 -0 0.568 0.578 0.248 
2 0.675 0.563 o/s 0.281 0.546 0.263 0.518 0.338 1.333 
3 0.361 0.635 0.093 o/s o/s o/s 0.075 0.006 1.025 
4 0.816 0.115 0.009 o/s 0.443 0.155 0.260 o/s 
5 o/s o/s o/s o/s 0.243 o/s . 0.264 0.320 1.307 
6 o/s 1.063 1.282 0.695 0.002 o/s 0.486 0.123 1.863 
7 0.695 o/s 0.022 0.075 0.001 1.448 . 0.278 0.008 1.125 
8 0.357 0.130 __ 0.830 -0 -0 0.194 0.192 0.813 
The "standard" dosing concentration was based on the metastable limit concentrations of the two samples 
collected prior to ascorbic acid ingestion. 
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Table 6.16 Initial calcium oxalate crystallization rates determined after administration 
of a "standard" sodium oxalate dosing concentration . Coulter multisizer data . 
(particles.min -J ). 
PT ES PR SH -MG GV BM cw RG AM 
1 303.4 206.9 13.5 8.9 298.5 600.7 
2 30.9 o/s 346.2 332.3 235.0 
3 132.7 134.9 441.9 o/s o/s 303.3 254.6 
4 o/s 92.6 11.0 218.3 391.4 505.3 o/s 613.2 o/s 
5 o/s 291.7 397.9 52.8 o/s 511.1 398.1 
6 o/s o/s o/s 133.1 18.7 o/s 668.3 304.0 163.9 
7 277.9 o/s 191.1 8.9 253.9 239.4 266.7 
8 1.4 o/s 323.4 138.7 
6.5 Sedimentation of Calcium Oxalate in Urine 
In a trial investigation, an attempt was made !o determine the rate of aggregation of 
calcium oxalate monohydrate (COM) crystals using the method developed by Hess et al. [12]. 
However, the results obtained by turbidiometery were erratic. Consequently, a different 
monitoring method was used in which an aliquot of supersaturated urine was transferred to a 
spectrophotometer cuvette and absorbance measurements were determined in lieu of 
turbidiometry measurements. The decrease in absorbance 'is due to the settling of particles, _ 
controlled by particle size [12]. Facilities were inadequate to carry out a detailed examination 
of this method (Chapter 7) and hence results were only obtained in a few urine samples. A plot 
of absorbance as a function of time (Figure 6.9) illustrates the trend of calcium oxalate crystal 
sedimentation in the urine of one of the participants in this study. The gradient of the linear 
portion of the graph is equivalent to the aggregation rate (terminal velocity) of the COM 
crystals settling in supersaturated urines. The COM aggregation rates presented in Table 6.17 
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have been determined from 2 urine samples supplied by the same individual. These urine 
samples (analysis 1 and 2) were collected as "once off' samples in order to test the COM 
sedimentation experiment and are not associated with the full sample analysis carried out for 
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Figure 6.9 A typical experimental plot of absorbance vs time showing the rate of 
calcium oxalate crystal sedimentation in urine. 
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Table 6.17 The crystal aggregation rate of COM crystals in saturated urines with the 
correlation coefficient corresponding to the linear portion-of the plot. 
Analysis No. COM Aggregation Rate (s-1) r 
1 0.21 x 10·2 0.9914 
2 4.80 x w·2 0.9910 
6.6 Ascorbic Acid Concentration 
Table 6.18 Key to specific urine voidings used for ascorbic acid analysis during the 24 
hour urine collection. 
voiding x = the second voiding during the 24 hour collection period 
voiding y = the fourth voiding during the 24 hour collection period 
voiding z = the final voiding during the 24 hour collection period (i.e. the voiding 
Ascorbic acid was determined by FIA using the same chemicals as in the manual titration 
(Chapter 4). The ascorbic acid analysis by FIA was limited to a maximum concentration of 
150 J,lg.cm·3• After the determination of ascorbic acid by manual titration, the urine sample 
was diluted to ensure that the ascorbic acid concentration was within this range. The diluted 
sample was titrated with 2,6 DCPIP and analysed by FlA. This was carried out for each urine 
voiding for each participant. The results for both methods are shown in Table 6.19. 
The table uses the following abbreviations : 
# 1- 8 : sample number (Table 6.1) 
Vx, Vy, Vz : voiding times (Table 6.19) 
PT, ES, PR, SH, MG, GV, BM, CW, RG, AM participants' initials 
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Table 6.19 Ascorbic acid concentration determined in diluted urine samples 
by (a) manual titration (MT) and (b) flow-injection analysis (FIA). 
PT ES PR- SH 
MT FIA MT FIA MT FIA MT FIA 
#1 Vx 32.6 26.3 10 13.4 51.1 46.7 46.9 122.5 
Vy 58.8 54.1 10 4.4 15.9 44.5 48.6 110.5 
Vz 18.6 14.6 80.8 83.2 17.3 31.3 84.6 71.4 
#2vx 10 8.9 55.3 64.4 10 13.7 59.0 60.4 
Vy 10 10.8 10 14.4 -17.9, 20.6 56.0 43.3 
Vz 11.6 7.1 67.5 80.1 10 4.2 25.5 50.92 
#3vx 51.2 52.1 39.5 46.1 10 37.9 15.1 13.7 
Vy 94.6 133.6 67.9 69.2 121.6 109.9 52.0 41.9 
Vz 56.8 54.0 102.5 98.5 94.1 142.1 160.3 141.0 
#4vx 39.8 38.3 122.7 102.1 171.5 113.8 92.5 74.8 
Vy 66.8 78.2 44.7 54.4 131.7 126.8 126.1 100.0 
Vz 76.7 71.4 125.5 107.5 142.5 153.1 160.2 110.1 
#5vx 17.3 65.9 116.4 105.5 138.5 145.9 73.8 72.8 
Vy 138.1 119.6 47.1 57.1 116.5 123.7 68.0 63.9 
Vz 127.4 124.4 174.8 160.8 197.9 205.3 172.8 143.5 
#6vx 68.1 85.3 113.3 127.8 50.3 71.9 81.5 -
Vy 67.5 92.1 127.8 165.0 112.2 104.6 100.4 -
Vz 97.4 145.4 62.2 116.5 159.8 148.9 99.1 123.0 
#7vx 25.4 21.7 61.3 53.3 63.1 52.3 26.6 21.5 
Vy 76.6 52.9 24.3 22.7 81.7 81.6 22.9 22.9 
Vz 21.7 17.3 32.2 -- 28.4 92.2 79.5 33.4 40.7 
#8vx 14.3 13.3 31.3 40.1 69.8 69.4 24.2 -
Vy 28.5 20.1 10 6.3 93.2 102.6 151.9 -
Vz 18.6 29.0 10 24.9 194.7 159.4 14.7 -
continues overleaf . .. 
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Table 6.19 continued 
MG GV BM cw 
MT FIA MT FIA MT FIA MT- FIA 
#1 Vx 10.0 11.7 - - 10.0 18.5 37.0 55.5 
Vy 10.0 8.2 - - - - 20.3 47.3 
Vi 40.0 46.0 10.0 18.9 10.0 25.3 19.7 53.4 
#2vx 39.5 44.9 10.0 13.1 11.5 16.7 16.0 62.4 
Vy 10.0 8.5 21.5" 23.4 40.7 33.1 46.4 57.9 
Vz 10;0 13.7 10.0 9.9 22.~ 66.7 30.2 95.8 
#3vx 173.4 104.3 35.9 32.6 10.0 30.5 25.7 71.4 
Vy 102.8 80.9 94.7 81.1 10.0 19.9 61.7 117.7 
Vz 97.5 77.8 69.5 58.2 98.2 65.1 227.9 ---
#4vx 102.3 86.1 80.3 90.0 92.5 73.5 78.4 40.7 
Vy 64.6 71.6 91.8 96.3. 80.9 72.7 138.6 99.7. 
Vz 84.6 87.4 91.9 92.0 87.6 73.4 133.7 73.3 
#5vx --- 103.5 75.6 - - 31.9 22.6 49.0 52.7 
Vy 63.8 70.8 60.3 67.5 33.5 45.2 42.9 45.2 
Vz 133.9 142.8 51.2 60.0 69.0 82.7 53.1 73.0 
#6vx - - 124.7 120.9 45.1 63.8 45.5 62.0 
Vy - - - - 26.4 33.7 51.0 74.7 
Vz 24.7 21.5 24.1 32.0 32.4 47.5 40.8 68.5 
#7vx 29.6 53.0 32.7 30.0 -10.0 5.6 60.6 51.9 
Vy 21.5 18.1 - - 10.0 5.4 19.5 15.2 
Vz 16.4 13.0 10.0 6.1 10.0 11.8 62.7 61.4 
#8vx 20.7 49.4 135.1 111.6 - - 55.2 -
Vy 10.0 11.6 - - - - 22.1 -
-· Vz - 12.9 20.9 66.3 79.1 - - 22.2 -
continues overleaf ... 
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Table 6.19 continued 
RG AM 
MT PIA MT PIA 
#1 Vx - 62.8 112.1 137.0 
Vy - 5.7 72.8 78.9 
Vz - 24.2 . 86.8 178.8 
#2vx 27.6 57.3 113.4 155.5 
Vy 19.9 43.5 106.7 142.4 
Vz 10.0 23.4 43.5 79.9 
#3vx 82.1 122.9 52.6 47.1 
Vy 53.4 89.4 84.6 132.9 
Vz 85.5 146.5 64.6 108.3 
#4vx 119.0 -93.7 89.2 78.2 
Vy 93.1 84.8 86.9 80.4 
Vz 69.3 58.8 48.6 46.8 
#5vx 75.5 67.6 68.8 54.3 
Vy 161.6 136.1 58.3 47.3 
Vz 87.3 77.4 45.4 45.7 
#6vx 49.0 49.5 34.7 45.3 
Vy 72.0 76.1 69.8 76.1 
--
Vz 96.7 91.7 10.0 7.8 
#7vx 10.0 29.3 10.0 11.0 
Vy 45.3 62.9 10.0 16.6 
Vz 25.2 50.8 10.0 19.7 
#8vx 29.1 60.8 10.0 20.5 
Vy 45.2 86.2 10.0 17.7 
Vz 10.0 19.0 10.0 9.41 
The individual ascorbic acid concentrations determined by manual titration at the 
specified collections during the 24 hour collection period for each of the participants during the 
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experimental period are given in Appendix D. The mean ascorbic acid concentrations for all 
participants at each of the above defined voiding times during the 12 day experimental period 
are given in Table 6.20. 
Table 6.20 Mean ascorbic acid concentrations (!lg.cm-3) for the three specified 
voidings determined by manual titration at different stages of the experimental period. 
Mean ascorbic acid concentration (~g.cm-3) for participants 
# Voiding "x" Voiding "y" Voiding "z" 
1 78 37 26 
2 44 -44 26 
3 287 785 1201 
4 1034 845 935 
5 863 762 1132 
6 470 364 201 
7 189 141 92 
8 49 56 24 
Statistical analysis was carried out to establish the relationship of mean ascorbic acid 
concentration for each of the three voiding times. The least squares pr()bability values are 
listed in Table 6.21, showing the comparison between voidings "x" and "y", voidings "x" and 
"z" and voidings "y" and "z" for each of the sample collections during the experimental period. · 
169 
Ascorbic Acid and Calcium Oxalate Kidney Stone Formation 
Table 6.21 Probability values determined- using least-squares comparing the mean 
ascorbic acid concentration at each of the voiding times during the experimental period. 
Probability Values 
Sample Number Voiding "x" vs Voiding "x" vs Voiding "y" vs 
Voiding "y" Voiding "z" Voiding "z" 
1 0.8313 0.7692 0.9508 
2 0.9956 0.9122 0.9078 . 
3 0.0023* 0.0001* 0.0107* 
4 0.2448 0.5399 0.5811 
--
5 0.5472 0.1074- 0.0231 
6 0.5479 0.1073 0.3491 
--
7 ~- 0.7737 0.5506 0.7719 ---
8 0.9662 0.8868 0.8575 
* significantly different at 95 % confidence 
Figure 6.10 shows the trend of the mean ascorbic acid concentration during the 12 day 
experimental period observed for each of the three voiding times. 
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Figure 6.10 Graph showing the trends observed for mean ascorbic acid concentrations 
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6. 7 Tiselius Risk Index 
The values calculated for the Tiselius biochemical risk index [13] for each participant for 
the corresponding 24 hour collection are presented in Table 6.22. 
Table 6.22 Mean Tiselius risk index of samples during the 12 day experimental period. 
# PT ES PR SH MG GV BM cw RG AM 
1 241.0 207.5 362.8 240.1 179.6 53.8 52.0 311.8 135.5 99.2 
2 142.4 222.1 219.1 175.5 115.0 81.2 114.5 266.6 96.9 164.2 
3 171.1 129.9 147.3 477.1 233.0 -90.5 122.1 334.4 191.6 127.6 
4 280.5 91.7 160.9 225.6 94.6 84.4 479.4 520.9 177.4 255.4 
5 182.6 198.3 182.7 184.6 131.4 116.8 606.6 629.5 142.1 160.7 
6 164.4 259.8 165.0 372.1 83.4 74.1 270.9 247.7 257.2 143.6 
7 85.5 144.6 307.2 260.3 192.0 180.6 99.2 123.4 116.1 104.4 
8 149.1 183.8 344.8 242.7 203.9 70.0 206.1 387.5 29.9 
The probability values determined in the comparison of the day-to-day effects on the risk 
index values of ascorbic acid ingestion during the collection period are shown in Table 6.23. 
The trend observed in the mean risk index for each of the samples during the ascorbic acid 
experimental period is shown in Figure ~~11 
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Table 6.23 .Probability values determined using least-squares comparing the risk index 
for urine samples collected during the experimental period. 
Probability values observed for the Tiselius 
risk index during the experimental period 
samples 1,2 vs samples 3,4,5 0.0665* 
trend samples 3-4-5 0.2842 
samples 3,4,5 vs sample 6 0.4833 
' 
trend samples 6-7-8 0.9426 
samples 1,2 vs samples 6,7,8 0.5748 
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Figure 6.11 Trend shown by the mean risk index determined for each sample collection 
during the experimental period. 
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6.8 Calci1:1m Oxalate Relative Supersaturation 
The calcium oxalate relative supersaturation values [14] for each participant during the 
experimental period are shown in Table 6.24. The statistical probability values, determined by 
least-squares, comparing the trends observed during the experimental period are shown in 
-
Table 6.25. 
Table 6.24 Mean values for the calcium oxalate relative supersaturation for the 
samples during the 12 day experimental period. 
# PT ES PR SH MG GV BM cw RG AM 
1 5.307 1.913 6.151 4.787 2.884 0.544 0.389 4.363 1.564 2.257 
2 1.964 2.314 3.089 6.113 1.731 1.634 0.316 4.145 0.781 0.436 
3 1.630 1.647 1.400 6.244 5.088 2.141 1.489 3.921 1.569 1.103 
4 3.893 1.489 1.469 2.389 2.550 1.850 2.700 12.28 3.113 1.262 
5 3.063 2.450 3.200 3.522 3.280 1.708 7.877 6.714 2.227 1.707 
6 2.741 3.537 2.102 8.988 2.962 1.199 1.590 3.020 2.584 0.385 
7 1.279 1.874 5.478 4.662 3.855 2.527 1.139 1.543 2.020 0.545 
8 .2.323 2.572 3.378 3.629 6.639 0.821 1.919 1.879 0.438 
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Table 6.25 Probability values comparing the mean calcium oxalate relative 
supersaturation during the 12 day experimental period. 
samples 1,2 vs samples 3,4,5 
trend samples 3-4-5 
samples 3,4,5 vs sample 6 
trend samples 6-7-8 
samples 1,2 vs samples 6,7,8 
Probability values observed for CaOx Rei. SS during the 
experimental period 
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Chapter 7. 
Discussion and Conclusions 
Several variables were measured in each of the urines collected by each of the ten 
participants. In addition, individual urines were divided. into fractions for various analyses (e.g. 
effect of an EDTA presetvative, oxalate and ascorbate determinations). As such, many 
comparisons need to be made and many possible trends need to be investigated. The approach 
which follows is to introduce meaningful points for qiscussion by means of appropriate 
questions which will focus attention on key issues relating to the role of ascorbic acid in 
calcium oxalate kidney stone formation. 
7.1 Analysis of creatinine, citrate, chloride, sodium and 
calcium 
All urinary components were determined in each urine sample. Despite collection in the 
presence and absence of the EDTA presetvative, the urinary components discussed in this and 
the following section were analysed in the absence of EDTA. Mean values for each 
component analysed in the "bulk, 24 hour _urine collection are detailed in Table 6.2. The 
following sub-sections discuss the components which did not change significantly during the 12 
day experimental period. 
.7.1.1 Is there a significant change in the urznary component 
excretion after ingestion of ascorbic acid ? 
No significant difference was obsetved in the excretion of creatinine, chloride, citrate, 
calcium or sodium in urine samples collected during ascorbic acid ingestion (samples 3, 4 and 
5) relative to values prior to commencement of the protocol (samples 1 and 2) (Table 6.3). 
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Hence, dietary ascorbic acid has no significant effect on the excretion of any of the 
aforementioned urinary components. 
7.1.2 Is there a significant change in the excretion of the urinary 
components during the protocol itself, i.e. as the ingestion of 
ascorbic acid proceeds ? 
No significant increase or decrease occurred in ~rinary creatinine, chloride, citrate, 
calcium or sodium during the ascorbic acid protocol (trend 3-4-5, Table 6.3). Thus, prolonged 
periods of ascorbic acid intake have no effect on the aforementioned chemical components 
excreted in the urine. 
7.1.3 Is there a significant change in the excretion of the urinary 
components immediately post cessation of the protocol ? 
There is no significant change in the urinary creatinine, chloride, citrate, calcium or 
sodium excretion immediately post cessation ascorbic acid ingestion (3, 4, 5 vs 6, Table 6.3). 
Thus, cessation of ascorbiC acid ingestion has no effect on the urinary components. 
7.1.4 Is there a significant change in the excretion of the urinary 
components during the 5 day period following cessation of ascorbic 
acid ingestion ? 
No significant changes occur in any of the urinary components during this period (trend 
6-7-8, Table 6.3). 
179 
Ascorbic Acid and Calcium Oxalate Kidney Stone Formation 
7.1.5 Is there a difference between-pre-protocol and post-protocol 
values? 
Table 6.3 shows that the values after cessation of the protocol (samples 6, 7 and 8) are 
not significantly different to control values (samples 1 and 2) indicating that ascorbic acid 
ingestion.has no effect, delayed or otherwise, on the excretion of these components. 
7.1.6 Comments 
Megadose ascorbic acid ingestion has not been reported to have had any effects on 
creatinine, chloride, calcium or sodium levels excreted in the urine. The results of the present 
study are thus in agreement with other studies with respect to these components. 
The results of the present study indicate that there is no significant effect on citrate 
excreted in the urine, despite the megadose ingestion of ascorbic acid for an extended period. 
··' 
Previous literature has indicated an impairment of ascorbic acid absorption and a decreased 
citrate and ascorbate excretion in the urine of stone forming patients [1 ]. The results obtained 
in the latter study show that ascorbic acid and citrate, both of which are hydrocarboxylic acids, 
share a common carrier in the human gut which is possibly defective in stone forming subjects. 
As a result, stone formers show decreased citrate and increased oxalate and calcium 
excretions. Results of the investigation showed that citrate depressed ascorbate absorption 
from the gut into the blood. The inability of ascorbate to inhibit citrate uptake is consistent 
with a greater affinity of the carrier for citrate. The inhibition of citrate on the uptake of 
ascorbic acid has significant bearing on calcium stone disease, since in stone formers the. 
malabsorption of ascorbate will be potentiated by the presence of citrate [1 ]. These 
interactions result in an increase in the amount of ascorbate available for conversion to oxalate 
in the gut and may subsequently result in hyperoxaluria. 
The finding in the present study that citrate levels are unaffected by ascorbic acid 
ingestion suggests that normal individuals ingesting high doses of ascorbic acid are not 
exposed to competition for a carrier in the gut. Since ascorbic acid does not significantly affect 
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citrate levels, the possibility of hyperoxaluria due to lower levels of this component is 
diminished. 
It is of interest to note that the citrate excretion levels in the special case (Chapter 5) 
were not significantly different to those observed in the other participants in this investigation. 
Nor did the levels fluctuate significantly during the course of the 16 day protocol. It is thus 
concluded that ascorbic acid and citrate do not interac~ and compete for a carrier in the gut in 
normal individuals nor in the case of the single potential stone former analysed in this study. 
7.2 Analysis of magnesium, potassium, phosphate, urate, pH 
and volume 
Significant changes in the concentration of some of the urinary components were 
observed during the 12 day investigation. These changes were ascertained statistically by 
comparing the mean excretion, for all 10 participants, of a particular urinary component during 
a 24 hour collection period with the mean excretion of the same urinary component during 
other 24 hour collection periods. Significant changes were observed during the experimental 
period for magnesium (Figure 6.1), potassium (Figure 6.2), phosphate (Figure 6.3) and urate 
(Figure 6.4) as well as for pH (Figure 6.5) and volume (Figure 6.6). The mean excretion and 
probability values for each of the components are shown in Table 6.2 and 6.4 respectively. 
As discussed in Section 3.3, determination of urate concentration in the presence of very 
high ascorbic acid concentrations is not possible due to masking effects of the latter. The 
results obtained for urate excretion levels are thus speculative. 
7.2.1 Is there a significant change in the urznary component 
excretion after ingestion of ascorbic acid ? 
There is a significant increase in magnesium excretion during the period of ascorbic acid 
ingestion (p = 0.0050, Tables 6.2 and 6.4). Since magnesium is a low molecular weight 
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inhibitor in urine, an increase in the excretion of this component will result in a reduced risk in 
the stone forming potential of the urine [2, 3, 4]. Thus with regard to this parameter, it would 
seem that ingestion of ascorbic acid reduces the risk of stone formation. 
No significant changes were observed in the excretion of urinary potassium (p = 0.9913) 
and phosphate (p = 0.7457) during the period of ascorbic acid ingestion relative to values prior 
to commencement of the protocol (samples 1 and 2 vs samples 3, 4 and 5, Table 6.4). 
A significant decrease in the urate excretion is observed between the two samples 
collected prior to ascorbic ·acid ingestion and the sample collected on the fifth day of ascorbic 
' 
acid ingestion period (p = 0.040). 
A significant decrease (p = 0.0495) is observed in the pH of the urines after 
commencement of the protocol (samples 1 and 2 vs samples 3, 4 and 5, Table._ 6.4). This result 
is not surprising since the ascorbic acid is acidic by nature and hence excessively high ingestion 
of the vitamin would result in a decrease in pH. Since the solubility of calcium oxalate in urine 
- increases at lower pH values, ingestion of ascorbic acid would decrease the risk of stone 
formation. 
Urine volumes showed a significant increase (p = 0.0350) in sample collections during 
the 5 day ascorbic acid ingestion period relative to control collections (Table 6.4). The 
increase in urinary volume is probably due to the increase in fluid intake required for ingestion 
of ascorbic acid tablets four times during the 24 hour period. Although participants were 
encouraged to consume extra fluid during the control collections, it appears that they failed to 
do so. It is therefore retrospectively concluded that a placebo should have been administered 
during the control collections. 
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7.2.2 Is tftere a significant change- in the excretion of the urinary 
components during the_ protocol itself, i.e. as the ingestion of 
ascorbic acid proceeds ? 
No significant change is observed in the magnesium (p = 0.1696) or phosphate 
(p = 0.8687) during the period of ascorbic acid ingestion. Thus, although there was a 
significant increase in magnesium excretion when the protocol commenced, it does not 
continue with prolonged ingestion of aScorbic acid. 
A significant decrease (p = 0.0368) in urinary potassium excretion occurs during the 5 
day period of ascorbic acid ingestion (Table 6.4). Prolonged ascorbic acid ingestion causes a 
decrease in potassium excreted in the urine. Studies have shown that potassium depletion can 
decrease urinary citrate [5] but can increase urinary calcium excretion [6]. In the present 
study, neither of these two urinary components were affected. Nevertheless, the rep~rted 
effects on citrate and calcium both represent an increasing risk of calcium oxalate stone 
formation and therefore the depleted urinary potassium levels are noteworthy. 
No significant changes in urinary pH (p = 0.7415) and volume (p = 0.1504) are observed 
during the period of ascorbic acid ingestion. Therefore, once the urine has been acidified by 
the initial ingestion of ascorbic acid, further lowering of urinary pH does not occur during the 
course of further ascorbic acid ingestion. This is expected, since once the body has absorbed 
the necessary ascorbic acid to saturate the body pool [7, 8], excess amounts are excreted 
unchanged iii the urine [9]. Urinary volumes did not change significantly. Since ascorbic acid 
tablets were ingested four times daily, participants consumed a constant intake of fluid during 
the 5 day period. 
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7.2.3 Is there a significant change in the excretion of the urinary 
components immediately post cessation of the protocol ? 
The magnesium excretion during the 24 hour period immediately post cessation of 
ascorbic acid ingestion is not significantly different to the mean magnesium excretion during 
the ascorbic acid ingestion period (p = 0.3016). Thus, the original increase in urinary 
magnesium observed during ascorbic acid ingestion is maintained as would be the inhibitory 
activity. 
A significant difference is not observed in the urinary potassium excretion (p = 0.1924) 
for samples collected during the 24 hour period post cessation of the protocol, relative to the 
-
protocol itself (samples 3, 4 and 5 vs sample 6, Table 6.4). The significant decrease observed 
·in potassium excretion during the 5 day· ascorbic acid ingestion period is thus maintained 
during the first 24 hour period post cessation of ascorbic acid ingestion. 
A significant decrease in the urinary phosphate (p = 0.0465) excreted in the urine is 
observed in the 24 hour period immediately post cessation of ascorbic acid ingestion. Low 
urinary phosphate excretion with concomitantly high calcium excretion has been observed in 
previous work [10] with the result that urinary phosphate concentration has been linked with 
the risk of stone formation. A further study has shown that phosphate may play a role in the 
pathogenesis of urinary calculi [11 ]. In the present study, the urinary calcium levels were 
unaffected during the experimental period. However, the reported effect on urinary phosphate 
represents an increasing risk of calcium oxalate stone formation and therefore depleted levels 
of phosphate are noteworthy. 
A significant difference was not observed in the urate excretion (p = 0.6183) post 
cessation of ascorbic acid ingestion. 
A significant change in urinary pH is not observed during the 24 hour collection period 
immediately post cessation of ascorbic acid ingestion (p = 0.5186) indicating that the acidifying 
effect previously described is maintained. 
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A significant decrease in urinary volume (p = 0.0482) occurs during the 24 hour period 
immediately post cessation of ascorbic acid ingestion. As discussed earlier, this decrease in 
urinary volume is probably due to the suspension of the protocol in which ascorbic acid was 
taken, with water, 4 times in 24 hours. 
7.2.4 Is there a significant change in the excretion of the urinary 
components during the 5 day period following cessation of ascorbic 
acid ingestion ? 
The decreasing trend in magnesium excretion exhibited by samples 3, 4 and 5 is 
continued by samples 6, 7 and 8 (Table 6.2) but is not significant (p = 0.2059). Inspection of 
the va!ues in Table 6.2 suggests that magnesium excretion gradually returns to its pre-protocol 
level. 
No significant change occurs in the excretion of urinary potassium (p = 0.4920) or 
urinary phosphate (p = 0.2717) during the 5 day period post cessation of ascorbic acid 
ingestion. Hence, the effects of the ascorbic acid ingestion which resulted in a decrease in 
urinary potassium carry over into the period after cessation of ascorbic acid ingestion i.e. 
ascorbic acid has long term effects on the urinary potassium excretion (Section 7.2.5). 
Although there is a significant decrease in urinary phosphate immediately post ascorbic acid 
cessation, no further decreases are observed. 
There is a significant linear increase in urate (p = 0.0003) excreted in the urines collected 
during the post protocol period. 
Urinary pH (p = 0.5878) and volume (p = 0.5463) do not change significantly during the_ 
five day post ascorbic acid collection period (Table 6.2), suggesting that there are no long term 
effects on the urinary pH or volume after megadose ingestion of ascorbic acid. 
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7.2.5 Is there a difference between pre-protocol and post-protocol 
-
values? 
Table 6.4 shows that the magnesium values· after cessation of the protocol are not 
significantly different to control values .. Thus, although ascorbic acid ingestion produced an 
initial increase in magnesium excretion, which was maintained throughout the protocol, values 
returned to control levels after cessation of the protocol. This indicates that ascorbic acid has 
no long term or delayed effects on the excretion of magnesium. 
Potassium values after the cessation of ascorbic acid ingestion are marginally lower than 
control values indicating that the decreasing trend observed during the protocol has a "carry-
over" effect. However, the potassium excretion for sample 8 (Table 6.2) suggests that the 
values would probably return to control values within a few more days. 
Pre- and post- protocol values for phosphate are significantly different (p = 0.0292, 
Table 6.4). The significant decrease in urinary phosphate excretion which occurred 
immediately post cessation of ascorbic acid is thus retained. 
Although urate excretion continues to be significantly depressed in samples 6, 7 and 8 
relative to control values 1 and 2, the mean value for sample 8 appears to be approaching pre-
protocol values. 
Finally, Table 6.4 shows that pH and volume values have returned to their control values. 
-7.2. 6 What are the overalL trends and effects of ascorbic acid 
ingestion on potassium, phosphate, magnesium, urate, pH and 
volume? 
A significant increase in magnesium excretion occurs after ascorbic acid ingestion 
commences. However, prolonged ingestion of ascorbic acid does not result in a continued 
increase in magnesium levels - the trend observed during the five day ascorbic acid ingestion 
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period shows no significant change. In the period post cessation of ascorbic acid ingestion, a 
noticeable (but not significant) decrease in urinary magnesium is observed suggesting that in 
the absence of the ascorbic acid, magnesium excretion returns to control levels. Thus, with 
respect to this risk factor, it appears that ascorbic acid ingestion reduces the stone forming 
potential of the urine, but only while the ingestion continues. As soon as the ingestion ceases, 
the effect weakens. 
Ascorbic acid ingestion does not have an immediate effect on the levels of potassium , 
excreted in the urine. However, urinary potassium does decrease significantly during 
prolonged ascorbic acid ingestion. The results of the present study indicate that continued 
ingestion of ascorbic acid may cause long term effects in the excretion of this component. 
Because potassium depletion is associated with hypocitraturia [5] and raised calcium excretion 
[6], it is concluded that ascorbic acid ingestion, if continued long term may increase the risk of 
calcium oxalate stone formation. 
While there were no significant differences in phosphate excretion immediately after the 
commencement of ingestion of ascorbic acid and during the protocol itself, a significant 
decrease occurred in the excretion of this component in the 24 hour period immediately post 
cessation of ascorbic acid ingestion. This suggests that ascorbic acid may have some sort of 
delayed effect on urinary phosphate in which a decrease in the excretion of this component 
occurs. Despite the increasing trend in the phosphate concentrations during the five day period 
post ascorbic acid cessation, the increase is not significant. Control values (samples 1 and 2) 
are significantly raised compared to the urinary phosphate levels determined during the post 
protocol period. Thus the effect_ of ascorbic acid on phosphate excretion, may be long term. 
Decreased phosphate excretion is associated with hypocalciuria [10, 11] and hence long term 
ingestion of ascorbic acid may increase the risk of calcium oxalate stone formation. 
Although urate excretion trends have been suggested, results must be regarded as 
speculative as previously described (Section 3.3). 
Ascorbic acid ingestion causes a significant decrease in urinary pH. However, the effect 
appears to be short term as values return to their control values after the protocol is suspended 
(Table 6.2 and 6.4). 
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During the ingestion of ascorbic acid the urinary volume increased significantly relative 
to control sainple collections. After the ingestion of ascorbic acid had ceased, there was a 
significant decrease in the urinary volumes.· These trends indicate that urinary volume was 
probably dependent on additional fluid intake for the ingestion of ascorbic acid tablets during 
the five day ascorbic acid ingestion period. 
7.3 Oxalate Analysis 
Urinary oxalate is an essential parameter in the asse~sment of the stone forming potential 
of the urine. Mean urinary oxalate excretion values and the relevant statistical details are 
shown in Tables 6.6, 6. 7 and 6.8. The effect of ascorbic acid and the relevance of EDTA as a 
preservative-to prevent the conversion of ascorbic acid to oxalic acid are discussed in the 
following sub-sections. 
7.3.1 Is there a significant difference between oxalate values in the 
unpreserved urine samples (i.e. between the bulk sample and the 
representative sample - EDTA) ? 
Tables 6.6 and 6.7 shows that there is no significant difference (p = 0.1565) when the 
respective means for the oxalate excretion in the "bulk" (0.205 mmol/24 hr) and the 
"- EDTA" (0.226 mmol/24 hr) samples are compared. It is thus concluded that the"- EDTA" 
sample is truly representative of the "bulk" sample. 
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7.3.2 Is there a significant difference between the oxalate values in 
·the preserved representative 24 hour sample (" + EDTA ") and the 
unpreserved samples ("bulk" and"- EDTA ") ? 
Tables 6.6 and 6.7 shows that significant differences exist between the preserved sample 
(mean value = 0.160 mmol/24 hr) and the "bulk" sample (mean value = 0.205 mmol/24 hr) 
(p = 0.0015) and between the preserved sample and the "- EDTA'; sample (mean value = 
0.226 mmol/24 hr) (p = 0.0001). 
Since the unpreserved samples have higher oxalate values (Table 6.6), it is concluded 
that in vitro conversion of ascorbic acid to oxalic acid is occurring in these samples but the 
conversion is prevented in the presence of EDTA~ These results therefore demonstrate the 
need for such a preservative when analysing for oxalate in the presence of ascorbate. Thus, the 
oxalate values in the present study which have been determined in the presence of EDTA are 
not erroneously high (due to in vitro conversion of ascorbate) and can be regarded with 
confidence. 
7.3.3 How do the preservatives affect each sample and the an~lysis 
thereof? 
There is no significant difference (p = 0.9874) in the trends for each of the collections 
(with and without preservative) collected during the 12 day experimental period (Figure 6.7). 
-Thus, since the trend for the "bulk", "+ EDTA" and "- EDTA" collections are the same, it can 
be concluded that the preservative did not interfere with the analysis. Both "+ EDTA" and 
''- EDTA" samples can therefore be regarded as true representations of the 24 hour urine 
collected as far as the trends are concerned. However, accurate, quantitative, oxalate values 
can be obtained only from the"+ EDTA" sample. 
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7.3.4 Is there a significant change in oxalate excretion after 
ingestion of ascorbic acid ? 
One of the participants showed extremely high oxalate concentrations in the "bulk" and 
the "- EDTA" urine samples on day 7 of the protocol, which are outliers. This might indicate 
that in this participant, in vitro conversion of ascorbate to oxalate occurred to a very large 
extent, more so than in other participants. The outliers were thus considered as true values of 
oxalate excretion in this individual and statistical analysis was carried out in the presence of the 
outlying values. 
A comparison between the mean oxalate excretion for the controls (samples 1 and 2) and 
the mean oxalate excretions during the 5 day period of ascorbic acid ingestion (samples 3, 4 
and 5) in the "bulk" and"+ EDTA" samples indicates no significant difference (p = 0.0723 and 
0.2873 respectively, Table 6.8). Thus, it is concluded that ascorbic acid ingestion does not 
result in an immediate in vivo conversion to oxalate. (The significantly higher oxalate in the 
"- EDTA" sample (p = 0.0093) confirms the in vitro conversion of ascorbate to oxalate 
discussed earlier). 
7.3.5 Is there a significant change in oxalate excretion during the 
protocol itself, i.e. as the ingestion of ascorbic acid proceeds ? 
There is no significant change in urinary oxalate excretion in the EDTA preserved sample 
(p > 0.05) or in the "bulk' sample (p = 0.3587) during the 5 days of ascorbic acid ingestion 
(3-4-5, Table 6.8). This confirms the results of Hughes et al. [12] who assumed that there is a 
--
rate limiting step in the absorption and excretion of urinary oxalate, resulting in a plateau effect -
in the oxalate excretion. Thus, in the present study, continued ascorbic acid intake does not 
cause an increase in oxalate excretion. (The significant increase in oxalate excretion observed 
in the"- EDTA" sample (p = 0.0461) once again demonstrates in vitro conversion of ascorbic 
acid to oxalic acid). 
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7.3.6 Is there a significant change in urinary oxalate excretion after 
cessation of the ascorbic acid protocol ? 
No significant change in the "+ EDTA" and"- EDTA" fractions (p = 0.1764 and 0.0640 
respectively, Table 6.8) is observed in the mean oxalate excretion when the values obtained 
during the ascorbic acid protocol are compared to , values obtained after its suspension. 
However, the significant increase (p = 0.0252) in oxalate excretion observed in the "bulk" 
sample is due to in vitro conversion of ascorbate to oxalate. Thus, it can be concluded that 
oxalate excretion is not affected after ascorbic acid ingestion has been halted. 
I 
7.3. 7 Is there a significant change in unnary oxalate excretion 
during the 5 day period post cessation of ascorbic acid ingestion ? 
Table 6.8 shows that no significant difference occurred in the trend of oxalate excretion 
in samples 6, 7 and 8. This is contrary to the findings of Hatch et a/. (13] who demonstrated 
that there may be retention of urinary oxalate which only manifests itself after a period in which 
no ascorbic acid is ingested. 
7.3.8 Is there a difference between pre- protocol and post- protocol 
values? 
Table 6.8 shows that the values after the cessation of the protocol (samples 6, 7 and 8) 
are not significantly different to control values (samples 1 and 2) indicating that ascorbic acid 
ingestion does not have a delayed effect on oxalate excretion. 
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7.3.9 Comments 
An EDTA preservative is necessary to prevent the in vitro conversion of ascorbic acid to 
oxalic acid. This precaution prevents erroneously high urinary oxalate concentrations being 
determined and supports the findings of several other workers [12, 13, 14, 15]. 
The presence or absence of a preservative in th~ urine collections does not affect the 
determination of excretion trends i.e. observed trends in preserved and unpreserved samples 
are consistent and do not show any significant differences. Representative samples are no 
different to the bulk 24 hour collection with respect to th~ trends and hence can be considered 
as being truly representative of the 24 hour collection . Therefore, data collected for the 
samples containing EDT A are indeed "representative" of the "bulk" sample and can be used 
the determination of both qualitative and quantitative results. 
The present study has demonstrated that megadose ingestion of ascorbic acid has no 
effect, delayed or otherwise, on the excretion of urinary oxalate. This is in agreement with 
several studies [12, 16, 17, 18, 19] but in conflict with others [13, 14, 20, 21, 22, 23]. 
7.4 Metastable Limits 
As explained in Section 6.3, metastable limit (MSL) data were combined to form two-
way tables (Table 6.11 and 6.12). The hypothesis tested in the two way tables was whether 
the proportions of data falling into the three categories·(Section 6.3) are constant. Fischer's 
exact test was employed to test this hypothesis in each of the tables for the MSL's determined 
by turbidiometry and Coulter multisizer. 
The probabilities from the Fischer exact test indicate that the proportions do not change 
significantly in either determination (turbidiometry : p = 0.798 and Coulter multisizer : 
p = 0.833). Since the proportions obtained in the analysis were consistent it was concluded 
that a more complex analysis was unwarranted. Thus no particular trends were evident in the 
MSL's obtained by the two techniques in this study (Table 6.9 and Table 6.10). The absence 
of a definite trend suggests that megadose ingestion of ascorbic acid does not influence the 
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nucleating potential of the urine. This supports the findings of several other workers who have 
reported that ascorbic acid does not influence the formation of kidney stones (12, 17, 18, 24 ]. 
7.5 Kinetics of Crystallization 
The metastable limit of a urine, as measured in this study, indicates the level of sodium 
oxalate required to induce crystallization with respect to calcium oxalate. At supersaturation, 
calcium oxalate crystal nucleation no longer occurs. Instead, calcium oxalate crystal growth 
and/or aggregation take place. These mechanisms can be monitored by measuring the 
response of the urine to a fixed sodium oxalate load equivalent to or above the metastable limit 
[25]. This is achieved by measuring the increase in turbidity or particle number as a function of 
time. A typical plot (obtained in experimental analysis in the present study) of this relationship . 
has been shown previously in Figure 6.8 The initial time lag is followed by a linear portion, the 
gradient of which is a measure of the rate of crystallization (growth or aggregation or both). 
Calcium oxalate crystal growth rates, measured for each of the ten participants by 
turbidiometry and Coulter multisizer, are shown in Tables 6.13 and 6.14 respectively. The 
crystallization rates in both tables were determined at the sodium oxalate dosing concentration 
which corresponded most closely with the experimentally determined MSL. In some cases, 
kinetic data could not be obtained by Coulter multisi_zer due to maintenance requirements of 
the instrument. 
Although crystallization rates were determined under the same experimental conditions 
for each urine sample, results obtained by both techniques showed no specific trend during the 
twelve day experimental period. Statistical analysis was QOt attempted. This indicates that 
despite megadose ingestion of the vitamin, ascorbic acid has no obvious effect on the growth -
and aggregation of calcium oxalate crystals in urine. Once again, this supports the results of 
other studies which indicate that ascorbic acid does not influence the formation of kidney 
stones [12, 16, 17, 18, 24]. Since no trends were established in the rate of crystallization in 
urine, no generalisations can be made. Some individuals might not be able to handle _ 
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megadoses of ascorbic acid and will show high crystallization rates which may promote stone 
formation, whereas in other cases the ascorbic acid ingestion may have no effect. 
In addition to dosing each urine at its own specific MSL, a "standard" ·sodium oxalate 
challenge was also administered to aliquots of each urine. This load was equivalent to the 
MSL of the control specimens of the particular urine under investigation and was maintained 
throughout the 12 day experimental period. By administering a fixed NaOx load, comparisons 
of crystallization rates in different samples could be made. Any trends observed in this 
approach can be directly attributed to- the ascorbic acid regimen. However, in this study no 
trends in crystallization rates were identified (Tables 6.15.and 6.16). Thus, it can be deduced 
that, in general, ingestion of ascorbic acid does not affect the rate of in vitro calcium oxalate 
crystallization. However, different individuals may respond differently to the ingestion of 
ascorbic acid, but this would be dependent on that individual's renal handling capacity for the 
vitamin. 
7.6 Sedimentation of Calcium Oxalate Crystals in Urine 
The time course plot (Figure 6.10) obtained experimentally in this study for the 
supersaturated urine, is similar to that reported by Hess et al. [26] (Figure 3.5). During slow 
stirring (500 rpm), the number of particles forced downward by gravity equals the number of 
particles forced upwards by the stirrer [26]. Despite this, the graph reported by Hess et al. 
[26] showed an initial instability for 3 minutes before reaching equilibrium, after which the 
stirring was stopped and the calcium oxalate sedimentation rate measured. Figure 6.9 does not 
clearly show the initial period of instability. The period of equilibrium is not as noticeable as in 
the reported work [26]. This can be attributed to the fact that supersaturation levels were 
attained by dosing urine at 0.2 M sodium oxalate and monitoring the crystal growth and 
aggregation by turbidiometry. Unfortunately, the available spectrophotometer was limiting 
since facilities to stir the urine were unavailable, and hence this method could not be used to 
detect supersaturation. Numerous attempts to measure the sedimentation rate by 
turbidiometry were made, but without success. Hence an alternative detection method 
(spectrophotometry) was used. This necessitated the transfer of urine from one cuvette to 
another during the period of equilibrium, with the result that this period is not clearly 
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noticeable in Figure 6.9. Absorbance measurement at time zero is seen to be similar to the 
measurement at a time of 2 minutes. Thereafter the decrease in absorbance observed for a 
period of 20 minutes is linear. The slope decreases and tapers off with time. Despite that the 
linear decrease reported by Hess et a/. [26] is over a very much shorter time period, before the 
graph begins to taper off, the trend observed in this study is the same as that observed in the 
slurry investigation. 
Experimentation was carried out using two different urines from the same individual. 
The results must be regarded as preliminary only, since numerous problems and queries arose. 
These are addressed in Section 7.6.1. The two urine collections were effected randomly. As a 
result, no comparison of the effect of ascorbic acid on urinary crystal sizes, derived from the 
gradients of the plot, can be shown. (The slopes obtained in these urine samples are 
0.274 x 10·2 s·1 (r = 0.9914) and 4.80 x 10·2 s·1 (r = 0.9910), Table 6.17). 
7.6.1 Problems Associated with the Experiment 
It is vitally important that the urine is stirred at 500 rpm [26] in order to maintain a 
homogenous solution. A stirring rate of less than 500 rpm does not allow for all the particles 
to be sufficiently suspended in solution, with the result that there may be a premature 
sedimenting out of calcium oxalate crystals. The transfer of the urine form the HACH RATIO 
screw-cap glass cuvette to the LKB NOVOSPEC spectrophotometer tube caused agitation in 
the solution, thereby destroying its homogeneity and creating the possibility of crystal 
sedimentation. In this study, adequate facilities to measure and maintain the stirring rate at 
500 rpm were not available. 
Temperature control is also vitally important in the determination of particle size by 
means of sedimentation. It is necessary to incubate the system continuously at 37 °C since a 
change in temperature of 1 °C causes a decrease in reproducibility (private consultation with B. 
Hess, 1994). In this study, temperature could not be adequately controlled since suitable 
facilities to accurately incubate the experimental system were unavailable. 
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Furthermore, the presence of dust in the atmosphere and on glassware is sufficient to 
affect the reproducibility of the solution and hence the transfer of analyte from one cuvette to 
another during the analysis would have caused errors in the results obtained. 
Stirring results in homogeneity being established, i.e. in the number of particles in the 
solution forced down due to gravity is equivalent to the number of particles forced up by the 
stirrer. However Hess et al. [26] indicate that despite this, a period of instability occurs until 
stabilisation is established. Since stirring is not continuous in the present study, due to the 
transfer of solution from_ the turbidimeter to the spectrophotometer, it is not possible to 
determine whether there was a decrease in absorbance initially and when a stable value was 
obtained. This would increase the error of the system. Thus, without stirring and constant 
temperature facilities in the spectrophotometer a high possibility of error exists. It is also 
necessary to run the samples at least in duplicate. Hence, a spectrophotometer which can 
analyse more than one sample concurrently is essential. Since this facility was not available, it 
was not possible to perform more than one analysis at a time. 
Preliminary data from the analysis is shown in Section 6.5, but the results, although 
showing literature agreement with those of Hess et al. (26], should be regarded as preliminary 
only. Clearly, this method has potential. Time did not allow the above problems to be 
resolved. However, future studies involving the role of ascorbic acid in in vitro crystallization 
should incorporate this approach. 
7.7 Ascorbic Acid Analysis 
Ascorbic acid analysis was carried out on three separate samples collected at pre-
determined voidings during each 24 hour collection period for the investigation period for each 
participant. 
The data are characterised by three outliers with the result that the distribution is 
somewhat skewed. When these outliers are omitted, the estimate of the error variance is 
reduced by 28 % in magnitude. However, the nature of this study involves a diverse range of 
factors which may influence the results and thus cause what may appear to be outlying values. 
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Therefore, these values should not be omitted since they depend on the time of urine voiding, 
the amount of fluid consumed by the individual and whether or not this has caused diuresis 
which may result in varied concentrations of ascorbic acid being excreted at different times of. 
the day. A high concentration of ascorbic acid may have been excreted in the voiding 
immediately prior to analysis resulting in a lower excretion of ascorbic acid in the subsequent 
voiding. Alternatively, a high ascorbic acid concentration may be excreted if the urine has been 
retained for a long period in the bladder with the result that all excess ascorbic acid is passed in 
a single sample. Due to the nature of the collections, outliers were not omitted from the 
analysis. 
7.7.1 Is there a significant change in ascorbic acid excretion after 
commencement of megadose ingestion of ascorbic acid ? 
A sigtJ.ificant increase in ascorbic acid excretion relative to control values is observed 
immediately .. after commencement of ascorbic acid ingestion (samples 1 and 2 vs sample 3, 
Table 6.20, Figure 6.11). Statistical analysis was not performed with these results, as the 
significant increase in ascorbic acid excretion is obvious. 
The increase in ascorbic acid excretion as the protocol proceeds is not smprising. The 
body absorbs the ascorbic acid until the metabolic pool is saturated [8, 27], after which excess 
ascorbic acid is excreted in the urine. A megadose of ascorbic acid will thus be expected to 
cause a significant increase in the ascorbic acid excreted in the urine. 
?· 7.2 Is there a significant change in ascorbic acid excretion during 
the_protocol itself, ·i.e. as the ingestion of ascorbic acid proceeds ? 
Table 6.20 show that there is a signifie3:nt increase in ascorbic acid excretion as the 
protocol begins but this appears to level off as the protocol proceeds (Figure 6.10). This is 
easily explained in terms of the results found by other researchers. The body absorbs ascorbic 
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acid at a maximal rate of 2.16 cm3.min·l, so that when the vitamin is presented to the tubules 
at a rate greater than this, all excess ascorbic acid is excreted in the urine [28]. As the ascorbic 
acid dose increases so the absorption decreases [8, 9, 16] and the process eventually attains a 
level of supersaturation [7, 12]. The overall result is that an increase in ascorbic acid intake 
results in an increase in the amount which is excreted unmetabolised in the urine [9]. 
Therefore, a significant and constant increase in the ascorbic acid excretion during the period 
of ingestion is not expected, since the body pool would have been saturated resulting in 
consistently high amounts being excreted in the urine. The plateau effect observed in the' 
present study is consistent with the results of Schmidt et al. [17] who reported a similar effect . 
as the body approaches ascorbic acid saturation. It thus appears that although ascorbic a~id 
ingestion continues, the body probably only absorbs what it requires while the remainder is 
excreted. 
7. 7.3 Is there a significant change in ascorbic acid excretion 
immediately post cessation of the protocol ? 
Table 6.20 show that there is a significant decrease in the ascorbic acid excreted in the 
urine during the 24 hours immediately post cessation of ascorbic acid ingestion (sample 6 vs 
sample 3, 4 and 5) This is not surprising since the body metabolic pool would still be saturated 
with ascorbic acid and since no further ingestion occurs, there would be less excreted in the 
urine. From Figure 6.10, it is seen that the ascorbic acid excretion during the 24 hour period 
immediately post cessation of ~scorbic acid ingestion (sample 6) is raised relative to the 
ascorbic acid excreted during the control collections (samples 1 and 2). This is to be expected, 
since the body would have been saturated with ascorbic acid for a period of 5 days. Some of 
this is probably retained and excreted during the day following cessation of the protocol. Thus 
despite no more ascorbic acid being ingested, there is a "carry-over" from the saturation 
period, resulting in slightly raised levels of excretion relative to excretion prior to ascorbic acid 
ingestion. 
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7. 7.4 Is there a significant change in the urinary excretion of 
ascorbic acid during the 5 day period post cessation of ascorbic acid 
ingestion ? 
A continued decreasing trend in urinary ascorbic acid excretion is observed in the 5 day 
period post ascorbic acid ingestion (samples 6, 7 and 8; Table 6.20, Figure 6.10). The post 
ingestion period allows the body to rid itself of excess ascorbic acid. As a result, the levels of 
excretion three days after the cessation of ingestion are still slightly higher than the control 
values. By the 51h day post cessation of ingestion, the urinary ascorbic acid excretion level has 
returned to that of the control samples, indicating that a minimum period of about 5 days is 
required in order for the body to attain normal levels after a period of megadose ingestion of 
ascorbic acid. Despite the massive ingestion of-ascorbic acid for an extended period, the carry 
over effects are minimal and there does not appear to be any long term effects as a direct result 
of the ascorbic acid ingestion in any of the 10 participants. 
7. 7.5 Is there a significant difference in ascorbate excretion between 
the three voidings collected at specified times ? 
Table 6.21 shows that there is no significant difference in the three voidings which 
correspond to specific times during the 24 hour collection, except in the case of sample three. 
In this sample, voidings "y" and "z" have significantly higher values for the ascorbic acid 
excreted in the urine than voiding "x" (P x,y = 0.0023; P x,z = 0.0001), while voiding ''y" has a 
significantly lower value than that of voiding "z" (P y,z = 0.0107). This trend can be explained 
~s follows. Sample 3 corresponds to the 24 hour period during which ascorbic acid ingestion 
commenced. Since ingestion occurred in the morning and since sample "x" corresponds to the 
second voiding of the day, the initial ascorbic acid boost may be absorbed to a large extent, 
particularly in cases where the participant was ascorbic acid-deficient. Despite absorption, 
excretion (287 ~--tg.cm-3 per 24 hours) is higher than in the control samples (78 and 44 1-1g.cm-3 
per 24 hours). As ingestion proceeds, decreasing quantities are absorbed as saturation 
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approaches. This would be accompanied by increasing quantities which are excreted [7, 8] as 
can be seen with the value of 785 f.lg.cm-3 per 24 hours for voiding "y". It is only after a level 
of supersaturation is reached that all excess ascorbic acid would be excreted in the urine (value 
of 1201 f.lg.cm-3 per 24 hours in voiding"z"). 
. After sufficient ascorbic acid has been absorbed to saturate the body pool, all excess 
ascorbic acid is passed in the urine and thus excretion values for the vitamin, whether in the 
early morning samples or at other times during the day, would remain raised relative to control 
values but would not increase relative to each other. The results of the present study therefore 
suggest that saturation is achieved during the first 24 hours of ascorbic acid ingestion, after 
which the amount excreted remains constant until ingestion ceases. 
Table 6.19 shows the results obtained for ascorbic acid when determined by the manual 
titration method as well as the flow-injection method developed in the present study. The 
comparison of the two methods is discussed comprehensively in Chapter 4. 
7. 7. 6 Summary of the overall trends of ascorbic acid excretion. 
Ascorbic acid excretion increased steadily during the 24 hours following commencement 
of ingestion. Thereafter, a plateau effect was observed i.e. the amount of ascorbic acid 
excreted remained high, but constant. It is suggested that initially a large percentage of the 
ingested vitamin is absorbed which manifests itself by relatively low excretion values. 
However, it is further suggested that as the body pool of ascorbic acid becomes saturated, less 
js absorbed but more is excreted. After saturation is achieved, excess ascorbic acid is excreted. 
7.8 Tiselius Biochemical Risk Index 
Table 6.22 shows the mean Tiselius biochemical risk index [29] for the participants in 
this study. The probability values determined by least squares comparing the trends observed 
during the experimental period are shown in Table 6.23. The statistical analysis of the 
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biochemical risk index showed a fairly skew distribution, but a log transformation of the data is 
very similar to the untransformed data with the result that only the untransformed data was 
analysed. Figure 6.11 illustrates the trend of the risk index during the course of the study. 
7.8.1 Is there a significant change in the risk index after ingestion of 
ascorbic acid ? 
A comparison of the mean of the two control collections and the mean of the risk index 
values during the five day period of megadose ascorbic acid ingestion indicate that there is an 
increase in the ris~ index values (Table 6.22) and that this increase approaches significance 
(p = 0.0665) (Table 6.23). This indicates that prolonged ingestion of ascorbic acid tends to 
increase the Tiselius biochemical risk index and hence there is a possible increase in the stone 
forming potential of the urine (Figure 6.11). 
7.8.2 Is there a significant change zn the risk index during the 
protocol itself, i.e. as the ingestion of ascorbic acid proceeds ? 
No significant difference in the risk index occurred during the ascorbic acid ingestion 
period (p = 0.2842, Table 6.23). This indicates that although the initial ingestion of ascorbic 
acid may cause a marginal increase in the stone forming potential of the urine, the continued 
megadose ingestion of ascorbic _acid does not result in a continued increase in the Tiselius 
biochemical risk index. 
7.8.3 Is there a significant change in the risk index immediately post 
cessation of the protocol ? 
The mean value obtained for the risk index for the 10 participants over the period of 
ascorbic acid ingestion was compared to the mean value for the sample collection on the day 
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immediately post ascorbic acid cessation (samples 3, 4 and 5 vs sample 6, Table 6.23). A 
significant change in the risk index values is not observed (p = 0.4833), despite cessation of the 
megadose ingestion. 
7.8.4 Is there a significant change in the risk index during the 5 day 
period following cessation of ascorbic acid ingestion ? 
There is no significant change in the day to day risk index values during the five day post 
' 
cessation period (p = 0.9426, Samples 6, 7 and 8, Table 6.23). Thus the risk index values did 
not decrease significantly after cessation of ascorbic acid ingestion and thus the stone forming 
potential of the urine after the ingestion .of the ascorbic acid remained slightly raised. 
7.8.5 Is there a difference between pre-protocol and post-protocol 
values? 
Tiselius risk index values before the commencement of the protocol are not significantly 
different to values after the protocol had ended (p = 0.5748, Table 6.23). There are thus no 
long term or delayed effects on this parameter due to ascorbic acid ingestion. 
7.8.6 What are the overall trends of and effects on the Tiselius 
biochemical risk index ? 
There is a marginal increase in the risk index at the commencement of ascorbic acid 
ingestion. This increase in the risk index approaches significance, suggesting that the ingestion 
of ascorbic acid may increase the stone forming potential of the urine. The continued ingestion 
of ascorbic acid does not cause a further increase in the risk index values. Therefore prolonged 
ingestion of ascorbic acid does not increase the risk of stone formation significantly. 
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7.9 Calcium Oxalate Relative Supersaturation 
No significant changes occur in the calcium oxalate relative supersaturation of the urine 
in the period prior to, during or after ascorbic acid ingestion (Table 6.25). It can thus be 
concluded that prolonged ingestion of megadose quantities of ascorbic acid does not increase 
the risk of stone formation. 
7.10 Comparison of the Special Case with Participants of the 
Main Study 
It is noteworthy that a difference between the case study and the other 10 participants 
occurred in that in vitro conversion of ascorbic acid to oxalic acid did not occur in the urine of 
the former but did occur in those of the latter. Further investigation with respect to the renal 
handling of ascorbic acid by stone formers should address this question. 
Another intriguing difference exists between the results obtained for the special case 
(ChapterS) and those obtained for the 10 participants in the present investigation. The special 
case urinary oxalate excretion increased during ascorbic acid ingestion (Table 5.4) while no 
such increase occurred in the other participants of this investigation. This suggests that in vivo 
conversion of ascorbic acid to oxalic acid occurred in the special case. This might be a 
consequence of a much larger ascorbic acid load administered to this individual. Alternatively, 
this important difference might support the contention that the development of crystalluria and 
haematuria after ascorbic acid ingestion are associated with an impaired renal handling 
mechanism. 
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7.11 Concluding Comments 
In concluding this thesis, it is appropriate to assess to what extent the objectives of the 
study, outlined in Section 1.5, have been achieved. A new flow-injection analysis method for 
the determination of ascorbic acid in human urine has been developed, tested and successfully 
implemented. The method has been shown to be superior to the manual titration method in 
terms of precision, economy of solutions and time and has the potential to be fully automated 
for the rapid routine analysis of ascorbic acid. 
In this study, the need for EDTA (or other) preservatives to prevent in vitro conversion 
of ascorbic acid to oxalic acid has been clearly demonstrated. As a result, reliable, 
reproducible oxalate excretion values were obtained, lending confidence to the credibility of 
the interpretations on which they were based. 
The main objective of the project was to investigate the effect of megadose ingestion of 
ascorbic acid on several physico-chemical risk factors associated with calcium oxalate kidney 
stone formation. This has been achieved. As such, the study is original as no other 
investigation has singly addressed a multitude of risk factors. Rather, studies have been 
confined to the effects of ascorbic acid ingestion on urinary oxalate in the main. Therefore, the 
present study represents the first comprehensive investigation of the effects of ascorbic acid 
ingestion on stone formation risk factors. As far as the results themselves are concerned, these 
have shown that although there is no increase in the risk of stone formation due to megadose 
ingestion of ascorbic acid, some individuals (as demonstrated in the special case study), may 
exhibit adverse effects. This is probably quite rare, with an incidence of 1 in 11 in the present 
study. Individuals taking ascorbic acid should be aware of the potential dangers and should be 
wary of any increase in urine cloudines~, which would signify an increase in crystalluria. 
Perhaps individuals should begin with a low ascorbic acid load and gradually increase the 
intake to higher levels, to avoid the sudden formation of stones in instances where defective 
renal handling might result in ·a pre-disposition to this condition. 
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Appendix A 
Presentations 
Kroont, B.L., and Rodgers, A.L., "Haematuria After Megadose Ingestion Of Vitamin C: A 
Case Study", 51h European Urolithiasis Symposium, Manchester, 21 - 23 April, 1994. 
Publications 
Kroon, B.L., and Rodgers, A.L., "Haematuria After Megadose Ingestion Of Vitamin C : A 
Case Study" in Urolithiasis : Consensus and Controversies, (Eds. Rao, P.N., Kavanagh, J.P., 
and Tiselius, H-G.), 1994. 
t The author, Bronwyn Leigh Auer (nee Kroon), presented this work prior to her marriage in December 1994. 
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Appendix B 
Graduation of the Jackson Candle Turbidimeter 
Table B.l Calibration of the_ glass tube (Jackson Turbidity Units - JTU) which is essential 
in the structure of the Jackson Candle Turbimeter. 
Light Path (em) JTU Light Path (em) JTU Light Path (em) JTU 
2.3 1000 7.0 310. 16.6 130 
2.6 900 7.3 300 18.0 120 
2.9 800 7.5 290 19.6 110 
3.2 700 7.8 280 21.5 100 
3.5 650 8.1 270 22.6 95 
3.8 600 8.4 260 23.8 90 
4.1 550 8.7 250 25.1 85 
4.5 500 9.1 240 26.5 -80 
4.9 450 9.5 230 28.1 75 
5.5 400 9.9 220 29.8 70 
5.6 390 10.3 210 31.8 65 
5.8 380 10.8 200 34.1 60 
5.9 370 11.4 190 36.7 55 
6.1 360 12.0 180 39.8 50 
6.3 350 12.7 170 43.5 45 
6.4 340 13.5 160 48.1 40 
6.6 330 14.4 150 54.0 35 
6.8 320 15.4 140 61.8 30 
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Appendix C 
Table C.l Preparation of sodium oxalate dosing concentrations. 
Dosing Cone. No. Desired NaOx Cone. Vol. NaOx Stock Vol. water added 
1 0.01 0.50 9.50 
2 0.02 1.00 9.00 
3 0.03 1.50 8.50 
4 0.04 2.00 8.00 
5 0.05 2.50 7.50 
6 0.06 3.00 7.00 
7 0.07 3.50 6.50 
8 0.08 4.00 6.00 
9 0.09 4.50 5~50 
10 0.10 5.00 5.00 
11 0.11 5.50 4.50 
12 0.12 6.00 4.00 
13 0.13 6.50 3.50 
14 0.14 7.00 3.00 
15 0.15 7.50 2.50 
16 0.16 8.00 2.00 
17 0.17 8.50 1.50 
18 0.18 9.00 1.00 
19 0.19 9.50 0.50 
20 0.20 10.0 0.00 
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Appendix D 
Table D.l Urinary calcium excretion (mmol/24 hr) for each 24 hour urine sample 
collected by the 10 participants. 
# PT ES PR SH MG GV BM cw RG AM 
1 2.60 2.32 6.75 5.18 1.05 0.33 0.55 3.03 4.75 0.75 
2 2.46 4.62 3.68 5.42 1.83 0.60 1.34 1.95 1.05 0.66 
3 2.84 4.00 4.41 7.36 2.84 L16 1.07 1.77 3.06 0.48 
4 2.46 5.28 3.62 4.60 1.64 0.73 1.90 2.20 3.66 1.16 
5 2.47 5.70 4.91 3.32 2.05 0.65 1.71 2.10 4.18 0.84 
.. 
6 3.76 6.33 2.73 13.2 1.25 0.52 1.21 1.79 5.10 0.33 
7 1.70 2.93 5.55 4.04 1.28 0.53 0.97 0.99 2.61 0.98 
8 2.17 2.47 3.95 7.11 1.28 0.55 1.72 3.42 0.52 
Table D~2 Urinary magnesium excretion (mmol/24hr) for each 24 hour urine sample 
collected by the 10 participants. 
# PT ES PR SH MG GV BM cw RG AM 
1 4.21 3.67 4.77 4.08 3.20 2.20 1.31 1.16 5.31 1.69 
2 3.26 4.68 3.05 3.20 5.73 2.49 2.57 1.99 2.03 1.41 
3 4.46 5.90 5.45 5.72 6.65 3.54 2.45 3.47 3.61 1.74 
4 3.18 6.81 6.77 5.84 -3.98 2.82 2.42 2.49 3.96 2.63 
5 3.05 7.05 3.59 2.51 4.10 3.37 2.45 2.60 4.03 3.54 
6 3.51 6.84 3.07 7.40 2.96 2.40 1.84 2.13 4.85 0.96 
7 2.28 3.95 3.49 3.05 3.47 2.68 2.65 4.09 2.80 1.67 
8 1.92 3.38 4.32 3.62 3.16 2.74 4.22 2.99 1.60 
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Table D.3 Urinary sodium excretion (mmol/24hr) for each 24 hour urine sample 
-
collected by the 10 participants. 
# PT ES PR SH MG GV BM cw RG AM 
1 117.6 136.2 95.8 109.1 66.7 33.4 58.9 90.6 250.6 22.2 
2 114.7 209.5 64.0 49.8 89.1 40.1 133.4 100.8 136.7 17.8 
3 138.5 139.2 70.9 120.9 105.0 61.5 76.7 65.8 260.9 48.0 
4 102.3 129.4 70.9 158.2 15.5 21.5 73.6 97.2 105.3 89.1 
5 110.6 107.6 143.6 48.7 67.8 54.1 48.3 113.4 169.4 84.0 
6 129.1 154.8 70.8 230.6 38.1 40.9 112.2 65.5 289.8 21.1 
7 119.1 62.6 75.2 101.9 22.2 15.1 80.4 28.2 59.9 54.2 
8 127.3 56.4 181.2 155.1 60.1 113.1 126.3 132.9 56.4 
Table.D.4 Urinary potassium excretion (mmol/24hr) for each 24 hour urine sample 
.. -
collected by the 10 participants. 
# PT ES PR SH MG GV BM cw RG AM 
1 45.6 43.2 146.6 71.9 50.1 31.5 20.5 97.0 91.6 10.6 
2 44.7 73.6 44.5 36.9 51.5 44.6 51.8 69.0 76.2 25.5 
3 73.2 102.4 123.4 58.9 61.2 39.9 15.1 87.4 79.3 16.3 
-·· 
4 67.0 55.4 134.5 111.2 22.2 47.5 20.9 29.5 109.5 12.8 
5 53.5 84.5 18.4 40.9 49.6 44.7 12.1 32.0 62.0 22.7 
6 49 .. 0 106.4 13.8 60.1 38.5 46.8 15.1 28.3 80.4 4.91 
7 69.8 44.6 17.8 39.8 33.5 32.2 4.90 14.9 53.4 22.9 
8- 64.9 37.9 47.7 43.5 39.3 73.2 88.9 84.0 22.0 
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Table D.S Urinary citrate excretion (mmol/24hr) for each 24 hour urine sample 
collected by the 10 participants. 
# PT ES PR SH MG GV BM cw RG AM 
1 2.63 3.20 3.08 3.09 2.11 1.12 1.20 1.67 3.12 0.44 
2 3.16 3.67 2.68 1.95 2.97 1.33 1.34 1.56 1.98 0.93 ' 
3 2.55 2.62 2.68 2.47 2.90 1.49 1.25 1.34 2.36 1.42 
4 1.93 5.37 3.58 1.99 2.00 1.63 1.30 1.03 2.29 1.11 
5 1.48 3.16 2.38 2.41 2.03 2.37 1.04 1.24 2.50 1.97 
6 1.90 2.82 1.27 2.77 2.25 1.64 0.80 1.24 3.76 0.69 
7 2.97 2.90 1.91 2.72 1.79 1.37 1.28 0.93 2.33 2.32 
8 1.94 1.86 4.15 3.27 1.78 2.55 1.27 2.72 0.57 
Table D.6 Urinary pH for each 24 hour urine sample collected by the 10 participants. 
# PT ES PR SH MG GV BM cw RG AM 
1 5.35 6.55 6.50 6.55 6.05 5.85 6.15 6.65 6.55 4.30 
2 6.00 6.20 6.35 5.45 6.35 6.15 6.55 6.85 6.95 5.50 
3 5.20 5.95 6.10 5.90 6.25 6.10 6.20 6.35 6.85 5.85 
4 5.60 6.00 5.95 6.20 5.50 6.00 6.15 6.25 6.55 5.85 
5 5.20 5.90 5.65 6.40 6.45 .. 6.45· 6.05 6.10 6.20 5.85 
6 5.55 6.35 5.55 6.10 5.65 6.05 6.40 6.45 6.70 6.35 
7 6.05 6.15 5.30 5.60 6.30 6.25 6.35 6.05 6.65 6.55 
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Table 0.7 Urinary volume (cm3) for each 24 hour urine sample collected by the 10 
participants. 
# PT ES PR SH MG GV BM cw RG AM 
1 1260 2320 1160 1420 920 1385 2120 980 2560 440 
2 1860 2140 1840 975 1560 900 2375 840 1330 1240 
. - 3 3140 2000 2410 2350 1045 895 2035 1260 2275 1210 
4 1920 1985 2410 2780 1050 990 2160 735 1420 2420 
5 1660 1905 1440 2170 775 950 '1800 1360 1815 1985 
6 1780 1815 1545 1040 735 950 2150 1095 2080 1140 
7 1810 1600 1995 1860 1040 1260 1895 1075 1835 1830 
8 1440 1235 2170 2210 570 950 1400 1760 1760 
Table D.S Urinary urate excretion (mmol/24hr) for each 24 hour urine sample 
collected by the 10 participants. 
# PT ES PR SH MG GV BM cw RG AM 
1 3.30 3.48 4.70 3.90 2.59 2.24 2.40 2.50 5.68 0.66 
2 4.24 3.50 4.44 3.00 3.65 2.38 4.10 2.40 2.87 1.27 
3 * * * * * * * * * * 
4 * * * * * * * * * * 
5 * * * * * 0.07 * * * * 
6 2.03 1.85 * 1.0 0.37 0.19 1.20 0.90 2.37 0.35 
7 4.89 3.50 * 2.57 2.56 2.19 2.50 1.10 2.97 2.31 
8 3.11 2.59 2.99 4.91 2.40 3.20 2.40 1.88 3.90 
* : urate excretion could not be determined in urines with a high ascorbic acid load due 
to the interference and masking effects of the vitamin on the determination of urate. 
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Table D.9 Urinary creatinine excretion (mmol/24hr) for each 24 hour urine sample 
--
collected by the 10 participants. 
# PT ES PR SH MG GV BM cw RG AM 
1 14.3 15.3 12.6 14.9 10.2 9.4 10.2 9.8 19.2 5.0 
/ 
2 16.1 14.5 13.5 13.6 14.9 11.4 11.8 9.4 11.2 6.5 
3 16.3 14.8 12.9 15.1 13.9 11.9 12.3 9.7 15.2 6.9 
4 14.0 17.1 12.9 16.9 12.0 11.9 7.0 9.3 14.8 7.5 
5 13.9 -13.4 13.0 17.7 11.2 11.8 10.3 8.9 16.2 8.5 
6 15.1 14.9 9.3 16.0 12.9 11.2 8.3 7.5 15.0 2.3 
7 17.6 11.0 14.1 15.0 12.2 10.6 11.6 6.9 15.4 8.4 
8 13.0 9.0 14.1 16.8 10.7 12.7 9.6 6.6 15.0 
TableD.lO Urinary phosphate excretion (mmol/24hr) for each 24 hour urine sample 
collected by the 10 participants. 
# PT ES PR SH MG GV BM cw RG AM 
1 30.2 32.2 34.7 25.7 18.8 15.7 13.7 22.8 39.6 10.0 
2 42.2 31.0 39.0 20.4 28.4 18.5 19.5 18.2 27.9 15.3 
3 31.1 27.2 31.1 25.8 26.3 18.8 12.7 22.7 35.6 13.5 
4 24.8 40.1 34.6 33.2 22.4 18.2 15.7 13.7 33.0 8.3 
5 27.1 35.1 34.1 20.2 19.2 29.9 13.7 18.6 36.4 15.1 
6 27.2 34.1 17.8 21.7 22.6 21.6 10.3 11.6 29.9 3.3 
7 28.8 26.2 8.9 26.0 24.8 19.8 15.3 14.0 22.6 16.6 
8- 31.0 18.9 22.1 33.5 23.5 21.6 24.9 14.1 28.1 
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Table D.ll Urinary chloride excretion (mmol/24hr) for each 24 hour urine sample 
collected by the 10 participants. 
# PT ES PR SH MG GV BM cw RG AM 
1 110 195 140 114 196 89 66 100 230 27 
2 162 214 59 70 198 117 140 105 107 29 
3 170 176 87 98 256 147 63 95 189 42 
4 129 119 60 136 97 106 48 87 97 102 
5 144 108 140 154 184 141 54 106 158 81 
6 198 168 77 132 129 168 112 83 154 22 
- 7 186 72 84 112 105 64 63 41 44 122 
8 166 80 156 197 104 202 116 55 112 
Table D.12 Urinary oxalate excretion (mmol/24hr) for each "bulk" 24 hour urine 
sample collected by the 10 participants. 
# PT ES PR SH MG GV BM cw RG AM 
1 0.32 0.33 0.21 0.21 0.26 0.14 0.10 0.17 0.19 0.05 
2 0.23 0.21 0.20 0.12 0.22 0.19 0.16 0.20 0.15 0.14 
3 0.26 0.14 0.12 0.34 0.30 0.15 0.21 0.30 0.24 0.16 
4 0.35 0.11 0.16 0.26 0.13 0.19 0.24 0.35 0.19 0.20 
5 0.22 0.15 0.13 0.26 0.14 0.30 0.56 0.42 0.16 0.21 
6 0.17 0.21 0.10 0.20 0.15 0.19 0.22 0.14 0.24 0.04 
7 0.20 0.12 0.22 0.26 0.28 0.42 0.17 0.10 0.16 0.11 
8 0.17 0.12 0.35 0.20 0.27 0.22 0.19 0.13 0.10 
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Table D.13 Urinary oxalate excretion (mmol/24hr) for each "+ EDTA" 24 
representative hour urine sample collected by the 10 participants. 
# PT ES PR SH MG GV BM cw RG AM 
1 0.30 0.12 0.09 0.13 0.11 0.11 0.06 0.14 0.48 0.03 
2 0.16 0.10 0.12 0.11 0.14 0.13 0.17 0.16 0.24 0.14 
3 0.30 0.18 0.09 0.17 0.16 0.13 0.14 0.20 0.38 0.08 
4 0.32 0.10 0.09 0.18 0.11 0.13 0.16 0.21 0.29 0.17 
5 0.19 0.14 0.17 0.18 0.09 0.13 0.28 0.26 0.20 0.07 
6 0.16 0.11 0.06 0.10 0.09 0.11 0.22 0.07 0.41 0.04 
7 0.14 0.10 0.19 0.21 0.16 0.15 0.12 0.19 0.14 0.08 
-· 
8 0.13 0.10 0.22 0.18 0.08 0.10 0.28 0.26 0.07 
Table D.14 Urinary oxalate excretion (mmol/24hr) for each "-EDTA" representative 
24 hour urine sample collected by the 10 participants. 
# PT ES PR SH MG GV BM cw RG AM 
1 0.27 0.22 0.17 0.22 0.20 0.23 0.12 0.21 0.30 0.04 
2 0.26 0.14 0.21 0.13 0.14 0.15 0.16 0.18 0.27 0.26 
3 0.35 0.17 0.11 0.23 0.29 0.21 0.15 0.26 0.29 0.14 
4 0.43 0.10 0.15 0.24 0.17 0.22 0.34 0.32 0.31 0.23 
5 0.22 0.18 0.29 0.30 0.20 0.24 0.60 0.48 0.26 0.15 
6 0.18 0.35 0.10 0.17 0.21 0.20 0.23 0.25 0.26 0.05 
7 0.16 0.15 0.32 0.28 0.42 0.36 0.18 0.11 0.17 0.16 
8 0.23 0.22 0.32 0.32 0.21 0.21 0.17 0.18 0.13 
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Table D.15 Urinary ascorbic acid excretion (f,tg.cm-3) for voiding "x" collected by 
each of the 10 participants. 
# PT ES PR SH MG GV BM cw RG AM 
1 33 13 21 47 12 18 37 239 
2 9 55 14 59 37 13 12 16 28 192 
3 249 39 37 15 1127 937 31 26 145 263 
4 201 874 835 1365 1490 1396 2018 1138 929 89 
5 276 1865 977 727 1306 422 1162 755 72 
6 308 580 528 822 627 552 473 1057 35 
7 25 61 50 279 284 .173 6 489 29 11 
8 14 31 70 24 46 135 55 29 21 
Table D.16 Urinary ascorbic acid excretion (f..tg.cm-3) for voiding "y" collected by 
each of the 10 participants. -~ 
# PT ES PR SH MG GV BM cw RG AM 
1 59 4 16 49 8 20 73 
2 11 14 18 56 8 21 41 46 20 209 
3 414 1542 682 496 2313 1240 20 577 264 306 
4 581 219 1217 1114 1240 1866 81 1388 661 87 
5 905 181 1096 699 1168 1220 349 982 965 58 
6 67 474 112 516 26 141 725 70 
7 77 24 82 307 21 5 209 45 17 
8 28 6 93 152 12 22 45 18 
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Table D.17. Urinary ascorbic acid excretion (~g.cm-3) for voiding "z" collected by 
each of the 10 participants. 
# PT ES PR SH MG GV BM cw RG AM 
1 19 81 18 85 40 19 26 20 87 
2 12 67 4 25 14 16 22 30 23 44 
3 278 1461 523 1220 1521 1283 1510 1982 929 1306 
4 1257 1121 1003 1189 790 184 88 2643 607 463 
5 962 1095 1181 1243 2675 1062 624 1194 804 478 
6 97 62 160 459 190 531 183 226 97 8 
. 
- 7 22 32 600 33 16 6 12 155 25 20 
8 19 25 195 15 13 66 22 19 9 
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Appendix E 
Table E.l Summary of the manifold details used in the determination of ascorbic acid using 




Gilson Minipuls 2; PVC calibrated pump tubes (yellow tags); flow 
rates were calibrated gravimetrically 
lf\iection Valve Rheodyne Type 5020 teflon rotary injection valve. 
Manifold Tubing 0.5 mm and 0.8 mm inner diameter tubing was used throughout. 
Reaction Coil A 100 em length of tubing (0.5 mm i.d.) was tightly coiled around a 
teflon cylinder (i.d. = 15 mm) and firmly mounted. 
Detector An LKB Novas pee spectrophotometer was employed in time-base 
mode, the output analogue port was connected to an SP4290 
integrator. 
Flow Cell Florescence flow through cell, U-shaped of constant pathlength 
0.205 em. 
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Appendix F 
Figure F.l The difference of the FIA - manual titration methods plotted against the 
average of the two methods. Confidence limits are drawn at 95 % confidence. 
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